Gastrointestinal (Noncolorectal) Cancer:

J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, J. Raoul, S. Zeuzem, M. Poulin-Costello, M. Moscovici, D. Voliotis, J. Bruix for the SHARP Investigators Study Group

Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA1. [Abstract]  

P. A. Philip, J. Benedetti, C. Fenoglio-Preiser, M. Zalupski, H. Lenz, E. O'Reilly, R. Wong, J. Atkins, J. Abruzzese, and C. Blanke

Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study
J Clin Oncol (Meeting Abstracts) 2007 25: LBA4509. [Abstract]  

V. Boige, J. Pignon, B. Saint-Aubert, P. Lasser, T. Conroy, O. Bouché, P. Segol, L. Bedenne, P. Rougier, and M. Ychou

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4510. [Abstract]  

M. Stahl, M. K. Walz, M. Stuschke, N. Lehmann, M. H. Seegenschmiedt, J. Riera Knorrenschild, P. Langer, M. Bieker, A. Königsrainer, W. Budach, and H. Wilke

Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4511. [Abstract]  

P. G. Thirion, S. Michiels, A. Le Maître, J. Tierney on behalf of the MetaAnalysis of Chemotherapy in Esophagus Cancer Collaborative Group

Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4512. [Abstract]  

N. Boku, S. Yamamoto, K. Shirao, T. Doi, A. Sawaki, W. Koizumi, H. Saito, K. Yamaguchi, A. Kimura, A. Ohtsu Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group

Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA4513. [Abstract]  

H. Narahara, W. Koizumi, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, and TS-1 Advanced Gastric Cancer (AGC) Clinical TrialGroup

Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4514. [Abstract]  

V. Heinemann, A. Hinke, S. Böck, R. Labianca, and C. Louvet

Gemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta- analysis of sixteen randomized trials
J Clin Oncol (Meeting Abstracts) 2007 25: 4515. [Abstract]  

M. Ychou, F. Desseigne, R. Guimbaud, M. Ducreux, O. Bouché, Y. Bécouarn, A. Adenis, C. Montoto-Grillot, E. Luporsi, and T. Conroy

Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4516. [Abstract]  

H. Riess, U. Pelzer, J. Stieler, I. Schwaner, G. Heil, M. Görner, M. Mölle, A. Hilbig, B. Dörken, and H. Oettle

A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003
J Clin Oncol (Meeting Abstracts) 2007 25: 4517. [Abstract]  

M. Posner, K. J. Chang, A. Rosemurgy, J. Stephenson, M. Khan, T. Reid, W. E. Fisher, I. Waxman, D. Von Hoff, and R. Hecht, Jr.

Multi-center phase II/III randomized controlled clinical trial using TNFerade combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4518. [Abstract]  

B. A. Burtness, M. Powell, J. Berlin, D. Liles, A. Chapman, E. Mitchell, A. B. Benson, and Eastern Cooperative Oncology Group

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology
J Clin Oncol (Meeting Abstracts) 2007 25: 4519. [Abstract]  

F. Mornex, T. André, C. Louvet, J. Seitz, M. Ychou, G. Lledo, E. Touboul, C. Partensky, and J. Balosso

Postoperative adjuvant gemcitabine plus oxaliplatin (GemOx) chemotherapy followed by chemoradiation in patients with pancreatic carcinoma: A multicenter phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4520. [Abstract]  

M. J. Moore, G. da Cunha Santos, S. Kamel-Reid, K. Chin, D. Tu, W. Parulekar, O. Ludkovski, J. Squire, F. Richardson, and M. Tsao

The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3
J Clin Oncol (Meeting Abstracts) 2007 25: 4521. [Abstract]  

A. C. Berger, K. Winter, J. Hoffman, W. Regine, R. Abrams, H. Safran, A. Konski, A. Benson, III, J. MacDonald, and C. Willet

Post-resection CA 19–9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: A secondary endpoint of RTOG 9704
J Clin Oncol (Meeting Abstracts) 2007 25: 4522. [Abstract]  

R. A. Abrams, K. A. Winter, W. F. Regine, H. Safran, J. P. Hoffman, A. A. Konski, A. B. Benson, J. S. Macdonald, T. A. Rich, and C. G. Willett

Correlation of RTOG 9704 (adjuvant therapy (rx) of pancreatic adenocarcinoma (pan ca)) radiation therapy quality assurance scores (RTQASc) with survival (S)
J Clin Oncol (Meeting Abstracts) 2007 25: 4523. [Abstract]  

D. Schrag, L. Archer, X. Wang, D. Romanus, M. Mulcahy, R. Goldberg, H. Kindler for the Cancer and Leukemia Group B (CALGB)

A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303
J Clin Oncol (Meeting Abstracts) 2007 25: 4524. [Abstract]  

K. Chin, H. Iishi, H. Imamura, O. Kobayashi, H. Imamoto, T. Esaki, M. Kato, Y. Tanaka, and H. Furukawa

Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002)
J Clin Oncol (Meeting Abstracts) 2007 25: 4525. [Abstract]  

F. Lordick, S. Lorenzen, S. Hegewisch-Becker, G. Folprecht, E. Wöll, T. Decker, E. Endlicher, N. Röthling, F. Fend, and C. Peschel

Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1^st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group
J Clin Oncol (Meeting Abstracts) 2007 25: 4526. [Abstract]  

M. Hejna, J. Zacherl, A. Ba-Ssalamah, A. Püspök, U. Pluschnig, T. Brodowicz, C. C. Zielinski, and M. Raderer

Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001
J Clin Oncol (Meeting Abstracts) 2007 25: 4527. [Abstract]  

N. Tebbutt, T. Sourjina, A. Strickland, G. Van Hazel, V. Ganju, D. Gibbs, V. Gebski, S. Munro, and M. Cummins

ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago- gastric cancer, final results of an AGITG trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4528. [Abstract]  

K. Minashi, A. Ohtsu, K. Mera, M. Muto, T. Yano, M. Tahara, T. Doi, M. Nishimura, and K. Nihei

Combination of endoscopic mucosal resection and chemoradiotherapy as a nonsurgical treatments for patients with clinical stage I esophageal squamous cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4529. [Abstract]  

H. Carstens, M. Albertsson, S. Friesland, G. Adell, G. Frykholm, G. Wagenius, H. E. Myrvold, I. Farago, and D. Stockeld

A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4530. [Abstract]  

G. Crehange, F. Bonnetain, S. Seng, T. N'guyen, X. Mirabel, C. Marchal, P. Verrelle, B. Roullet, P. Maingnon, and L. Bedenne

Impact of radiation (RT) regimen on palliative procedures (PP) for patients with resectable locally advanced esophageal cancer treated with exclusive chemoradiation (CRT) or preoperative chemoradiation (CRT+S): results from a phase III trial of the Federation Francophone de Cancerologie Digestive (FFCD 9102)
J Clin Oncol (Meeting Abstracts) 2007 25: 4531. [Abstract]  

T. Conroy, Y. Yataghene, P. L. Etienne, P. Michel, H. Senellart, J. L. Raoul, L. Mineur, M. Rives, X. Mirabel, and A. Adenis

Definitive chemo-radiotherapy (CRT) with folfox 4 or 5FU-cisplatin as first line treatment for patients (pts) with inoperable esophageal cancer (IEC): Final results of a randomized phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4532. [Abstract]  

L. Kleinberg, M. E. Powell, A. Forastiere, S. Keller, P. Anne, and A. B. Benson

E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus
J Clin Oncol (Meeting Abstracts) 2007 25: 4533. [Abstract]  

B. E. Chatterton, I. Ho-Shon, N. Lenzo, A. Patrikeos, B. Kelley, A. Baldey, J. Ramshaw, and A. Scott

Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project
J Clin Oncol (Meeting Abstracts) 2007 25: 4534. [Abstract]  

D. Kandioler, M. Hejna, R. Zwrtek, S. Kappel, C. Bichler, F. Wrba, A. Ba-Ssalamah, C. Zielinski, R. Jakesz, J. Zacherl, and p53 Research Group Study

p53 adapted neoadjuvant therapy for esophageal cancer: Pilot study
J Clin Oncol (Meeting Abstracts) 2007 25: 4535. [Abstract]  

D. Vallboehmer, E. Kuhn, J. Brabender, R. Metzger, U. Warnecke-Eberz, S. E. Baldus, U. Drebber, A. H. Hölscher, and P. M. Schneider

Survivin expression in esophageal cancer: Association with histomorphological response to neoadjuvant therapy and prognosis
J Clin Oncol (Meeting Abstracts) 2007 25: 4536. [Abstract]  

H. H. Helgason, J. Y. Engwegen, A. Cats, H. Boot, M. Kuiper, M. Zapatka, M. Joerger, J. H. Beijnen, and J. H. Schellens

Serum proteomic profiling of advanced gastric cancer and identification of proteomic changes following response to epirubicin, cisplatin and capecitabine chemotherapy as diagnostic and predictive biomarkers
J Clin Oncol (Meeting Abstracts) 2007 25: 4537. [Abstract]  

M. Teo, H. T. Huynh, S. W. Hee, Y. P. Phoon, R. Quek, P. Wang, and H. C. Toh

FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4538. [Abstract]  

J. Matsubara, Y. Yamada, Y. Hirashima, D. Takahari, N. Tsuda, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, and T. Shimoda

Impact of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), and HER2 expressions on outcomes of patients with gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4539. [Abstract]  

I. Altomare, A. Pennathur, L. Xi, W. E. Gooding, V. R. Litle, J. D. Luketich, and T. E. Godfrey

Molecular detection of occult nodal metastases in esophageal adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4540. [Abstract]  

H. Ishii, J. Furuse, K. Nakachi, E. Suzuki, S. Shimizu, M. Yoshino, M. Satake, and T. Hayashi

Predictive factors of transcatheter arterial chemoembolization for hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4541. [Abstract]  

H. Yoshitomi, A. Togawa, F. Kimura, H. Shimizu, H. Yoshidome, M. Miyazaki, and Chiba study group of adjuvant chemotherapy for pancreatic cancer (CSAP)

A randomized phase II trial of adjuvant chemotherapy with uracil / tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4542. [Abstract]  

T. Buanes, S. Bernhardt, K. Lislerud, I. Gladhaug, M. Moeller, J. A. Eriksen, and G. Gaudernack

RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival
J Clin Oncol (Meeting Abstracts) 2007 25: 4543. [Abstract]  

S. Cascinu, R. Berardi, S. Siena, R. Labianca, A. Falcone, E. Aitini, S. Barni, F. Di Costanzo, L. Frontini, G. Tonini, and A. Zaniboni

The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD
J Clin Oncol (Meeting Abstracts) 2007 25: 4544. [Abstract]  

S. Al-Batran, J. T. Hartmann, R. Hofheinz, R. Mahlberg, N. Homann, S. Probst, J. Stoehlmacher, M. Fritz, V. Rethwisch, G. Seipelt, and E. Jäger

Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction: A multicenter phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
J Clin Oncol (Meeting Abstracts) 2007 25: 4545. [Abstract]  

Y. Kang, J. Lee, Y. Min, K. Lee, D. Zang, B. Ryoo, J. Kim, S. Park, W. Kang, and D. Shin

A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4546. [Abstract]  

W. B. Al-Refaie, P. W. Pisters, and G. J. Chang

Gastric adenocarcinoma in young patients: A population-based appraisal
J Clin Oncol (Meeting Abstracts) 2007 25: 4547. [Abstract]  

A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, D. Wong, J. Allen, and M. A. Tempero

A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): Update with completion of study accrual
J Clin Oncol (Meeting Abstracts) 2007 25: 4548. [Abstract]  

T. Evans, R. K. Ramanathan, S. Yazji, R. Glynne-Jones, A. Anthoney, J. Berlin, and J. W. Valle

Final results from cohort 1 of a phase II study of volociximab, an anti-5ß1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4549. [Abstract]  

H. Ueno, T. Okusaka, J. Furuse, K. Yamao, A. Funakoshi, N. Boku, S. Ohkawa, A. Makimoto, and T. Sato

A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4550. [Abstract]  

J. Spano, C. Chodkiewicz, J. Maurel, R. P. Wong, H. S. Wasan, Y. K. Pithavala, P. W. Bycott, K. Liau, S. Kim, and O. Rixe

A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component
J Clin Oncol (Meeting Abstracts) 2007 25: 4551. [Abstract]  

H. Takeuchi, Y. Kitagawa, Y. Saikawa, A. Suto, M. Mukai, T. Nakahara, A. Kubo, and M. Kitajima

Sentinel node mapping for esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4552. [Abstract]  

G. P. Kim, A. L. Oberg, N. R. Foster, A. Jaslowski, P. J. Flynn, D. Campbell, E. Hedrick, L. Gray, A. Grothey, and S. Alberts

Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4553. [Abstract]  

E. Oki, Y. Kakeji, E. Tokunaga, R. Yoshida, A. Egashira, N. Sadanaga, M. Morita, K. Taguchi, M. Kuwano, and Y. Maehara

Akt-mediated YB-1 phosphorylation induces resistance for chemotherapy of gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4554. [Abstract]  

A. D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig

Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 4555. [Abstract]  

I. A. Astsaturov, N. J. Meropol, R. K. Alpaugh, J. D. Cheng, N. L. Lewis, M. Beard, A. Rogatko, Z. Xu, L. M. Weiner, and S. J. Cohen

A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4556. [Abstract]  

A. van der Horst-Schrivers, E. de Vries, P. Willemse, I. Kema, T. Links, H. Boezen, and A. Wymenga

Polymorphisms of the serotonin transporter and Monoamine Oxidase A gene in patients with metastatic midgut carcinoid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 4557. [Abstract]  

L. Kvols, J. E. Glusman, E. A. Hahn, E. Wang, K. Öberg, L. Anthony, T. M. O’Dorisio, W. de Herder, C. H. Darby, B. Wiedenmann, G. and the Pasireotide Carcinoid Study Group

The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR
J Clin Oncol (Meeting Abstracts) 2007 25: 4558. [Abstract]  

E. de Winton, A. Heriot, M. Ng, R. Hicks, A. Hogg, A. Milner, T. Leong, M. Fay, J. MacKay, and S. Ngan

Utility of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging, radiotherapy planning and prognostication of anal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4559. [Abstract]  

B. R. Tan, W. S. Brenner, J. Picus, R. Suresh, S. Sorcher, J. S. James, C. Fournier, and H. L. Mcleod

Biweekly oxaliplatin with gemcitabine and capecitabine in advanced gastrointestinal malignancies: A phase I study
J Clin Oncol (Meeting Abstracts) 2007 25: 4560. [Abstract]  

S. Lorenzen, N. Weigert, V. Heinemann, M. Hentrich, T. Schuster, T. Seroneit, N. Röthling, C. Peschel, and F. Lordick

Docetaxel, cisplatin and leucovorin/fluorouracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4561. [Abstract]  

T. Ruhstaller, L. Widmer, S. Balmer Majno, W. Mingrone, V. Hess, R. von Moos, M. Borner, A. Schnider, D. Koeberle, and R. Popescu

Preoperative induction chemotherapy with docetaxel-cisplatin followed by concurrent docetaxel-cisplatin and radiation therapy in patients with locally advanced esophageal cancer: A prospective, multicenter phase ll trial of the Swiss Group for Clinical Cancer Research
J Clin Oncol (Meeting Abstracts) 2007 25: 4562. [Abstract]  

D. S. Oh, J. Cooc, S. R. DeMeester, R. Mori, H. Kuramochi, C. Rizzetto, K. Danenberg, P. Danenberg, J. A. Hagen, D. H. Harpole, and T. R. DeMeester

Molecular signature of esophageal adenocarcinoma derived from microarray analysis of paraffin-embedded specimens predicts systemic recurrence following resection
J Clin Oncol (Meeting Abstracts) 2007 25: 4563. [Abstract]  

D. Gold, H. Karacay, C. Chang, E. Rossi, W. McBride, D. Goldenberg, and R. Sharkey

A novel bispecific antibody (bsMAb) construct for nuclear imaging of pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4564. [Abstract]  

D. Zupanc, A. Roth, K. Kolaric, and Z. Tometic

A randomized clinical study of chemoradiotherapy versus radiotherapy in locoregional advanced unresectable esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4565. [Abstract]  

T. Kajiwara, T. Nishina, I. Hyodo, T. Moriwaki, S. Endo, J. Nasu, S. Hori, H. Iguchi, Y. Hiasa, and M. Onji

Impact of gene expression of orotate phosphoribosyl transferase for complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus
J Clin Oncol (Meeting Abstracts) 2007 25: 4566. [Abstract]  

M. B. Thomas, R. Chadha, M. Iwasaki, K. Glover, and J. L. Abbruzzese

The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4567. [Abstract]  

W. M. Eisterer, A. De Vries, B. Spechtenhauser, D. Kendler, A. Königsrainer, H. Nehoda, P. Lukas, E. Wöll, and D. Öfner

Triple induction chemotherapy and chemoradiotherapy in locally advanced esophageal cancer: Final results of a multicenter phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4568. [Abstract]  

G. A. Moviglia, C. Gaeta, G. Varela, N. Iraola, A. Paes de Lima, H. Costanzo, P. Farina, F. Bastos, C. Ayala, and G. Schuster

Tumor-associated stroma cell therapy in patients with pancreatic cancer potentiates therapeutic effect of tumor B-cell hybrid (TBH) auto-vaccines
J Clin Oncol (Meeting Abstracts) 2007 25: 4569. [Abstract]  

D. Malka, C. Dromain, F. Farace, S. Horn, J. Pignon, M. Ducreux, and V. Boige

Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring
J Clin Oncol (Meeting Abstracts) 2007 25: 4570. [Abstract]  

J. Ocvirk, M. Rebersek, and E. Skof

Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4571. [Abstract]  

K. Ott, F. Lordick, M. Feith, H. Bartels, U. Fink, H. J. Stein, M. Molls, E. Biemer, and J. Siewert

Cervical squamous cell carcinoma of the esophagus-a unique series of limited resection and free jejunal graft interposition after neoadjuvant RCTx in 94 patients
J Clin Oncol (Meeting Abstracts) 2007 25: 4572. [Abstract]  

R. Krempien, M. W. Munter, C. Timke, H. Friess, G. Hartung, K. K. Herfarth, A. Abdollahi, M. W. Buchler, P. E. Huber, and J. Debus

Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: A prospective phase II trial [PARC-Study ISRCTN56652283]
J Clin Oncol (Meeting Abstracts) 2007 25: 4573. [Abstract]  

W. Sun, D. G. Haller, K. Mykulowycz, M. Rosen, M. Soulen, M. Capparo, T. Faust, B. Giantonia, and K. Olthoff

Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4574. [Abstract]  

M. Milella, E. Bria, P. Carlini, F. Cuppone, A. Gelibter, C. Nisticò, E. M. Ruggeri, E. Terzoli, F. Cognetti, and D. Giannarelli

Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): Analysis of randomized clinical trials (RCTs) exploring gemcitabine (G)-based combinations
J Clin Oncol (Meeting Abstracts) 2007 25: 4575. [Abstract]  

L. H. Schwartz, S. Curran, R. Trocola, J. Randazzo, D. Ilson, D. Kelsen, and M. Shah

Volumetric 3D CT analysis - an early predictor of response to therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4576. [Abstract]  

J. Raoul, A. Devillers, A. de Lajarthe, M. Cuggia, E. Boucher, and E. Garin

18-FDG-PET and somatostatin receptor scintigraphy (SRS) can predict disease progression and survival in patients with metastatic endocrine tumors: Results of a prospective study
J Clin Oncol (Meeting Abstracts) 2007 25: 4577. [Abstract]  

R. R. McWilliams, N. R. Foster, F. J. Quevedo, R. F. Marschke, J. W. Kugler, E. L. Friedman, A. J. Jaslowski, J. R. Sande, and S. R. Alberts

NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results
J Clin Oncol (Meeting Abstracts) 2007 25: 4578. [Abstract]  

C. Bauer, M. Dauer, S. Saraj, M. Schnurr, K. Jauch, D. Rüttinger, C. Bruns, B. Emmerich, S. Endres, and A. Eigler

Immunological and clinical response after vaccination therapy of pancreatic carcinoma patients with autologous, tumor-lysate pulsed dendritic cells: Results of a phase II-study
J Clin Oncol (Meeting Abstracts) 2007 25: 4579. [Abstract]  

D. Shin, S. Lee, S. Park, J. Park, E. Cho, J. Lee, and W. Lee

Randomized phase II trial of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) for advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4580. [Abstract]  

H. A. Gonzalez, Sr., H. Londoño, J. Quiroz, A. Parra, A. Ramirez, M. González, A. Rodríguez, C. Varón, and N. Romero

Chemoimmunotherapy with 5-fluouracil, leucovorin and interferon alpha-2b as adjuvant therapy after surgery in Gastric Carcinoma patients
J Clin Oncol (Meeting Abstracts) 2007 25: 4581. [Abstract]  

M. Aglietta, Y. Pignochino, G. Cavalloni, I. Sarotto, J. Penachioni, C. Zanon, G. Migliardi, W. Piacibello, M. Risio, A. Bardelli, and F. Leone

Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4582. [Abstract]  

A. Maraveyas, M. Holmes, F. Lofts, K. K. Garadi, E. Gardiner, and J. Sgouros

Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): Results of the interim analysis of the FRAGEM trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4583. [Abstract]  

T. R. Halfdanarson, K. Rabe, J. Rubin, and G. M. Petersen

Pancreatic endocrine tumors (PETs): Incidence and recent trend toward improved survival
J Clin Oncol (Meeting Abstracts) 2007 25: 4584. [Abstract]  

D. Pastorelli, G. Cartei, F. Zustovich, S. Zovato, G. Artioli, R. Ceravolo, M. Nicoletto, S. Binato, and M. Mattiazzi

A phase II study of pegylated liposomial doxorubicin (PLD) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4585. [Abstract]  

J. M. Brell, K. Matin, T. Evans, R. L. Volkin, G. J. Keifer, J. J. Schlesselman, S. Dranko, L. Rath, A. Schmotzer, and R. K. Ramanathan

Phase II study of gefitinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after first-line therapy. Final results
J Clin Oncol (Meeting Abstracts) 2007 25: 4586. [Abstract]  

K. Ribi, E. Nitzsche, J. Schuller, B. Klaeser, T. Hany, A. Roth, V. Hess, M. Zuend, N. Lombriser, and T. Ruhstaller

PET scanning and patient reported dysphagia before and after chemotherapy (CT) for prediction of pathological response after CT and chemoradiotherapy (CRT) in patients with locally advanced esophageal cancer (EC): A multicenter phase ll trial of the Swiss
J Clin Oncol (Meeting Abstracts) 2007 25: 4587. [Abstract]  

S. Tsujitani, H. Saito, S. Tatebe, and M. Ikeguchi

Tumor progression and chemoradiosensitivity in relation to the expression of apoptosis related proteins in esophageal squamous cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4588. [Abstract]  

S. Collette, F. Bonnetain, X. Paoletti, M. Doffoel, O. Bouche, J. L. Raoul, P. Rougier, F. Masskouri, L. Bedenne, and J. C. Barbare

Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials
J Clin Oncol (Meeting Abstracts) 2007 25: 4589. [Abstract]  

L. A. Dawson, R. Tse, J. Kim, R. Dinniwell, G. Lockwood, M. Sherman, J. J. Knox, and S. Gallinger

Phase I study of stereotactic radiotherapy for unresectable hepatobiliary cancer and liver metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 4590. [Abstract]  

B. L. Brücher, F. Pühringer-Oppermann, and M. Sarbia

Smad4 is predictive for response in neoadjuvant treated esophageal squamous cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4591. [Abstract]  

T. Andre, P. Afchain, G. Lledo, S. Nguyen, J. Paitel, L. Mineur, P. Artru, F. Selle, A. de Gramont, and C. Louvet

First-line simplified GEMOX (D1-D1) versus classical GEMOX (D1-D2) in metastatic pancreatic adenocarcinoma (MPA). A GERCOR randomized phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4592. [Abstract]  

I. Takeyoshi, F. Makita, Y. Tanahashi, S. Iwazaki, S. Nakamura, H. Ishikawa, T. Ogawa, T. Ohya, S. Kawate, J. Horiguchi, and Y. Morishita

A phase II study of weekly paclitaxel and doxifluridine (an intermediate metabolite of capecitabine) combination chemotherapy for advanced/recurrent gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4593. [Abstract]  

S. Louafi, M. Hebbar, O. Rosmorduc, C. Tesmoingt, A. Asnacios, O. Romano, L. Fartoux, P. Artru, T. Poynard, and J. Taieb

Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO
J Clin Oncol (Meeting Abstracts) 2007 25: 4594. [Abstract]  

A. A. Meluch, D. R. Spigel, F. A. Greco, D. A. Yardley, H. A. Burris, III, C. Farley, J. D. Peyton, D. L. Shipley, R. G. Steis, and J. D. Hainsworth

Phase I/II trial of preoperative oxaliplatin, docetaxel, capecitabine, and radiation for localized esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4595. [Abstract]  

A. H. Ko, J. Scott, M. A. Tempero, and J. W. Park

Detection and significance of circulating tumor cells (CTC) in patients with metastatic pancreatic cancer (PC) receiving systemic therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4596. [Abstract]  

S. Kang, J. Han, K. Lee, J. Choi, J. Park, H. Lee, H. Kim, J. Kim, S. Kang, Y. Oh, and S. Sheen

Low expression of bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4597. [Abstract]  

V. Gruenwald, L. Wilkens, M. Gebel, T. F. Greten, S. Kubicka, A. Ganser, M. P. Manns, and N. P. Malek

A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results
J Clin Oncol (Meeting Abstracts) 2007 25: 4598. [Abstract]  

N. Dhillon, B. B. Aggarwal, R. A. Newman, R. A. Wolff, A. B. Kunnumakkara, J. L. Abbruzzese, D. S. Hong, L. H. Camacho, C. Ng, and R. Kurzrock

Curcumin and pancreatic cancer: Phase II clinical trial experience
J Clin Oncol (Meeting Abstracts) 2007 25: 4599. [Abstract]  

W. Ichikawa, T. Takahashi, and Y. Sasaki

Pharmacogenetic profiling and clinical outcome of patients (pts) with advanced gastric cancer (AGC) treated with S-1 monotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4600. [Abstract]  

F. D. Huitzil, M. Capanu, G. Jacobs, W. Smith, E. O’Reilly, M. Shah, G. K. Schwartz, L. B. Saltz, D. P. Kelsen, and G. K. Abou-Alfa

Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4601. [Abstract]  

S. Im, S. Kim, J. Kim, H. Lee, M. Kim, S. Kim, W. Kang, H. Yang, I. Song, and Y. Bang

A phase II trial of perioperative chemotherapy with folinic acid, 5-fluorouracil, and oxaliplatin in potentially resectable gastric cancer with regional lymph node metastasis
J Clin Oncol (Meeting Abstracts) 2007 25: 4602. [Abstract]  

Y. Bang, Y. Kang, W. Kang, N. Boku, H. Chung, S. Lanzalone, M. J. Lechuga, L. Sherman, R. Chao, and A. Sobrero

Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4603. [Abstract]  

F. L. Rojas Llimpe, F. Di Fabio, C. Ceccarelli, C. Pinto, S. Siena, S. Cascinu, C. Funaioli, V. Mutri, S. Giaquinta, and A. A. Martoni

Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study)
J Clin Oncol (Meeting Abstracts) 2007 25: 4604. [Abstract]  

P. Sunpaweravong, S. Sunpaweravong, D. Sangthawan, P. Puttawibul, and W. Mitarnun

Combination of gefitinib, cisplatin and 5-FU chemotherapy, and radiation therapy (RT) in newly-diagnosed patients with esophageal carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4605. [Abstract]  

S. Hashmi, G. Black, D. Bell, A. Steg, M. Johnson, R. B. Diasio, and M. W. Saif

Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase (TP) and its correlation with survival
J Clin Oncol (Meeting Abstracts) 2007 25: 4606. [Abstract]  

H. Oettle, T. Seufferlein, R. Schmid, T. Luger, S. Ludwig, S. Schmaus, G. Wuerth, H. Heinrichs, and K. Schlingensiepen

Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF- ß2 inhibitor AP 12009
J Clin Oncol (Meeting Abstracts) 2007 25: 4607. [Abstract]  

J. A. Wallace, G. Locker, S. Nattam, K. Kasza, K. Wade-Oliver, W. M. Stadler, E. E. Vokes, and H. L. Kindler

Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium
J Clin Oncol (Meeting Abstracts) 2007 25: 4608. [Abstract]  

K. Fujitani, M. Sasako, Y. Iwasaki, K. Yoshimura, T. Sano, A. Nashimoto, N. Fukushima, K. Arai, T. Kinoshita, O. Kobayashi, and H. Tanemura

A phase II study of preoperative chemotherapy (CX) with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancer: JCOG 0210
J Clin Oncol (Meeting Abstracts) 2007 25: 4609. [Abstract]  

B. C. Pestalozzi, S. Heinrich, M. Schäfer, and C. Pierre-Alain

Neoadjuvant chemotherapy for resectable adenocarcinoma of the panctreatic head - a prospective phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4610. [Abstract]  

C. Gomez-Martin, J. C. Camara, H. Cortes, C. Jara, C. Gravalos, B. Rubio, M. L. Amador, and M. Hidalgo

A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4611. [Abstract]  

J. A. Ajani, A. Phan, L. Ho, E. D. Tetzlaff, J. Baker, and Q. Wei

Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4612. [Abstract]  

H. Cortés-Funes, F. Rivera, I. Alés, A. Márquez, A. Velasco, R. Colomer, R. García-Carbonero, J. Sastre, J. Guerra, and C. Grávalos

Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification
J Clin Oncol (Meeting Abstracts) 2007 25: 4613. [Abstract]  

T. D. Yan, D. Black, P. H. Sugarbaker, Y. Yonemura, J. Zhu, and D. L. Morris

A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4614. [Abstract]  

Z. K. Stadler and K. E. Stuart

Characteristics, treatment and outcome of patients with hepatocellular carcinoma (HCC) in the United States: An analysis of 328 patients from 1998–2005
J Clin Oncol (Meeting Abstracts) 2007 25: 4615. [Abstract]  

F. W. Nugent, C. Cunningham, M. A. Barve, W. Fisher, H. Patel, E. Meiri, Y. V. Oza, Z. Yang, E. C. Jurkowski, and M. J. Uprichard

Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4616. [Abstract]  

A. O. Kaseb, M. Bansal, I. Wollner, V. Shah, D. Moonka, G. Divine, and M. Abouljoud

A 10-year retrospective analysis of risk factors, patterns of cancer recurrence, and survival after liver transplant for cirrhosis and hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4617. [Abstract]  

L. Yan, Y. Hu, M. R. D’Andrea, M. A. Towers, Y. Wang, P. Kesavan, M. DeWitte, M. T. Nakada, and S. Ahrendt

Association between high tumor CCL2 expression and poor survival in patients with resectable pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4618. [Abstract]  

M. Harlan, E. Sheehy, J. Randazzo, D. Schrag, M. M. Kemeny, D. P. Kelsen, and M. A. Shah

Initial findings from the Memorial Sloan-Kettering Early Onset and Familial Gastric Cancer Registry (EOFGCR)
J Clin Oncol (Meeting Abstracts) 2007 25: 4619. [Abstract]  

G. Cadiot, F. Bonnetain, B. Landi, O. Bouché, E. Mitry, L. Bedenne, P. Ruszniewski, F. Ricard, F. Vitry, and J. L. Jouve

Simplified LV5FU2-irinotecan (FOLFIRI) in the first-line therapy of well-differentiated endocrine carcinomas of the duodeno- pancreatic area: Preliminary results of the FFCD 0302 phase II trial with GTE participation
J Clin Oncol (Meeting Abstracts) 2007 25: 4620. [Abstract]  

S. Iqbal, B. Goldman, H. J. Lenz, C. M. Fenoglio-Preiser, and C. D. Blanke

S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4621. [Abstract]  

A. Mancuso, S. Sacchetta, P. Saletti, C. Tronconi, L. Milesi, M. Garassino, O. Martelli, R. Labianca, F. Cavalli, and C. N. Sternberg

Clinical and molecular determinants of survival in pancreatic cancer patients treated with second line chemotherapy: results of an Italian/Swiss multicenter survey
J Clin Oncol (Meeting Abstracts) 2007 25: 4622. [Abstract]  

Y. Yamada, T. Arao, K. Nishio, F. Koizumi, D. Saito, T. Gotoda, T. Shimoda, H. Taniguchi, K. Shirao, N. Saijo, and M. Sasako

Identification of prognostic biomarkers for gastric cancer by gene expression analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 4623. [Abstract]  

M. Wiedmann, M. Haefner, M. Niederhagen, K. Schoppmeyer, C. Wittekind, C. Moebius, J. Mossner, and K. Caca

Treatment of pancreatic cancer with two novel histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589
J Clin Oncol (Meeting Abstracts) 2007 25: 4624. [Abstract]  

J. W. Clark, J. A. Meyerhardt, D. V. Sahani, S. Namasivayam, T. A. Abrams, K. Stuart, P. Bhargava, L. S. Blaszkowsky, S. R. Jain, and A. X. Zhu

Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers
J Clin Oncol (Meeting Abstracts) 2007 25: 4625. [Abstract]  

S. OH, H. Kwon, H. Yoo, S. Lee, S. Kim, S. Kim, J. Jang, M. Kim, J. Jeong, K. Kim, and H. Kim

Preoperative level of VEGF and IL-6 are associated with lymph node invasion and stage in gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4626. [Abstract]  

D. J. Cohen, T. Ryan, E. Newman, S. Iqbal, M. Liu, M. Utate, S. Moore, M. Potmesil, H. Hochster, and F. M. Muggia

Intraperitoneal(IP) 5’-fluoro-2’deoxyuridine(FUDR): Safety and outcome when administered prior to adjuvant chemoradiotherapy(chemoRT) following R₀ resection for gastric adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4627. [Abstract]  

M. Reni, S. Cereda, P. Passoni, A. Rognone, E. Mazza, R. Nicoletti, P. G. Arcidiacono, A. Zerbi, G. Balzano, and V. Di Carlo

A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4628. [Abstract]  

T. Nishina, J. Matsubara, M. Toshikazu, Y. Yamada, T. Kajiwara, T. Shimoda, Y. Okayama, Y. Sugimoto, T. Oka, and K. Shirao

Clinical significance of dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), and excision repair cross-complementing gene 1 (ERCC1) gene expression of tumor tissue in patients with advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4629. [Abstract]  

H. Takamori, K. Kanemitsu, A. Chikamoto, T. Ishiko, T. Beppu, M. Hirota, and H. Baba

A novel multimodality treatment for resectable pancreatic cancer (PC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4630. [Abstract]  

G. Y. Ku, D. Kelsen, B. Minsky, V. Rusch, M. Bains, and D. H. Ilson

Small cell carcinoma of the esophagus: Review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
J Clin Oncol (Meeting Abstracts) 2007 25: 4631. [Abstract]  

N. Mathieu, T. Aparicio, F. Roudot-Thoraval, N. Lemarchand, P. Bauer, C. Hennequin, E. Mitry, C. Romelaer, L. Abramowitz, and I. Sobhani

Comparison of squamous cell carcinoma of the canal anal (SCCA) prognosis in patients infected or not by human immunodeficiency virus (HIV)
J Clin Oncol (Meeting Abstracts) 2007 25: 4632. [Abstract]  

S. R. Park, M. S. Park, Y. L. Park, N. K. Kim, J. S. Lee, H. K. Kim, and H. S. Lim

CYP2A6 genetic polymorphism as a predictive marker for clinical outcomes in patients (pts) with metastastic gastric carcinoma (MGC) treated with S-1 plus docetaxel
J Clin Oncol (Meeting Abstracts) 2007 25: 4633. [Abstract]  

J. J. Lee, S. Y. Kim, H. C. Chung, K. H. Lee, H. S. Song, I. S. Woo, Y. S. Hong, W. K. Kang, J. H. Choi, and I. S. Choi

A multi-center phase II study of S-1 plus paclitaxel as first-line therapy in patients with advanced or relapsed gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4634. [Abstract]  

K. Hiraiwa, H. Takeuchi, Y. Kitagawa, H. Hasegawa, Y. Saikawa, T. Ando, T. Irino, T. Yoshikawa, S. Ishii, and M. Kitajima

Circulating tumor cells detected in patients with gastrointestinal cancers associate with tumor stage and response to chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4635. [Abstract]  

M. Nasu, H. Orita, M. Gibson, M. Brock, J. Herman, E. Gabrielson, M. Tsurumaru, and A. Forastiere

Normal esophageal mucosae adjacent to esophageal adenocarcinomas in both Japanese and U.S. patients have a field defect of methylation changes
J Clin Oncol (Meeting Abstracts) 2007 25: 4636. [Abstract]  

A. X. Zhu, D. V. Sahani, E. di Tomaso, D. Duda, V. Sindhwani, S. S. Yoon, L. S. Blaszkowsky, J. W. Clark, D. P. Ryan, and R. K. Jain

A phase II study of sunitinib in patients with advanced hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4637. [Abstract]  

S. Shin, H. Jeung, J. Ahn, H. Choi, B. Cho, S. Rha, N. Yoo, J. Roh, H. Chung, and H. Chung

Mobilized circulating endothelial progenitor cells after the first cycle of chemotherapy with prophylactic G-CSF can be used as a predictive biomarker and patient selection marker for anti-angiogenesis combination treatment
J Clin Oncol (Meeting Abstracts) 2007 25: 4638. [Abstract]  

A. B. El-Khoueiry, C. Rankin, H. J. Lenz, P. Philip, S. E. Rivkin, and C. D. Blanke

SWOG 0514: A phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas
J Clin Oncol (Meeting Abstracts) 2007 25: 4639. [Abstract]  

S. Sym, H. Chang, M. Ryu, J. Lee, T. Kim, J. Yook, S. Oh, B. Kim, and Y. Kang

A phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine and cisplatin (DXP) in patients with advanced unresectable or intra-abdominal metastatic gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4640. [Abstract]  

M. Hassan, C. Dagohoy, C. Leary, D. Li, and J. C. Yao

Risk factors for low-grade neuroendocrine carcinoma (LGNET): Hospital-based case-control study in US
J Clin Oncol (Meeting Abstracts) 2007 25: 4641. [Abstract]  

H. Toh, Y. P. Phoon, R. Quek, A. H. Banham, and S. Y. Tan

Increased foxp3+ regulatory T cells predicts for superior relapse-free and overall survival in early stage hepatocelullar carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4642. [Abstract]  

T. Okusaka, T. Sato, S. Hinotsu, Y. Shioyama, H. Kasugai, K. Tanaka, M. Kudo, T. Saisho, Y. Osaki, M. Sata, and S. Fujiyama

Transarterial infusion chemotherapy alone versus transarterial chemoembolization for the treatment of hepatocellular carcinoma: Results of a multicenter randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4643. [Abstract]  

D. Fu, J. Chong, C. Foss, J. Fox, S. Wang, G. Green, J. Chen, M. V. Lemas, M. Pomper, and R. Ambinder

Imaging and therapy for Epstein-Barr virus-associated gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4644. [Abstract]  

K. Kang, B. Choi, H. Jang, S. Bae, M. Ryu, Y. Kang, J. Jang, G. Choi, and I. Choi

Cyberknife stereotactic radiosurgery in patients with primary hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4645. [Abstract]  

D. Morales-Espinosa, A. Martínez-Velasco, T. Cerón-Lizárraga, V. Rosas-Camargo, J. L. Rodríguez-Díaz, D. Flores- Estrada, A. Gamboa-Domínguez, and O. Arrieta

Clinical and pathologic factors associated with development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: A long-term follow-up study
J Clin Oncol (Meeting Abstracts) 2007 25: 4646. [Abstract]  

H. Chang, M. Azuma, B. Goldman, F. Nagashima, S. Iqbal, K. Danenberg, J. Benedetti, W. Zhang, C. Blanke, and H. Lenz

Gene expression levels of HER2 and IL-8 and polymorphism in IL-8 associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG 0413 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4647. [Abstract]  

A. Duffy, M. Capanu, G. K. Abou-Alfa, D. Huitzel, P. Williams, W. Jarnagin, Y. Fong, D. P. Kelsen, and E. M. O’Reilly

Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4648. [Abstract]  

B. Keam, H. Kim, S. Im, H. Ham, S. Han, E. Cho, J. Lee, D. Oh, T. Kim, and Y. Bang

Comprehensive analysis of ERCC, XPD, and XRCC polymorphisms: Association with clinical outcomes in patients with advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4649. [Abstract]  

Plenary:

B. L. Powell

Effect of consolidation with arsenic trioxide (As₂O₃) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710
J Clin Oncol (Meeting Abstracts) 2007 25: 2. [Abstract]  

B. Escudier, P. Koralewski, A. Pluzanska, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, B. Melichar, N. Moore on behalf of the AVOREN investigators

A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-2a vs placebo/interferon- 2a as first-line therapy in metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3. [Abstract]  

B. Slotman, C. Faivre-Finn, G. Kramer, E. Rankin, M. Snee, M. Hatton, G. de Schaetzen, L. Collette, S. Senan on behalf of the EORTC Radiation Oncology and LungCancer Groups

A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993–22993)
J Clin Oncol (Meeting Abstracts) 2007 25: 4. [Abstract]  

Breast Cancer:

B. Nordlinger, H. Sorbye, L. Collette, B. Glimelius, G. J. Poston, P. M. Schlag, P. Rougier, W. Bechstein, E. Walpole, and T. Gruenberger

Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases
J Clin Oncol (Meeting Abstracts) 2007 25: LBA5. [Abstract]  

P. Rastogi, J. Jeong, C. E. Geyer, J. P. Costantino, E. H. Romond, M. S. Ewer, D. L. Keefe, T. Levine, S. M. Swain, and N. Wolmark

Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)paclitaxel (T) vs. ACT with trastuzumab (H)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA513. [Abstract]  

J. A. Dewar, J. S. Haviland, R. K. Agrawal, J. M. Bliss, P. Hopwood, B. Magee, J. R. Owen, M. A. Sydenham, K. Venables, J. R. Yarnold on behalf of the START Trials centers

Hypofractionation for early breast cancer: First results of the UK standardization of breast radiotherapy (START) trials
J Clin Oncol (Meeting Abstracts) 2007 25: LBA518. [Abstract]  

M. W. Verrill, J. Lee, D. A. Cameron, R. Agrawal, R. E. Coleman, K. McAdam, A. Wardley, A. Bowman, L. Ferrigan, and A. Yellowlees

Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA1005. [Abstract]  

M. Pegram, J. Forbes, T. Pienkowski, V. Valero, W. Eiermann, G. Von Minckwitz, M. Martin, J. Crown, H. Taupin, D. Slamon on behalf of the BCIRG007 investigators

BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA1008. [Abstract]  

Breast CancerLocal-Regional and Adjuvant:

J. Mortimer, S. Flatt, B. Parker, E. Gold, J. P. Pierce Women’s Healthy Eating and Living (WHEL) Investigators

Tamoxifen, hot flashes, and breast cancer recurrence: Support for pharmacogenetics
J Clin Oncol (Meeting Abstracts) 2007 25: 500. [Abstract]  

V. Stearns, D. F. Hayes, L. Li, J. Robarge, T. Skaar, A. Nguyen, A. Schott, A. Storniolo, D. A. Flockhart, Y. Jin Consortium on Breast Cancer pharmacogenomics (COBRA)

Tamoxifen-induced hot flashes are associated with estrogen receptor polymorphisms
J Clin Oncol (Meeting Abstracts) 2007 25: 501. [Abstract]  

R. S. Punglia, E. P. Winer, J. C. Weeks, and H. J. Burstein

Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 502. [Abstract]  

D. Serrano, D. Macis, S. Gandini, H. Johansson, A. Guerrieri-Gonzaga, G. Mellgren, E. A. Lien, F. Mariett, M. Sandri, A. Decensi, and B. Bonanni

Correlation of low dose tamoxifen and its metabolites plasma level with Cyp 2D6, and SULT polymorphism; a pharmacogenetics study within a chemoprevention trial
J Clin Oncol (Meeting Abstracts) 2007 25: 503. [Abstract]  

M. Rizzo, N. Reisman, S. G. Gabram, H. L. Bumpers, J. Okoli, O. W. Brawley, and M. Lund

Differences in treatment in stage III breast cancer in African American women
J Clin Oncol (Meeting Abstracts) 2007 25: 504. [Abstract]  

L. Favier, A. Berriolo-Riedinger, B. Coudert, C. Touzery, J. Riedinger, M. Toubeau, L. Arnould, F. Brunotte, and P. Fumoleau

Predicative value of [18F]-FDG PET scan for pathological complete response to neoadjuvant chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 505. [Abstract]  

L. Dunnwald, J. Gralow, G. Ellis, R. Livingston, H. Linden, J. Specht, R. Doot, T. Lawton, W. Barlow, and D. Mankoff

Tumor metabolism, blood flow changes, and prognosis by positron emission tomography: A prospective cohort of locally advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 506. [Abstract]  

V. Russu, B. Lex, M. Popovich, K. Pfaffenberger, H. Volkholz, and A. Tulusan

MRI of the breast before and after primary systemic therapy correlates with histopathological tumor size in patients with locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2007 25: 507. [Abstract]  

M. P. Patel, S. Saha, S. Ali, D. Iddings, D. Wiese, H. Sankaran, M. Arora, T. Singh, T. Branigin, and K. Barber

Comparative analysis of bone marrow (BM) micrometastasis (M) with sentinel lymph node (SLN) status in early breast cancer (BRCa)
J Clin Oncol (Meeting Abstracts) 2007 25: 508. [Abstract]  

S. M. Swain, S. M. Steinberg, Z. Modrusan, V. Smith, F. de Sauvage, and S. X. Yang

Molecular pathways and gene ontology categories in association with response to combination chemotherapy plus bevacizumab in inflammatory and locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 509. [Abstract]  

D. G. Generali, A. Berruti, S. B. Fox, M. Brizzi, S. Bonardi, M. Milani, A. Bersiga, R. Dionisio, L. Dogliotti, A. Bottini, and A. L. Harris

Down-regulation of HIF-1 expression by letrozole in ER+ve breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 510. [Abstract]  

S. Paik, C. Kim, J. Jeong, C. E. Geyer, E. H. Romond, O. Mejia-Mejia, E. P. Mamounas, D. Wickerham, J. P. Costantino, and N. Wolmark

Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31
J Clin Oncol (Meeting Abstracts) 2007 25: 511. [Abstract]  

E. A. Perez, E. H. Romond, V. J. Suman, J. Jeong, N. E. Davidson, C. E. Geyer, S. Martino, E. P. Mamounas, P. A. Kauffman, N. Wolmark NCCTG/NSABP

Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 512. [Abstract]  

A. M. Storniolo, M. Koehler, A. Preston, E. Rappold, J. Byrne, and M. S. Ewer

Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA)
J Clin Oncol (Meeting Abstracts) 2007 25: 514. [Abstract]  

J. A. Sparano, M. Wang, S. Martino, V. Jones, E. Perez, T. Saphner, A. C. Wolff, G. W. Sledge, Jr, W. C. Wood, and N. E. Davidson

Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199
J Clin Oncol (Meeting Abstracts) 2007 25: 516. [Abstract]  

D. M. Loesch, F. Greco, J. O’Shaughnessy, J. D. Hainsworth, S. J. Vukelja, J. Sandbach, K. A. Boehm, D. Ilegbodu, L. Asmar, and N. J. Robert

A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 517. [Abstract]  

M. N. Ibrahim, Z. Abdullah, L. Healy, C. Murphy, I. Y. Yousif, and M. J. Martin

Comparison of survival rates in carcinoma in situ of the breast treated with total mastectomy to breast-conserving surgery and radiotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 519. [Abstract]  

I. Wapnir, J. Dignam, T. B. Julian, S. Land, E. P. Mamounas, S. Anderson, V. Fourchotte, J. Costantino, and N. Wolmark

Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24
J Clin Oncol (Meeting Abstracts) 2007 25: 520. [Abstract]  

A. S. Coates, H. Mouridsen, Z. Sun, M. Rabaglio, M. Castiglione-Gertsch, B. Thürlimann, L. Mauriac, K. N. Price, M. Colleoni, and I. Smith

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98
J Clin Oncol (Meeting Abstracts) 2007 25: 521. [Abstract]  

C. K. Anders, S. D. Hsu, C. R. Acharya, Y. Zhang, Y. Wang, J. A. Foekens, P. K. Marcom, J. R. Marks, J. Nevins, A. Potti, and K. L. Blackwell

Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status
J Clin Oncol (Meeting Abstracts) 2007 25: 522. [Abstract]  

M. Filipits, M. Rudas, M. Lehnert, E. Kubista, O. Dietze, R. Greil, S. Lax, H. Samonigg, R. Jakesz, M. Gnant G. Austrian Breast and Colorectal Cancer Study Group

Cyclin D1 expression in breast cancer patients and tamoxifen therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 523. [Abstract]  

M. F. Press, G. Sauter, M. Buyse, L. Bernstein, W. Eiermann, T. Pienkowski, V. Bee, H. Taupin, S. Seelig, and D. J. Slamon

Alteration of topoisomerase II-alpha gene in human breast cancer and its association with responsiveness to anthracycline- based chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 524. [Abstract]  

C. M. Dumontet, J. C. Reed, M. Krajewska, I. Treilleux, J. R. Mackey, M. Martin, C. Vogel, M. Rupin, E. Brunel, and J. Hugh

BCIRG 001 molecular analysis: Identification of prognostic factors in patients (pts) receiving adjuvant therapy for node- positive (N+) breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2007 25: 525. [Abstract]  

L. J. Goldstein, R. Gray, B. H. Childs, D. Watson, S. G. Rowley, S. Shak, S. Badve, N. E. Davidson, G. W. Sledge, Jr., and J. A. Sparano

Abstract Submission
J Clin Oncol (Meeting Abstracts) 2007 25: 526. [Abstract]  

A. Makris, C. Creighton, K. C. Osborne, S. Hilsenbeck, M. K. Harrison, P. J. Ostler, C. Spears, P. Brown, R. Elledge, and J. C. Chang

Predictive gene expression patterns of response to adriamycin and cyclophosphamide (AC) in human breast cancers
J Clin Oncol (Meeting Abstracts) 2007 25: 527. [Abstract]  

J. C. Chang, X. Li, H. Wong, C. Creighton, S. G. Hilsenbeck, C. K. Osborne, J. M. Rosen, and M. T. Lewis

Therapeutic resistance and tumor-initiation: Molecular pathways involved in breast cancer stem cell self-renewal
J Clin Oncol (Meeting Abstracts) 2007 25: 528. [Abstract]  

D. T. Ross, C. Kim, G. Tang, O. M. Mejia, R. A. Beck, B. Z. Ring, R. S. Seitz, S. Paik, J. P. Constantino, and N. Wolmark

Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 529. [Abstract]  

C. Mazouni, F. Peintinger, S. Wan-Kau, F. Andre, A. M. Gonzalez-Angulo, F. Symmans, F. Meric-Bernstam, V. Valero, G. Hortobagyi, and L. Pusztai

Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 530. [Abstract]  

J. K. Litton, A. M. Gonzalez, C. L. Warneke, S. Kau, A. U. Buzdar, M. Bondy, S. Mahabir, G. N. Hortobagyi, and A. Brewster

Body mass index and response to neoadjuvant chemotherapy in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 531. [Abstract]  

L. Gianni, V. Semiglazov, G. M. Manikhas, W. Eiermann, A. Lluch, S. Tjulandin, A. Feyereislova, B. Vanhauwere, P. Valagussa, and J. Baselga

Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 532. [Abstract]  

F. Peintinger, A. Buzdar, H. Kuerer, A. Gonzalez-Angulo, C. Hatzis, L. Pusztai, F. Esteva, M. Green, G. Hortobagyi, and W. Symmans

The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab
J Clin Oncol (Meeting Abstracts) 2007 25: 533. [Abstract]  

H. Earl, L. Hiller, J. A. Dunn, S. Bathers, R. J. Grieve, D. Spooner, R. K. Agrawal, L. Foster, C. Twelves, C. J. Poole NEAT and SCTBG Investigators

The National Epirubicin Adjuvant Trial (NEAT) and Scottish Cancer Trials Breast Group (SCTBG) br9601 randomized phase III adjuvant early breast cancer trials: The updated definitive joint analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 534. [Abstract]  

A. Moliterni, M. Mansutti, D. Aldrighetti, L. Merlini, L. Zuccarino, M. Bari, A. Farris, P. Mariani, S. Fava, and L. Gianni

Anthracycline-based sequential adjuvant chemotherapy in operable breast cancer: Five-year results of a randomized study by the Michelangelo Foundation
J Clin Oncol (Meeting Abstracts) 2007 25: 535. [Abstract]  

J. J. Dignam, V. M. Dukic, S. J. Anderson, E. P. Mamounas, J. H. Jeong, and J. P. Costantino

Time-dependent patterns of recurrence after early stage breast cancer: Preliminary observations and methodological issues
J Clin Oncol (Meeting Abstracts) 2007 25: 536. [Abstract]  

F. Andre, K. Broglio, H. Roche, M. Martin, F. Penault-Lorca, G. N. Hortobagyi, D. A. Berry, and L. Pusztai

Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials
J Clin Oncol (Meeting Abstracts) 2007 25: 537. [Abstract]  

B. B. Rasmussen, M. M. Regan, A. E. Lykkesfeldt, P. Dell’Orto, B. Del Curto, K. L. Henriksen, M. G. Mastropasqua, B. Thürlimann, and G. Viale

Central assessment of ER, PgR and HER2 in BIG 1–98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 538. [Abstract]  

M. Ciccarese, E. Bria, F. Cuppone, C. Nisticò, P. Carlini, I. Sperduti, V. Lorusso, E. Terzoli, F. Cognetti, and D. Giannarelli

Disease-free survival (DFS) as surrogate end point for overall survival (OS) in adjuvant aromatase inhibitors (AIs) trials for breast cancer (BC): Meta-analysis of 10 randomized clinical trials (RCTs) exploring the magnitude of the benefit
J Clin Oncol (Meeting Abstracts) 2007 25: 539. [Abstract]  

J. Chapman, D. Meng, L. Shepherd, W. Parulekar, J. N. Ingle, H. B. Muss, M. Palmer, C. Yu, and P. E. Goss

Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 540. [Abstract]  

J. Cuzick, P. Sasieni, and A. Howell

Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?
J Clin Oncol (Meeting Abstracts) 2007 25: 541. [Abstract]  

G. Von Minckwitz, S. Kümmel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, S. Loibl for the German Breast Group

Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from 278 patients with cT4a-d tumors of the GeparTRIO trial
J Clin Oncol (Meeting Abstracts) 2007 25: 542. [Abstract]  

F. Cuppone, E. Bria, D. Giannarelli, C. Nisticò, I. Sperduti, P. Carlini, M. Milella, M. Ciccarese, F. Cognetti, and E. Terzoli

Meta-analysis of adjuvant trastuzumab for early breast cancer: Cardiotoxicity and brain metastases incidence
J Clin Oncol (Meeting Abstracts) 2007 25: 543. [Abstract]  

H. R. Bonnefoi, A. Potti, M. Piccart, L. Mauriac, M. Tubiana-Hulin, D. Cameron, J. Bergh, M. Delorenzi, J. R. Nevins, and R. Iggo

Clinical validation of in vitro drug sensitivity microarray data: Regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00–01)
J Clin Oncol (Meeting Abstracts) 2007 25: 544. [Abstract]  

A. K. Nowak, T. Ferguson, N. R. Wilcken, and D. Ghersi

A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer (EBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 545. [Abstract]  

G. A. Beinart, A. M. Gonzalez-Angulo, K. Broglio, J. Mejia, A. Ruggeri, E. Mininberg, G. N. Hortobagyi, and V. Valero

Clinical course of 771 patients with bilateral breast cancer (BBC): Characteristics associated with overall and recurrence-free survival
J Clin Oncol (Meeting Abstracts) 2007 25: 546. [Abstract]  

V. H. Bramwell, K. I. Pritchard, D. Tu, K. Tonkin, H. Vachhrajani, J. Robert, A. Arnold, T. Vandenberg, B. Graham, and L. Shepherd

Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG MA.12
J Clin Oncol (Meeting Abstracts) 2007 25: 547. [Abstract]  

L. Pusztai, F. Andre, C. Mazouni, C. Liedtke, S. Kau, D. Frye, M. Green, A. M. Gonzalez-Angulo, W. F. Symmans, and G. N. Hortobagyi

HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 548. [Abstract]  

A. M. Gianni, G. Bonadonna, G. Michelangelo Cooperative Group

Updated 12-year results of a randomized clinical trial comparing standard-dose to high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than three positive nodes (LN+)
J Clin Oncol (Meeting Abstracts) 2007 25: 549. [Abstract]  

M. J. Burnell, IV, M. N. Levine, J. A. Chapman, V. Bramwell, T. Vandenberg, H. I. Chalchal, K. Albain, E. Perez, H. Rugo, and K. Pritchard

A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)
J Clin Oncol (Meeting Abstracts) 2007 25: 550. [Abstract]  

T. Watanabe, M. Sano, S. Takashima, T. Kitaya, Y. Tokuda, M. Yoshimoto, N. Kono, K. Nakagami, H. Iwata, and Y. Ohashi

Oral uracil-tegafur (UFT) compared to classical cyclophosphamide/methotrexate/5-fluorouracil (CMF) as postoperative chemotherapy in patients with node-negative, high-risk breast cancer (BC): Results of the national surgical adjuvant study for breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 551. [Abstract]  

R. R. Love, N. V. Dinh, T. T. Quy, N. D. Linh, E. M. Hade, G. S. Young, and D. Jarjoura

Survival with adjuvant surgical oophorectomy and tamoxifen in premenopausal women with operable breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 552. [Abstract]  

J. E. Lester, S. A. Gutcher, S. P. Ellis, R. Thorpe, J. M. Horsman, J. E. Brown, O. P. Purohit, D. Dodwell, and R. E. Coleman

Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study
J Clin Oncol (Meeting Abstracts) 2007 25: 553. [Abstract]  

N. Denduluri, A. W. Berman, U. Vatas, C. K. Chow, D. R. Rosing, and S. M. Swain

Cardiotoxicity after doxorubicin and AZD2171, an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, in patients (pts) with breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 554. [Abstract]  

J. A. Ligibel, N. Campbell, H. Chen, T. Salinardi, W. Chen, A. Partridge, C. Mantzoros, and E. Winer

Impact of physical activity on insulin levels in breast cancer survivors
J Clin Oncol (Meeting Abstracts) 2007 25: 555. [Abstract]  

S. Kaura, J. Karnon, and F. di Trapani

International comparison of the cost-effectiveness of 5 years letrozole or anastrozole compared to 5 years tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Belgium, Canada, UK, and US analyses
J Clin Oncol (Meeting Abstracts) 2007 25: 556. [Abstract]  

J. Karnon, F. di Trapani, and S. Kaura

Comparison of the cost per distant disease-free year gained for upfront letrozole or anastrozole, or switched exemestane compared to tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: The UK perspective
J Clin Oncol (Meeting Abstracts) 2007 25: 557. [Abstract]  

Q. J. Khan, A. P. O’Dea, R. Dusing, P. Sharma, S. M. Roling, C. J. Fabian, and B. F. Kimler

Integrated FDG-PET/CT for initial staging of breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 558. [Abstract]  

H. L. Sommer, J. K. Jueckstock, E. Genss, K. Annecke, B. Rack, D. Steinfeld-Birg, N. Harbeck, M. Kiechle-Bahat, W. J. Janni, and K. Friese

Influence of sequencing of chemotherapy and radiotherapy regarding adverse effects of the cytostatic treatment: Results of the ADEBAR trial
J Clin Oncol (Meeting Abstracts) 2007 25: 559. [Abstract]  

E. McCloskey, R. Hannon, G. Lakner, G. Clack, A. Miyamoto, and R. Eastell

Interaction between body mass index and bone turnover during aromatase inhibition: Evidence from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial
J Clin Oncol (Meeting Abstracts) 2007 25: 560. [Abstract]  

E. L. Mayer, K. D. Miller, H. S. Rugo, J. M. Peppercorn, L. A. Carey, N. Ryabin, E. P. Winer, and H. J. Burstein

A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 561. [Abstract]  

J. Houghton on behalf of the ATAC Trialists’ Group

A detailed analysis of the risk factors influencing local and distant breast cancer recurrence during adjuvant endocrine therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 562. [Abstract]  

O. Gluz, R. Kates, M. Schmitt, K. Mengele, H. Royer, S. Mohrmann, E. Ting, R. Diallo-Danebrock, M. Kiechle-Bahat, U. Nitz, and N. Harbeck

YB-1 expression and effectiveness of different dose-intensification strategies in high-risk breast cancer: Five-year follow-up results of prospective randomized WSG-AM-01 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 563. [Abstract]  

K. Ziegler, M. Warm, C. Oberhoff, T. Reimer, S. Mohrmann, C. Schumacher, O. Gluz, U. Nitz, I. Zuna, and F. Werner

Second interims analysis of the ARA Plus study: Breast Cancer (BC) adjuvant chemotherapy (CT) with and without darbepoetin- alpha, analysis of serious adverse events
J Clin Oncol (Meeting Abstracts) 2007 25: 564. [Abstract]  

J. K. Jueckstock, B. Rack, E. Thurner-Hermanns, H. Forstbauer, K. Pantel, H. Ulmer, M. Beckmann, W. Lichtenegger, W. J. Janni, and K. Friese

Detection of minimal residual disease (MRD) in peripheral blood of primary breast cancer patients: Translational research in the SUCCESS study
J Clin Oncol (Meeting Abstracts) 2007 25: 565. [Abstract]  

C. M. Schilder, P. C. Eggens, W. Boogerd, F. S. van Dam, and S. B. Schagen

Neuropsychological sequelae of tamoxifen and exemestane after AC-chemotherapy in postmenopausal women with early breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 566. [Abstract]  

M. N. Dickler, T. Traina, K. Panageas, R. Steingart, C. Dang, M. Fornier, S. Sugarman, L. Norton, C. Hudis, and H. Rugo

Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety
J Clin Oncol (Meeting Abstracts) 2007 25: 567. [Abstract]  

H. Stemmler, D. Laessig, P. Stieber, I. Bauerfeind, P. Fasching, M. Glattes, U. Goldmann-Posch, V. Hoffmann, M. Untch, and V. Heinemann

Follow-up for breast cancer: Results of a patients survey
J Clin Oncol (Meeting Abstracts) 2007 25: 568. [Abstract]  

V. Moebus, H. Lueck, C. Thomssen, N. Harbeck, U. Nitz, R. Kreienberg, C. Jackisch, A. Schneeweiss, J. Huober, A. du Bois, and M. Untch

The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial)
J Clin Oncol (Meeting Abstracts) 2007 25: 569. [Abstract]  

M. J. Ellis, Y. Tao, A. S. Bhatnagar, H. Chaudri Ross, D. Evans, W. R. Miller, and W. Eiermann

Cell-cycle complete response after neoadjuvant letrozole predicts superior relapse-free and overall survival: Long-term follow- up of the letrozole P024 study
J Clin Oncol (Meeting Abstracts) 2007 25: 570. [Abstract]  

D. L. Ellsworth, R. E. Ellsworth, T. E. Becker, B. Deyarmin, H. L. Patney, J. A. Hooke, and C. D. Shriver

Genomic heritage of sentinel lymph node metastases: Implications for clinical management of breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 571. [Abstract]  

D. G. Kieback, N. Harbeck, W. Bauer, P. Hadji, G. Weyer, and A. Hasenburg

Endometrial effects of exemestane compared to tamoxifen within the TEAM trial: Results of a prospective randomized study
J Clin Oncol (Meeting Abstracts) 2007 25: 572. [Abstract]  

R. L. Jones, J. Salter, A. Nerurkar, M. Parton, R. A’Hern, I. E. Smith, and M. Dowsett

Prognostic (Px) significance of Ki67 before and after neoadjuvant chemotherapy (CT) in early breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 573. [Abstract]  

A. Sun, T. Yu, L. Wang, J. Lu, G. Gonzales, L. Pusztai, S. Singletary, M. I. Ross, Q. Wei, and T. A. Buchholz

Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 574. [Abstract]  

D. A. Mankoff, L. Dunnwald, J. Gralow, G. Ellis, H. Linden, J. Specht, R. Doot, W. Barlow, E. Schubert, and R. Livingston

Use of changes in blood flow PET measurements to predict post-therapy lymph node status among locally advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 575. [Abstract]  

A. H. Kamal, C. L. Loprinzi, C. Reynolds, A. C. Dueck, X. J. Geiger, J. N. Ingle, R. W. Carlson, T. J. Hobday, E. P. Winer, E. A. Perez, and M. P. Goetz

How well do standard prognostic criteria predict oncotype DX (ODX) scores?
J Clin Oncol (Meeting Abstracts) 2007 25: 576. [Abstract]  

S. S. Lo, J. Norton, P. B. Mumby, J. Smerage, J. Kash, H. K. Chew, D. Hayes, A. Epstein, and K. S. Albain

Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection
J Clin Oncol (Meeting Abstracts) 2007 25: 577. [Abstract]  

E. Rossi, G. Esposito, F. Di Rella, A. Gravina, G. Landi, F. Nuzzo, C. Pacilio, K. Monaco, M. Piccirillo, A. de Matteis The NCI Naples Breast Cancer Group

Endocrine effects of letrozole + triptoreline compared to tamoxifen + triptoreline as adjuvant treatment of premenopausal patients with early breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 578. [Abstract]  

L. A. Kutteh, T. Hobday, A. Jaffe, B. LaPlant, D. Hillman, P. Kaufman, N. Davidson, S. Martino, A. Moreno, E. Perez North Central Cancer Treatment Group

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 579. [Abstract]  

T. Petit, M. Wilt, J. Rodier, D. Muller, J. Ghnassia, P. Dufour, and J. Fricker

Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers?
J Clin Oncol (Meeting Abstracts) 2007 25: 580. [Abstract]  

R. C. Ng, G. R. Pond, P. A. Tang, P. W. MacIntosh, L. L. Siu, and E. X. Chen

Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966–2006
J Clin Oncol (Meeting Abstracts) 2007 25: 581. [Abstract]  

D. N. Church, M. Flubacher, A. Cameron, A. Bahl, and J. Braybrooke

Toxicity of concurrent radiotherapy with CMF chemotherapy in the E-CMF adjuvant breast carcinoma regimen
J Clin Oncol (Meeting Abstracts) 2007 25: 582. [Abstract]  

M. Melisko, A. Lin, and H. Rugo

Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS)
J Clin Oncol (Meeting Abstracts) 2007 25: 583. [Abstract]  

D. Giannarelli, E. Bria, F. Cuppone, M. Ciccarese, C. Nisticò, P. Carlini, M. Milella, V. Lorusso, E. Terzoli, and F. Cognetti

Three-year disease-free survival (DFS) as surrogate end-point for predicting five-year overall survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC): Analysis of 10 randomized clinical trials (RCTs)
J Clin Oncol (Meeting Abstracts) 2007 25: 584. [Abstract]  

J. W. Janni, H. Sommer, B. Rack, D. Augustin, W. Simon, D. Steinfeld, K. Annecke, N. Harbeck, K. Friese, and M. Kiechle-Bahat

The ADEBAR trial: Final toxicity analysis of a phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement
J Clin Oncol (Meeting Abstracts) 2007 25: 585. [Abstract]  

N. T. Ueno, S. Kim, W. F. Symmans, M. A. Detry, L. Pusztai, L. F. Sanchez, H. Ishihara, G. N. Hortobagyi, and S. Noguchi

Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes
J Clin Oncol (Meeting Abstracts) 2007 25: 586. [Abstract]  

C. Perou, C. Moisa, S. Gulick, and D. Tripathy

Expression profiles can predict specific responses of capecitabine/docetaxel (C/D) based primary systemic therapy in breast cancer (BC) patients receiving neoadjuvant therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 587. [Abstract]  

S. C. Partridge, P. R. Eby, R. K. Doot, S. W. White, B. F. Kurland, E. K. Schubert, L. K. Dunnwald, C. D. Lehman, and D. A. Mankoff

Comparison of vascularity measures from PET and MRI for improved breast tumor characterization and therapeutic response evaluation
J Clin Oncol (Meeting Abstracts) 2007 25: 589. [Abstract]  

S. Gonzalez-Santiago, R. Zárate, J. Haba-Rodríguez, A. Gómez, E. Bandrés, S. Moreno, P. Borrega, J. García-Foncillas, and E. Aranda

CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen
J Clin Oncol (Meeting Abstracts) 2007 25: 590. [Abstract]  

R. S. Mehta, T. Schubbert, K. Kong, D. Hsiang, J. Butler, and C. Baick

Pathologic complete response (pCR) following weekly (wkly) paclitaxel (cremophor or albumin-bound) and carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in patients (pts) with doxorubicin/cyclophosphamide-resistant (AC-Res) and AC-sensitive (AC-S) large and inflammatory breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 591. [Abstract]  

P. Carlini, E. Bria, F. Cuppone, P. Papaldo, C. Nisticò, A. Fabi, E. M. Ruggeri, E. Terzoli, F. Cognetti, and D. Giannarelli

Adjuvant LH-RH agonists for premenopausal early breast cancer: A meta-analysis of randomized clinical trials (RCTs) exploring the magnitude of the disease-free and overall survival (DFS/OS) benefit
J Clin Oncol (Meeting Abstracts) 2007 25: 592. [Abstract]  

K. Corbin, C. G. Shields, M. Weiss, J. J. Griggs, and D. R. Lambert

Factors associated with concerns about recurrence in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 593. [Abstract]  

H. J. Burstein, E. L. Mayer, J. Peppercorn, L. M. Parker, K. Hannagan, B. Moy, J. Younger, L. Schapira, G. Wulf, R. Gelman, and E. P. Winer

Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study
J Clin Oncol (Meeting Abstracts) 2007 25: 594. [Abstract]  

A. Sanchez, R. Dueñas-García, A. Jaén-Morago, I. Chacón, A. García-Tapiador, E. Martínez-Ortega, C. de la Torre-Cabrera, B. Dueñas, N. Ribelles, and P. Sánchez-Rovira

Neoadjuvant chemotherapy with a dose-dense sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer. Correlation between pathologic complete response (pCR) and biologic markers
J Clin Oncol (Meeting Abstracts) 2007 25: 595. [Abstract]  

P. P. Gor, R. J. Gray, M. Horn, T. R. Rebbeck, P. A. Gimotty, R. Aplenc, M. Pins, M. S. Tallman, and A. DeMichele

Association of polymorphic drug metabolizing enzymes (DME) with outcomes in breast cancer patients treated on the ECOG 2190/Intergroup 0121 (E2190/Int0121) study
J Clin Oncol (Meeting Abstracts) 2007 25: 596. [Abstract]  

M. R. Kell, C. Dunne, C. Canning, and M. Morrow

The effect of margin status on local recurrence following breast conservation and radiation therapy for DCIS
J Clin Oncol (Meeting Abstracts) 2007 25: 597. [Abstract]  

J. E. Lang, R. Rao, L. Feng, F. Meric-Bernstam, I. Bedrosian, H. M. Kuerer, S. E. Singletary, K. K. Hunt, G. N. Hortobagyi, and G. V. Babiera

Impact on overall survival of primary tumor extirpation in breast cancer patients who present with stage IV disease
J Clin Oncol (Meeting Abstracts) 2007 25: 598. [Abstract]  

S. B. Edge, A. Stewart, L. Patel-Parekh, G. Gay, B. Palis, and C. Ko

Measuring the quality of breast cancer care: National variation in the use of radiation among women under age 70
J Clin Oncol (Meeting Abstracts) 2007 25: 599. [Abstract]  

W. T. Yang, H. T. Le-Petross, A. Gonzalez-Angulo, H. Macapinlac, H. Macapinlac, S. Dawood, E. Resetkova, G. N. Hortobagyi, and M. Cristofanilli

Functional (PET/CT) compared to conventional (mammography [M], sonography [US], MRI) imaging: Defining novel assessment modalities for inflammatory breast cancer (IBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 600. [Abstract]  

M. Ibusuki, Y. Yamamoto, T. Kawasoe, K. Kai, S. Shiraishi, S. Tomiguchi, and H. Iwase

Potential advantage of studying preoperative sentinel node mapping with three-dimensional images by a hybrid single photon emission CT (SPECT)/CT system for breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 601. [Abstract]  

J. A. Lopez-Guerrero, Z. Garcia-Casado, A. L. Guerrero-Zotano, A. Calatrava, A. Ruiz-Sauri, A. Fernandez-Serra, A. Ruiz, A. Llombart-Bosch, V. Guillem-Porta, and A. Llombart-Cussac

Corroboration of polymorphisms in the aromatase (CYP19A1) gene with response to neoadjuvant therapy with letrozole in postmenopausal women with stages II-II ER/PgR-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 602. [Abstract]  

L. Vallow, S. Packianathan, D. Feigel, E. DePeri, S. Buskirk, and E. A. Perez

Analysis of magnetic resonance imaging (MRI) in the detection of mammographically occult breast carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 603. [Abstract]  

C. Lehman, C. Gatsonis, C. Kuhl, E. Hendrick, E. Pisano, L. Hanna, S. Peacock, S. Smazal, D. Maki, M. Schnall American College of Radiology Imaging Network Trial 6667 Investigators Group

Factors influencing performance of MRI in newly diagnosed breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 604. [Abstract]  

M. Morrow, A. S. Hamilton, and S. J. Katz

Why do women get mastectomy? Results from a population-based study
J Clin Oncol (Meeting Abstracts) 2007 25: 605. [Abstract]  

S. Imoto, M. Kitajima, T. Aikou, and Y. Kitagawa

Multi-center prospective study on sentinel node navigation surgery in early breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 606. [Abstract]  

U. S. Kraus-Tiefenbacher, C. Herskind, L. Bauer, A. Scheda, and F. Wenz

Intraoperative radiotherapy (IORT) with low-energy x-rays for breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 607. [Abstract]  

J. Yu, E. Morris, A. Park, H. Cody, III, and M. L. Gemignani

Efficacy of breast MRI in elderly women
J Clin Oncol (Meeting Abstracts) 2007 25: 608. [Abstract]  

I. Langer, U. Guller, S. Hsu Schmitz, A. Ladewig, C. T. Viehl, H. Moch, E. Wight, F. Harder, D. Oertli, and M. Zuber

Sentinel lymph node biopsy is associated with a significantly improved survival compared to level Iand II axillary lymph node dissection in node-negative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 609. [Abstract]  

K. Hisamatsu

3-D MRI guided breast conserving surgery
J Clin Oncol (Meeting Abstracts) 2007 25: 610. [Abstract]  

H. C. Moore, R. Wesolowski, T. K. Choueiri, L. Rybicki, A. G. Shealy, G. Casey, and D. Weng

Therapeutic radiation for breast cancer in BRCA mutation carriers and contralateral breast cancer (CBC) risk
J Clin Oncol (Meeting Abstracts) 2007 25: 611. [Abstract]  

B. A. Pockaj, A. Dueck, K. Tenner, and E. Perez

Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapic trial
J Clin Oncol (Meeting Abstracts) 2007 25: 612. [Abstract]  

M. W. Braun, M. Pölcher, S. Schrading, O. Zivanovic, T. Kowalski, U. Flucke, C. Leutner, T. Park - Simon, C. Rudlowski, W. Kuhn, and C. K. Christiane Kuhl

Influence of preoperative MRI on the surgical management of patients with operable breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 613. [Abstract]  

J. R. Bernard, Jr., L. A. Vallow, S. Packianathan, D. G. Feigel, E. R. DePeri, S. J. Buskirk, and E. A. Perez

Identification of risk factors in mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging (MRI)
J Clin Oncol (Meeting Abstracts) 2007 25: 614. [Abstract]  

N. Tagaya

Intraoperative identification of sentinel lymph node guided by near-infrared fluorescence imaging for breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 615. [Abstract]  

B. Song, J. Bae, J. Kim, H. Jeon, and S. Jung

Comparing study of positron emission tomography and ultrasonography in the detection of axillary lymph node metastasis in patients with early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 616. [Abstract]  

Breast CancerMetastatic:

S. S. Dawood, K. Broglio, G. Hortobagyi, and S. Giordano

Trends in survival of stage IV breast cancer (BC) among Caucasian and African American (AA) BC patients (pts)
J Clin Oncol (Meeting Abstracts) 2007 25: 1000. [Abstract]  

C. Panabières, J. Vendrell, O. Pellé, X. Rebillard, S. Riethdorf, V. Müller, M. Fabbro, and K. Pantel

Identification of biologically active cancer cells in blood and bone marrow of cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 1001. [Abstract]  

J. M. Reuben, B. N. Lee, C. Li, K. R. Broglio, V. Valero, S. Jackson, N. T. Ueno, S. Krishnamurthy, G. N. Hortobagyi, and M. Cristofanilli

Genomic of circulating tumor cells in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1002. [Abstract]  

H. S. Rugo, A. Stopeck, A. A. Joy, S. Chan, S. Verma, A. Lluch, K. F. Liau, S. Kim, P. Bycott, and D. Soulieres

A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1003. [Abstract]  

J. Baselga, D. Cameron, D. Miles, S. Verma, M. Climent, G. Ross, V. Gimenez, and K. Gelmon

Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T
J Clin Oncol (Meeting Abstracts) 2007 25: 1004. [Abstract]  

L. T. Vahdat, E. Thomas, R. Li, J. Jassem, H. Gomez, H. Chung, R. Peck, P. Mukhopadhyay, J. Klimovsky, and H. Roché

Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes
J Clin Oncol (Meeting Abstracts) 2007 25: 1006. [Abstract]  

E. Alba, M. Ruiz-Borrego, M. Martín, M. Margelí, Á. Rodríguez-Lescure, P. Sánchez-Rovira, A. Ruiz, N. Ribelles, E. Calvo, and A. Casado

Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001–01 study
J Clin Oncol (Meeting Abstracts) 2007 25: 1007. [Abstract]  

P. A. Kaufman, G. Broadwater, K. Lezon-Geyda, L. G. Dressler, D. Berry, P. Friedman, E. P. Winer, C. Hudis, M. J. Ellis, A. D. Seidman, and L. N. Harris

CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1009. [Abstract]  

A. Goncalves, M. Deblock, B. Esterni, Y. Toiron, C. Tarpin, E. Charaffe-Jauffret, C. Chabannon, J. M. Extra, P. Viens, and J. P. Borg

Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment
J Clin Oncol (Meeting Abstracts) 2007 25: 1010. [Abstract]  

A. Di Leo, H. Gomez, Z. Aziz, Z. Zvirbule, M. Arbushites, C. R. Oliva, M. Koehler, L. S. Williams, J. Dering, and R. S. Finn

Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients
J Clin Oncol (Meeting Abstracts) 2007 25: 1011. [Abstract]  

N. U. Lin, V. Dieras, D. Paul, D. Lossignol, C. Christodoulou, D. Laessig, H. Roché, D. Zembryki, C. R. Oliva, E. P. Winer EGF105084 Study Group

EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)
J Clin Oncol (Meeting Abstracts) 2007 25: 1012. [Abstract]  

G. Sledge, K. Miller, C. Moisa, and W. Gradishar

Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1013. [Abstract]  

Z. I. Tomasevic, D. Jovanovic, L. Radosevic Jelic, Z. M. Tomasevic, S. Vasovic, L. Stamatovic, S. Jelic, and J. Spasic

Absence of brain metastases in late relapse of HER2-overexpressed breast carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 1014. [Abstract]  

A. Niwinska, M. Tacikowska, I. Lemanska, T. Pienkowski, and M. Murawska

Effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival
J Clin Oncol (Meeting Abstracts) 2007 25: 1015. [Abstract]  

S. M. Sawrie, II, R. F. Meredith, S. A. Spencer, J. M. Markert, and J. B. Fiveash

HER2-neu status as a predictor of survival in patients with brain metastases from primary breast adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 1016. [Abstract]  

S. Verma, J. S. Azzi, L. A. Vandermeer, and J. N. Spaans

Central nervous system (CNS) metastases (mets) in HER2+ metastatic breast cancer (MBC) patients (pts): Patterns of relapse and impact on survival
J Clin Oncol (Meeting Abstracts) 2007 25: 1017. [Abstract]  

M. C. Pinder, H. Chang, K. R. Broglio, L. B. Michaud, R. L. Theriault, A. Sahin, T. Buchholz, G. N. Hortobagyi, and F. J. Esteva

Trastuzumab treatment and the risk of central nervous system (CNS) metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 1018. [Abstract]  

Y. Tham, C. Creighton, C. Gutierrez, C. K. Osborne, P. Brown, and J. C. Chang

A gene expression signature of eventual brain metastases in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1019. [Abstract]  

V. Valero, H. Roche, T. Pienkowski, J. Canon, Y. Zhao, W. Carney, J. Mackey, H. Taupin, M. Buyse, and D. Slamon

BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1020. [Abstract]  

N. Fersis, D. Koliogiannis, L. Sisic, B. Schlehe, M. J. Battista, C. Sohn, and S. Kaul

Quantitative multimarker analysis in circulating tumor cells of patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1021. [Abstract]  

D. Marrinucci, K. Bethel, N. Lazarus, M. Leach, J. Kroener, R. Bruce, P. Kuhn, and J. Nieva

Detecting circulating tumor cells in metastatic breast cancer patients using fiber-optic array scanning technology
J Clin Oncol (Meeting Abstracts) 2007 25: 1022. [Abstract]  

U. Wilking, L. Skoog, G. Elmberger, N. Wilking, and J. Bergh

HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients
J Clin Oncol (Meeting Abstracts) 2007 25: 1023. [Abstract]  

R. J. Broom, P. Tang, C. Simmons, L. Bordeleau, F. P. O’Malley, N. Miller, I. L. Andrulis, D. M. Brenner, and M. Clemons

Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples
J Clin Oncol (Meeting Abstracts) 2007 25: 1024. [Abstract]  

M. Toi, J. Sperinde, W. Huang, S. Saji, S. Ohno, S. Nakamura, H. Iwata, N. Masuda, K. Aogi, and M. Bates

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1025. [Abstract]  

B. Sherrill, A. Allshouse, M. Amonkar, and S. Stein

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1026. [Abstract]  

J. P. Crown, H. A. Burris, III, S. Jones, K. M. Koch, A. Fittipaldo, R. Parikh, and M. Koehler

Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1027. [Abstract]  

C. C. Portera, J. M. Walshe, N. Denduluri, A. W. Berman, U. Vatas, D. R. Rosing, C. K. Chow, and S. M. Swain

A report of cardiac events in a phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1028. [Abstract]  

M. Ryberg, D. L. Nielsen, G. Cortese, G. Nielsen, P. K. Andersen, and T. Skovsgaard

Epirubicin (E) cardiac toxicity: A retrospective analysis of 1,097 patients (pts) treated for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1029. [Abstract]  

R. W. Carlson, C. M. Schurman, E. Rivera, C. T. Chung, S. C. Phan, E. K. Dice, E. Thomas, and V. Valero

Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1030. [Abstract]  

M. Stockler, T. Sourjina, P. Grimison, V. Gebski, M. Byrne, V. Harvey, P. Francis, A. K. Nowak, G. Van Hazel, J. Forbes ANZ Breast Cancer Trials Group

A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1031. [Abstract]  

W. Gradishar, D. Krasnojon, S. Cheporov, A. Makhson, G. Manikhas, A. Clawson, and M. J. Hawkins

Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1032. [Abstract]  

S. L. Moulder, A. O’Neill, C. Arteaga, M. Pins, J. Sparano, G. Sledge, N. Davidson G. Eastern Cooperative Oncology Group

Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1033. [Abstract]  

J. L. Blum, B. Pruitt, C. J. Fabian, R. R. Rivera, D. E. Shuster, N. L. Meneses, K. Chandrawansa, F. Fang, S. Z. Fields, and L. Vahdat

Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1034. [Abstract]  

C. E. Geyer, A. Martin, B. Newstat, M. A. Casey, M. S. Berger, C. R. Oliva, S. D. Rubin, S. Stein, and D. Cameron

Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data
J Clin Oncol (Meeting Abstracts) 2007 25: 1035. [Abstract]  

M. Wang, W. J. Gradishar, J. A. Sparano, E. A. Perez, and G. Sledge

A phase II trial of capecitabine (C) in combination with the farnesyltransferase (FT) inhibitor (FTI), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103
J Clin Oncol (Meeting Abstracts) 2007 25: 1036. [Abstract]  

T. Li, P. Christos, J. A. Sparano, D. L. Hershman, K. O’Brien, S. Hoschander, J. Wright, and L. T. Vahdat

Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer: New York Cancer Consortium Trial P6205
J Clin Oncol (Meeting Abstracts) 2007 25: 1037. [Abstract]  

Z. Guan, F. Feng, Q. L. Li, Z. Jiang, Z. Shen, S. Yu, J. Feng, J. Huang, Z. Yao, and M. J. Hawkins

Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1038. [Abstract]  

R. Adam, R. Salmon, D. Elias, M. Rivoire, D. Cherqui, D. Jaeck, J. Gigot, P. Le Treut, G. Mantion, J. Belghiti Association Française de Chirurgie

Breast cancer liver metastases (BCLM): What may be the role of surgery combined with chemotherapy?
J Clin Oncol (Meeting Abstracts) 2007 25: 1039. [Abstract]  

Z. Neskovic-Konstantinovic, M. Nooij, H. Khaled, B. De Valk, J. Vermorken, M. Welnicka-Jaskiewicz, M. Piccart, S. Marreaud, J. Bogaerts, and D. Cameron

Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995
J Clin Oncol (Meeting Abstracts) 2007 25: 1040. [Abstract]  

E. Seeley, R. E. Ellsworth, D. Ellsworth, M. Sanders, J. A. Hooke, R. Caprioli, and C. D. Shriver

Identification of proteins promoting development of metastatic breast tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 1041. [Abstract]  

M. Beeram, I. Krop, S. Modi, A. Tolcher, N. Rabbee, S. Girish, J. Tibbitts, S. Holden, S. Lutzker, and H. Burris

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1042. [Abstract]  

N. W. Peacock, D. R. Spigel, M. G. Mainwaring, D. S. Thompson, L. Simons, M. S. Rubin, M. McCleod, W. N. Harwin, F. J. Schreiber, and D. A. Yardley

Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1043. [Abstract]  

C. Simmons, G. Dranitsaris, M. Clemons, B. Y. Wong, R. Veith, and D. E. Cole

Alterations in calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer (MBC): A potential therapeutic target?
J Clin Oncol (Meeting Abstracts) 2007 25: 1044. [Abstract]  

M. Theodoulou, T. A. Traina, U. Dugan, D. Lake, M. Fornier, K. Feigin, S. Patil, C. Edwards, L. Norton, and C. A. Hudis

Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling
J Clin Oncol (Meeting Abstracts) 2007 25: 1045. [Abstract]  

R. V. Boccia, L. Vaughn, H. Zeigler, Y. Wang, J. Gill, A. Melemed, and O. Shonukan

Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1046. [Abstract]  

M. Blasinska-Morawiec, M. Martin, F. Salas, S. Falcon, J. Rolski, B. L. Ferrari, N. Guedez, L. Simms, S. Gulyas, and A. Melemed

A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1047. [Abstract]  

V. Roy, B. R. LaPlant, G. G. Gross, C. L. Bane, F. M. Palmieri, E. A. Perez G. North Central Cancer Treatment Group

NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1048. [Abstract]  

T. A. Traina, B. Higgins, M. Theodoulou, U. Dugan, K. Kolinsky, Y. Zhang, D. Heimbrook, K. Packman, C. Hudis, and L. Norton

Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model
J Clin Oncol (Meeting Abstracts) 2007 25: 1049. [Abstract]  

S. A. Massarweh, Y. L. Tham, H. Weiss, S. Fuqua, J. Huang, and R. Elledge

A phase II study of anastrazole and fulvestrant in combination with gefitinib in patients with newly diagnosed ER-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1050. [Abstract]  

E. M. Ciruelos, J. Baselga, H. Cortes-Funes, A. Lluch, J. I. Mayordomo, B. Ojeda, E. Gonzalez, M. Muñoz, C. Rodriguez, and J. Cortes

Multicentric phase II trial of gemcitabine plus capecitabine combination in the treatment of previously anthracycline(An)-treated metastatic breast cancer (MBC): SOLTI 0301 study
J Clin Oncol (Meeting Abstracts) 2007 25: 1051. [Abstract]  

A. Chan, V. Ganju, D. Becquart, P. Conte, L. Petruzelka, D. Aubert, G. Villanova, and N. Tubiana-Mathieu

Efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC): First results of an international phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1052. [Abstract]  

B. G. Somer, L. S. Schwartzberg, F. Arena, A. Epperson, D. Fu, and B. V. Fortner

Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1053. [Abstract]  

S. Mahner, S. Schirrmacher, V. Müller, C. Habermann, W. Brenner, and J. Dose Schwarz

Detection of distant metastases in breast cancer patients: Comparison between [18F]-fluorodeoxyglucose positron emission tomography and conventional imaging
J Clin Oncol (Meeting Abstracts) 2007 25: 1054. [Abstract]  

R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, G. J. Locker, M. Rudas, R. M. Mader, C. C. Zielinski, and G. G. Steger

Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1055. [Abstract]  

N. Tubiana-Mathieu, P. Bougnoux, D. Becquart, A. Chan, F. Majois, M. Espie, D. Aubert, G. Villanova, and P. F. Conte

An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1056. [Abstract]  

G. Somlo, M. Koczywas, T. Luu, M. McNamara, V. Bedell, M. L. Slovak, S. Wilczynski, R. Morgan, C. Russell, and P. Frankel

The combination of the HER2 antibody trastuzumab, the EGFR tyrosine kinase inhibitor gefitinib, and docetaxel as first-line therapy in patients with HER2 overexpressing stage IV breast carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 1057. [Abstract]  

R. Paridaens, Sr., H. Wildiers, F. Dalenc, O. Rixe, V. Cadic, M. Pinel, and H. Roche

Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1058. [Abstract]  

S. K. Dennison, S. A. Jacobs, J. Wilson, J. Seeger, T. Cescon, J. M. Raymond, C. E. Geyer, N. Wolmark, and S. M. Swain

A phase II clinical trial of ZD1839 (gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1059. [Abstract]  

M. De Tursi, C. Carella, E. Ricevuto, A. Gennari, C. Orlandini, A. Frassoldati, P. F. Conte, and S. Iacobelli

A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1060. [Abstract]  

J. F. Robertson, G. G. Steger, P. Neven, and S. Barni

Fulvestrant in the treatment of HER2-positive advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1061. [Abstract]  

L. Y. Dirix, A. Prové, C. Sweldens, P. Van Dam, P. Vermeulen, and I. Benoy

Phase II study of docetaxel, carboplatin and trastuzumab (THC) in patients with locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1062. [Abstract]  

A. Y. Salmon, B. Uziely, A. Meirowitz, N. Sharon, and T. Peretz

Improvement in survival of breast cancer patients with synchronous metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 1063. [Abstract]  

V. Trieu, S. Ran, C. Bivens, and N. Desai

Chemoprotection by VEGF: Rationale for combination nab-paclitaxel and bevacizumab
J Clin Oncol (Meeting Abstracts) 2007 25: 1064. [Abstract]  

P. N. Munster, D. C. Marchion, M. Schmitt, E. Bicaku, M. Lacevic, S. Minton, W. Carter, and A. Daud

Phase I/II trial combining the HDAC inhibitor, valproic acid (VPA) and FEC100 (5-fluorouracil, epirubicin and cyclophosphamide) in locally advanced/metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1065. [Abstract]  

G. Metro, M. Mottolese, S. Di Cosimo, P. Papaldo, G. Ferretti, P. Carlini, A. M. Cianciulli, D. Giannarelli, F. Cognetti, and A. Fabi

Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1066. [Abstract]  

C. Meille, L. Favier, B. Coudert, D. Barbolosi, A. Iliadis, F. Biville, J. Garnier, and R. Ferri-Dessens

Retrospective analysis of data from a phase I trial with a new adaptive method
J Clin Oncol (Meeting Abstracts) 2007 25: 1067. [Abstract]  

S. Jagdev, H. Berry, A. Newsham, A. Smith, L. Flanagan, T. Perren, D. Dodwell, and G. Velikova

Clodronate compared to ibandronate breast cancer bone metastases patient preference study
J Clin Oncol (Meeting Abstracts) 2007 25: 1068. [Abstract]  

N. Wilking, J. Bergh, U. Wilking, and B. Jönsson

Inter- and intra-country variations in the use of trastuzumab in Norway, Spain and Sweden
J Clin Oncol (Meeting Abstracts) 2007 25: 1069. [Abstract]  

M. Artac, M. Samur, H. Bozcuk, B. Afacan, and M. Ozdogan

The impact of waist-to-hip ratio (WHR) on survival in metastatic breast cancer patients treated with aromatase inhibitors (AIs)
J Clin Oncol (Meeting Abstracts) 2007 25: 1070. [Abstract]  

S. Thome, T. Hobday, D. Hillman, M. Aubry, W. Lingle, M. Reinholz, D. Graham, P. Flynn, A. Moreno, E. Perez North Central Cancer Treatment Group

Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1071. [Abstract]  

P. Schmid, A. Regierer, P. Kiewe, W. Schippinger, R. Greil, S. Lehenbauer-Dehm, N. Niederle, W. Freier, H. Van de Velde, K. Possinger, and D. Kuehnhardt

Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines: Final results of a phase I/II study
J Clin Oncol (Meeting Abstracts) 2007 25: 1072. [Abstract]  

J. Wang, S. Jain, W. Heller, D. Mackie, V. Watson, M. Dweck, R. C. Coombes, and C. Palmieri

Fulvestrant in advanced breast cancer following following failure of tamoxifen and a third generation aromatase inhibitor
J Clin Oncol (Meeting Abstracts) 2007 25: 1073. [Abstract]  

D. Laessig, U. Vehling-Kaiser, H. J. Stemmler, P. Fasching, F. Melchert, H. Koelbl, M. Stauch, A. Scharl, G. Morack, and V. Heinemann

Evaluation of gemcitabine plus carboplatin in pretreated, metastatic breast cancer patients: Final analysis of a phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1074. [Abstract]  

S. Kaul, M. Aggarwal, A. Eichler, C. Sohn, and N. Fersis

Low tumor cell detection rate in bone marrow of patients with primary breast cancer after elimination of stroma cells: Comparison of immunocytology and molecular analysis of CK19 and mammaglobin 1
J Clin Oncol (Meeting Abstracts) 2007 25: 1075. [Abstract]  

P. Spadaro, V. Pitini, G. Altavilla, M. Ingemi, and G. Dottore

Dental care and tooth extraction as a risk factor for developing osteonecrosis of the jaw after long-term bisphosphonate therapy in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1076. [Abstract]  

L. Francis, T. Olivier, P. Frédérique, A. Catherine, M. Marie-Ange, R. Ines, D. Xavier, G. Pierre, C. Hervé, and C. Philippe

Prognosis value of hormonal and HER2 receptors on overall survival (OS) and disease-free interval (DFI) in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1077. [Abstract]  

J. Zidan, A. Abzah, L. Chetver, W. Basher, J. Shneider, and S. Tamam

Influence of letrozole on plasma estrogen levels in postmenopausal patients with metastatic breast cancer and the effect of estrogen levels on response rates
J Clin Oncol (Meeting Abstracts) 2007 25: 1078. [Abstract]  

M. E. Cianfrocca, S. T. Rosen, J. H. von Roenn, A. W. Rademaker, S. D. Rubin, R. A. Friedman, C. P. Rozario, and W. J. Gradishar

A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): First evaluation of an anthracycline and lapatinib combination in the treatment of MBC
J Clin Oncol (Meeting Abstracts) 2007 25: 1079. [Abstract]  

C. G. Messina, F. Longo, M. Di Seri, M. Restuccia, A. Zivi, E. Proietti, M. Russillo, L. Cerbone, V. Bianco, I. Speranza, G. M. L. Basile, and L. De Filippis

Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1080. [Abstract]  

S. E. Jones, A. Benedict, D. Cameron, and S. Jourdan

Cost-effectiveness of docetaxel compared to paclitaxel in metastatic breast cancer: A UK health economic analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 1081. [Abstract]  

F. M. Penault-Llorca, B. Nayl, M. Mouret-Reynier, M. Leheurteur, I. Van Praagh, X. Durando, J. Ferriere, H. Cure, and P. Chollet

Gemcitabine oxaliplatin (GEMOX) is an active combination in heavily pretreated metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1082. [Abstract]  

M. Ruiz, J. Salvador, J. Bayo, M. Lomas, A. Moreno, M. Valero, R. Bernabé, D. Vicente, J. Jiménez, and A. Lopez-Ladrón

Multicenter study of weekly trastuzumab, paclitaxel and carboplatin followed by a week of rest every 28 days in patients with HER2+ metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1083. [Abstract]  

G. L. Moura, R. Pasquini, A. Frare, K. Vianna, L. Albini, and S. Padilha

Gemcitabine and cisplatin in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1084. [Abstract]  

A. Camerini, D. Amoroso, O. Garrone, M. Vincenti, G. Tartarelli, S. Donati, C. Valsuani, O. Siclari, V. Polla Mattiot, and A. Sgambato

Lipid lowering effect of fulvestrant in hormone-sensitive metastatic breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 1085. [Abstract]  

J. W. Chia, P. Ang, H. See, Z. Wong, L. Soh, Y. Yap, and N. Wong

Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 1086. [Abstract]  

P. Stieber, D. Laessig, V. Heinemann, M. Untch, S. Kahlert, and D. Nagel

Kinetics of CEA and CA15–3 correlate with response in patients undergoing chemotherapy for metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1087. [Abstract]  

M. Lidgren, C. Rehnberg, N. Wilking, and B. Jönsson

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer (MBC) patients in Sweden
J Clin Oncol (Meeting Abstracts) 2007 25: 1088. [Abstract]  

A. Ardavanis, P. Kountourakis, S. Malliou, F. Kyriakou, S. Koumna, E. Kardara, A. Garoufalli, I. Yioti, and G. Rigatos

Trastuzumab with taxanes in HER2-ECD(+), IHC/CISH(-) advanced and heavily pretreated, chemotherapy-refractory breast cancer patients: Findings from a case series
J Clin Oncol (Meeting Abstracts) 2007 25: 1089. [Abstract]  

S. Gori, A. Sidoni, M. Colozza, I. Ferri, C. Cioccoloni, D. Fenocchio, A. Mosconi, P. Anastasi, V. De Angelis, and L. Crinò

EGFR, MAPK, and Akt status by immunohistochemistry (IHC) are not correlated with clinical outcome in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) with or without chemotherapy (CT)
J Clin Oncol (Meeting Abstracts) 2007 25: 1090. [Abstract]  

M. Andersson, D. Nielsen, P. G. Sørensen, and M. Ewertz

Phase II trial of vinorelbine (V) days 1+8 every 3 weeks and trastuzumab (T) weekly as first-line chemotherapy for HER2+ metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1091. [Abstract]  

L. Mauriac, A. Trainaud, A. Floquet, C. Donamaria, M. Durand, V. Brouste, and M. Debled

Capecitabine (X) monotherapy as first-line chemotherapy (CT) for metastatic breast cancer (MBC): High efficacy regardless of prior therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 1092. [Abstract]  

B. Oksuzoglu, H. Abali, N. Ozdemir, B. Budakoglu, M. Hayran, and N. Zengin

Capecitabine/cisplatin doublet in antracycline and taxane pre-treated patients with metastatic breast carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 1093. [Abstract]  

T. Bachelot, L. Mauriac, C. Delcambre, P. Maillart, C. Veyret, M. Mouret-Reynier, I. Van Praagh, and P. Chollet

Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression
J Clin Oncol (Meeting Abstracts) 2007 25: 1094. [Abstract]  

M. Debled, A. Trainaud, M. Durand, A. Floquet, V. Brouste, and L. Mauriac

Administration of further chemotherapy (CT) after capecitabine as first-line chemotherapy (CT) for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1095. [Abstract]  

M. Lichinitser and N. N. Semenov

Efficacy of i.v. and oral ibandronate in bone metastases breast cancer patients and some clinical aspects of bisphosphonates studies: Clinical experience of one trial center
J Clin Oncol (Meeting Abstracts) 2007 25: 1096. [Abstract]  

A. Bensalem and K. Bouzid

Gemcitabine/paclitaxel compared to gemcitabine/vinorelbine in metastatic breast cancer: An interim analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 1097. [Abstract]  

M. Kurt, S. Aksoy, M. Hayran, and N. Guler

A retrospective review of breast cancer patients with central nervous nystem metastasis treated with capecitabine
J Clin Oncol (Meeting Abstracts) 2007 25: 1098. [Abstract]  

B. Xu, Z. Jiang, S. Kim, S. Yu, J. Feng, A. Malzyner, A. Del Giglio, H. Chung, M. Yu, and A. Serrano

Randomized phase II study of biweekly gemcitabine (gem)-paclitaxel (pac), gem-carboplatin (carb) and gem-cisplatin (cis) as first-line treatments in metastatic breast cancer (MBC) after anthracycline failure
J Clin Oncol (Meeting Abstracts) 2007 25: 1099. [Abstract]  

Y. Shen, C. Hsu, S. Kuo, Y. Lu, C. Lin, C. Huang, and A. Cheng

A phase II study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as first-line chemotherapy for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1100. [Abstract]  

J. S. Link, J. R. Waisman, B. Nguyen, and C. I. Jacobs

Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1101. [Abstract]  

W. S. Ooi, S. Popovic, M. Kalina, K. Harriette, G. Singh, M. C. Gainford, and M. Clemons

Mechanisms of bone metastasis (BM) growth in patients with metastatic breast cancer (MBC): An exploratory study
J Clin Oncol (Meeting Abstracts) 2007 25: 1102. [Abstract]  

M. Mousseau, D. Serin, T. Petit, F. Priou, and L. Zelek

Results of first-line weekly paclitaxel (P) + gemcitabine (G) in metastatic breast cancer (MBC): An AERO phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1103. [Abstract]  

A. K. Conlin, A. D. Seidman, M. E. Moynahan, T. Traina, J. R. Mace, E. Meiri, A. Bach, C. Edwards, and C. A. Hudis

Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
J Clin Oncol (Meeting Abstracts) 2007 25: 1104. [Abstract]  

M. Deblock, B. Esterni, C. Tarpin, E. Charaffe-Jauffret, J. M. Extra, P. Viens, and A. Goncalves

HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors
J Clin Oncol (Meeting Abstracts) 2007 25: 1105. [Abstract]  

E. Stickeler, D. O. Watermann, J. Woll, M. Foeldi, and G. Gitsch

Cardiac safety of pegylated liposomal doxorubicin (PLD) in combination with trastuzumab (T) in patients with metastatic breast cancer (MBC): Results from a multicenter phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 1106. [Abstract]  

D. Karacetin, O. Maral, O. Aksakal, B. Okten, B. Yalçin, and O. Incekara

Gemcitabine and docetaxel combination regimen in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1107. [Abstract]  

F. M. Peria, F. E. Zola, D. G. Tiezzi, H. H. Carrara, P. M. Philbert, H. R. Marana, and J. M. Andrade

Combination chemotherapy with gencitabine and cisplatin in anthracycline and taxane pretreated metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1108. [Abstract]  

A. Felici, S. Di Segni, M. Contestabile, B. Nuvoli, A. Fabi, P. Papaldo, G. Ferretti, I. Sperduti, G. Citro, and F. Cognetti

Dose scheduling and pharmacokinetic (PK) study of trastuzumab in patients (pts) with HER2/neu overexpressing breast cancer?
J Clin Oncol (Meeting Abstracts) 2007 25: 1109. [Abstract]  

H. G. Botto, Sr. and M. E. Botto

Gemcitabine and vinorelbine as third-line therapy in elderly patients (pts) with advanced breast cancer (ABC) pretreated with taxanes and anthracyclines
J Clin Oncol (Meeting Abstracts) 2007 25: 1110. [Abstract]  

M. Gornas and C. Szczylik

Oral treatment of metastatic breast cancer (MBC) with capecitabine (X): What influences the decision-making process?
J Clin Oncol (Meeting Abstracts) 2007 25: 1111. [Abstract]  

J. Fasano, D. Hershman, Y. Novik, K. Blozie, and A. Tiersten

Phase II evaluation of liposomal doxorubicin combined with docetaxel in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1112. [Abstract]  

V. Beck, E. Solomayer, M. Krimmel, C. Reinert, and T. Fehm

Bisphosphonate-induced osteonecrosis of the jaw: Incidence and risk factors in patients with breast cancer and gynecological malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 1113. [Abstract]  

R. von Moos, B. Thürlimann, C. B. Caspar, R. Inauen, R. Greil, F. Schütz, L. Flores, B. Bergstrom, K. Schmieding, and M. Pecherstorfer

Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases: A randomized, open-label study
J Clin Oncol (Meeting Abstracts) 2007 25: 1114. [Abstract]  

K. Miller, L. S. Rosen, S. Modi, B. Schneider, J. Roy, L. Chap, M. Paulsen, K. Kersey, A. Hannah, and C. Hudis

Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T)
J Clin Oncol (Meeting Abstracts) 2007 25: 1115. [Abstract]  

Cancer Prevention:

A. Decensi, S. Zanardi, M. Puntoni, R. Bandelloni, D. Branchi, A. Argusti, F. Campodonico, L. Turbino, M. Mori, and M. Maffezzini

Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
J Clin Oncol (Meeting Abstracts) 2007 25: 1500. [Abstract]  

B. Arun, C. Logan, G. Yin, G. Yun, G. G. Hortobagyi, D. Browne, and N. Sneige

Phase II prevention trial of celecoxib in women at increased risk for breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1501. [Abstract]  

A. W. Kurian, V. B. Sharma, E. J. Schwartz, M. A. Mills, A. D. Staton, N. M. Chun, K. E. Kingham, and J. M. Ford

A phase II breast cancer chemoprevention study of lovastatin in high-risk women: Initial feasibility data
J Clin Oncol (Meeting Abstracts) 2007 25: 1502. [Abstract]  

J. H. Miller, B. S. Kramer, A. R. Kreimer, P. C. Prorok, J. Xu, S. G. Baker, R. Fagerstrom, C. D. Berg, J. K. Gohagan The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Group

Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1503. [Abstract]  

C. K. Kuhl, S. Schrading, E. Wardelmann, M. Braun, W. Kuhn, and H. H. Schild

Magnetic resonance imaging versus mammography for diagnosing ductal carcinoma in situ
J Clin Oncol (Meeting Abstracts) 2007 25: 1504. [Abstract]  

A. Zwaagstra and K. Hoskins

Barriers to breast cancer risk screening
J Clin Oncol (Meeting Abstracts) 2007 25: 1505. [Abstract]  

P. A. Ganz, S. R. Land, D. L. Wickerham, M. Lee, M. Ritter, V. Vogel, J. P. Costantino, and N. Wolmark

The Study of Tamoxifen and Raloxifene (STAR): Change in patient-reported outcomes (PROs) after the end of treatment
J Clin Oncol (Meeting Abstracts) 2007 25: 1506. [Abstract]  

R. T. Chlebowski, G. L. Anderson, D. S. Lane, A. Aragaki, T. Rohan, S. Yasmeen, G. Sato, C. A. Rosenberg, F. A. Hubbell Women’s Health Initiative

Predicting risk of estrogen receptor positive breast cancers in postmenopausal women
J Clin Oncol (Meeting Abstracts) 2007 25: 1507. [Abstract]  

D. Euhus, D. Bu, S. Milchgrub, A. M. Leitch, and C. M. Lewis

Cell-based breast cancer risk stratification based on DNA methylation in fine needle aspiration samples
J Clin Oncol (Meeting Abstracts) 2007 25: 1508. [Abstract]  

S. Khan, H. A. Lankes, D. Patil, M. Bryk, R. Nayar, N. Hou, H. Krontiras, and A. Rademaker

Serial ductal lavage for biomarker assessment in a phase 2 prevention study with tamoxifen
J Clin Oncol (Meeting Abstracts) 2007 25: 1509. [Abstract]  

S. L. George, T. J. Polascik, D. M. Albala, P. J. Walther, J. Moul, J. F. Madden, D. C. Snyder, V. Hars, B. R. Switzer, R. T. Vollmer, and W. Demark-Wahnefried

Impact of flaxseed supplementation and dietary fat restriction on prostate cancer proliferation and other biomarkers: Results of a Phase II randomized controlled trial (RCT) using a presurgical model
J Clin Oncol (Meeting Abstracts) 2007 25: 1510. [Abstract]  

R. Govindarajan, E. R. Siegel, D. L. Simmons, and N. P. Lang

Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN)
J Clin Oncol (Meeting Abstracts) 2007 25: 1511. [Abstract]  

R. K. Schmutzler, M. K. Graeser, K. Rhiem, B. Schlehe, W. Hofmann, W. Jonat, I. Schönbuchner, M. Kiechle-Bahat, K. Strunz, C. Engel German Consortium of Hereditary Breast and Ovarian Cancer (CHBOC)

Increased risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers after breast-conserving therapy compared to mastectomy
J Clin Oncol (Meeting Abstracts) 2007 25: 1512. [Abstract]  

A. B. Chagpar and K. M. McMasters

What caused the decline in breast cancer incidence rates?
J Clin Oncol (Meeting Abstracts) 2007 25: 1513. [Abstract]  

B. Bonanni, B. Santillo, D. Serrano, N. Rotmensz, M. Muraca, A. Vella, C. Belloni, A. Ponti, U. Veronesi, and A. Decensi

The hormone replacement therapy opposed to low dose tamoxifen (HOT) study: safety data from an ongoing phase III trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1514. [Abstract]  

M. J. Mann, M. C. Benson, and J. M. McKiernan

Is African-America race (AAR) a risk factor for failure in prostate cancer (PCa)?
J Clin Oncol (Meeting Abstracts) 2007 25: 1515. [Abstract]  

E. Meadows, J. L. Mershon, J. Johnston, R. Iskander, K. DeLong, D. Taylor, K. Kerlikowske, and M. Weinstein

Impact of breast cancer risk assessment in primary care: Modeling clinical outcomes and effectiveness
J Clin Oncol (Meeting Abstracts) 2007 25: 1516. [Abstract]  

P. Sharma, J. R. Klemp, B. F. Kimler, Q. J. Khan, E. J. Smith, and C. J. Fabian

BRCA1 and BRCA2 germline mutation carriers have a lower breast density compared to high risk women without such mutations
J Clin Oncol (Meeting Abstracts) 2007 25: 1517. [Abstract]  

J. Eng-Wong, C. K. Chow, J. Orzano, D. Venzon, J. Zujewski, J. Yao, and S. Prindiville

The effect of raloxifene on breast MRI volume in premenopausal women at increased risk for invasive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1518. [Abstract]  

M. M. Tea, C. Grimm, D. Bikas, R. Kroiss, A. Fink-Retter, E. Kubista, and T. M. Wagner

The validity of complex breast cysts after surgery
J Clin Oncol (Meeting Abstracts) 2007 25: 1519. [Abstract]  

H. L. McArthur, M. Hensley, C. L. Brown, D. S. Chi, K. Offit, K. Hurley, Y. Li, M. L. Gemignani, M. E. Robson, and R. R. Barakat

Impact of risk-reducing oophorectomy on quality of life in women at risk for ovarian cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1520. [Abstract]  

S. G. Fisher, P. Mumby, and S. Kohli

Effect of familial breast cancer outcomes on health behaviors of relatives
J Clin Oncol (Meeting Abstracts) 2007 25: 1521. [Abstract]  

A. R. Bradbury, S. A. Cummings, J. J. Dignam, L. Patrick-Miller, M. Verp, M. A. White, L. Dudlicek, G. Newstead, H. Abe, R. Schmidt, and O. I. Olopade

Health-related quality of life among high-risk women in an MRI surveillance study
J Clin Oncol (Meeting Abstracts) 2007 25: 1522. [Abstract]  

J. Kim, D. Tsavachidou, K. Do, S. Wen, R. Babaian, L. Pisters, C. Pettaway, P. Troncoso, C. Logothetis, and T. McDonnell

Differential gene expression in preoperative study of selenium and vitamin E chemoprevention in prostate cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1523. [Abstract]  

S. N. Westin, C. C. Sun, K. H. Lu, K. M. Schmeler, P. T. Soliman, K. G. White, M. S. Daniels, B. K. Arun, S. K. Peterson, and D. C. Bodurka

Management strategies for women at high risk for breast and ovarian cancer: Are women satisfied?
J Clin Oncol (Meeting Abstracts) 2007 25: 1524. [Abstract]  

C. C. Sun, S. N. Westin, K. H. Lu, K. M. Schmeler, K. G. White, M. S. Daniels, B. K. Arun, S. K. Peterson, and D. C. Bodurka

Impact of BRCA 1/2 testing: Body image, sexual functioning, and quality of life (QOL)
J Clin Oncol (Meeting Abstracts) 2007 25: 1525. [Abstract]  

A. von Wachenfeldt, Y. Brandberg, H. Johansson, and T. Fornander

Socioeconomic status of women attending an oncogenetic counseling clinic
J Clin Oncol (Meeting Abstracts) 2007 25: 1526. [Abstract]  

L. J. Kirstein, Y. Martei, C. Roche, B. L. Smith, M. C. Specht, M. A. Gadd, B. Drohan, C. Lawrence, J. Michaelson, and K. S. Hughes

LCIS and tamoxifen use: A single institution review
J Clin Oncol (Meeting Abstracts) 2007 25: 1527. [Abstract]  

S. W. Gray, N. Wong, B. Kelly, A. Romantan, S. Ramirez, T. Fraze, A. Smith-McLallen, K. Armstrong, J. Schwartz, and R. Hornik

Physician initiated cancer screening discussions and patient intention to engage in screening behavior
J Clin Oncol (Meeting Abstracts) 2007 25: 1528. [Abstract]  

Y. Rino, N. Yukawa, T. Yamada, T. Imada, S. Morinaga, S. Ohkawa, K. Miyakawa, M. Ueno, and K. Tarao

Reduction therapy of ALT levels and prevention of HCC development in patients with HCV-associated cirrhosis
J Clin Oncol (Meeting Abstracts) 2007 25: 1529. [Abstract]  

J. Mershon, M. Geiger, E. Barrett-Connor, P. Collins, M. Kornitzer, S. Dowsett, S. Zheng, J. Song, and N. Wenger

Effect of coronary heart disease (CHD) risk factors and medications on invasive breast cancer risk in the Raloxifene Use for The Heart (RUTH) trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1530. [Abstract]  

H. Richardson, D. Johnston, P. E. Goss on behalf of the MAP.3 consortium

Participant characteristics on an international NCIC CTG breast cancer prevention trial
J Clin Oncol (Meeting Abstracts) 2007 25: 1531. [Abstract]  

M. M. Flynn

Comparison of weight loss with a National Cancer Institute diet and a plant-based olive oil diet in overweight women with invasive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1532. [Abstract]  

P. Ravdin, K. A. Cronin, N. Howlader, C. D. Berg, E. J. Feuer, and D. A. Berry

Major changes in breast cancer incidence in the United States over the period 2002 to 2004
J Clin Oncol (Meeting Abstracts) 2007 25: 1533. [Abstract]  

J. I. Zweig

Eradication of prostatic high grade intraepithelial neoplasia: Hypothesis and clinical proof
J Clin Oncol (Meeting Abstracts) 2007 25: 1534. [Abstract]  

M. S. Beg, A. Gupta, R. Komrokji, M. Atiq, S. Ali, and M. Safa

Impact of screening on presentation and survival of colorectal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1535. [Abstract]  

K. Pawlowski, L. Patrick-Miller, C. K. Daugherty, O. I. Olopade, J. J. Dignam, C. N. Ibe, F. J. Hlubocky, S. A. Cummings, M. A. White, L. Dudlicek, and A. R. Bradbury

Content and method of parental disclosure of genetic risk to young adult and minor children in BRCA families
J Clin Oncol (Meeting Abstracts) 2007 25: 1536. [Abstract]  

C. Kurkjian, N. B. Janakiram, S. Guruswamy, C. V. Rao, and H. Ozer

The effects of licofelone, a dual lipoxygenase and cyclooxygenase inhibitor, with and without rosiglitazone in human MCF-7 and MDA-MB-231 breast cancer cells
J Clin Oncol (Meeting Abstracts) 2007 25: 1537. [Abstract]  

M. Caleffi, A. J. Bedin, Jr, J. M. Zignani, L. G. Artico, J. M. Viegas-Butzke, R. Rutta, A. Schmidt, J. Giacomazzi, P. Ashton-Prolla, and B. Weber

Prevalence of breast cancer risk factors in two different cohorts in relation to health care access and preventive programs in southern Brazil
J Clin Oncol (Meeting Abstracts) 2007 25: 1538. [Abstract]  

A. Kwong, J. Rosenberg, M. A. Van den Bosch, B. L. Daniel, G. Lo, and D. M. Ikeda

MRI background enhancement: Its relationship with breast density and breast cancer risk
J Clin Oncol (Meeting Abstracts) 2007 25: 1539. [Abstract]  

S. A. Terekhova, A. F. Lazarev, V. D. Petrova, T. V. Sinkina, I. A. Selezneva, and J. N. Dimitriadi

Discriminatory analysis in determination of high risk of gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 1540. [Abstract]  

R. Lal and F. M. Watt

Prevention of MEK1-associated tumours in murine epidermis by inhibition of interleukin-1
J Clin Oncol (Meeting Abstracts) 2007 25: 1541. [Abstract]  

V. D. Petrova, T. V. Sinkina, N. A. Zarubina, S. A. Terekhova, J. N. Dimitriadi, I. A. Selezneva, and A. F. Lazarev

Algorithm of monitoring of patients with family history of cancer as a method of cancer prevention
J Clin Oncol (Meeting Abstracts) 2007 25: 1542. [Abstract]  

A. Rosenberg, L. Burke, P. Vos, and D. Liles

Self-exam is the most common method of breast cancer identification
J Clin Oncol (Meeting Abstracts) 2007 25: 1543. [Abstract]  

J. J. Zarba, S. V. Holgado, M. Sanchez Segura, A. Gonzalez, V. Audi, and A. Elias

Successful changes in the diagnosis of earlier stages in invasive cervical cancer following a cancer detection program in Tucuman, Argentina
J Clin Oncol (Meeting Abstracts) 2007 25: 1544. [Abstract]  

S. B. Cantor, M. Cárdenas-Turanzas, M. Follen, and D. D. Cox

The accuracy of colposcopy in diagnostic and screening settings
J Clin Oncol (Meeting Abstracts) 2007 25: 1545. [Abstract]  

A. F. Lazarev, V. D. Petrova, T. V. Sinkina, and S. A. Terekhova

New approaches to cancer prevention—preventive medical examination of patients from the high-risk pre-cancer registry
J Clin Oncol (Meeting Abstracts) 2007 25: 1546. [Abstract]  

W. Shen, L. F. Ross, L. Patrick-Miller, O. I. Olopade, S. A. Cummings, M. A. White, L. Dudlicek, and A. R. Bradbury

Tobacco use among individuals presenting for cancer risk assessment
J Clin Oncol (Meeting Abstracts) 2007 25: 1547. [Abstract]  

E. Andreopoulou, G. Ursin, K. Carapetyan, M. Utate, M. Alvear, M. Rosell, F. Muggia, and J. Smith

Effects of letrozole on mammographic density (MD) in post-menopausal (PM) women at high risk for breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2007 25: 1548. [Abstract]  

F. L. Roth, Sr., C. Bochi, E. I. Palmeiro, L. Kalakun, M. Callefi, R. Giugliani, and P. A. Prolla

Frequency and accuracy of the first-degree family history of cancer in a community-based sample of women with low literacy in the South of Brazil
J Clin Oncol (Meeting Abstracts) 2007 25: 1549. [Abstract]  

J. P. Janssens, L. Rotenberg, M. Sentis, and R. Schultz-Wendtland

Clinical experience with the new manual and automated large core biopsy systems based on a rotational cutting on a helix
J Clin Oncol (Meeting Abstracts) 2007 25: 1550. [Abstract]  

R. D. Legare, J. Scalia-Wilbur, and J. Kent

The importance of continued surveillance of high risk cancer families as illustrated in a family with Gardner’s syndrome
J Clin Oncol (Meeting Abstracts) 2007 25: 1551. [Abstract]  

P. Manente, G. Vicario, E. Scelzi, L. Sartor, L. Nicolardi, A. Rizzo, A. Pinarello, B. Spaliviero, and R. Sbeghen

Correlation of preoperative citology/histology in radiologically detected lesions and histologic findings at excision
J Clin Oncol (Meeting Abstracts) 2007 25: 1552. [Abstract]  

C. A. Adisa

Audit of excisional breast biopsies in a Nigeria teaching hospital
J Clin Oncol (Meeting Abstracts) 2007 25: 1553. [Abstract]  

Central Nervous System Tumors:

R. Stupp, R. Goldbrunner, B. Neyns, U. Schlegel, P. Clement, G. G. Grabenbauer, M. E. Hegi, J. Nippgen, M. Picard, and M. Weller

Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM)
J Clin Oncol (Meeting Abstracts) 2007 25: 2000. [Abstract]  

T. Batchelor, A. G. Sorensen, M. Ancukiewicz, D. G. Duda, D. N. Louis, S. R. Plotkin, P. Ivy, P. Y. Wen, J. S. Loeffler, and R. Jain

A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
J Clin Oncol (Meeting Abstracts) 2007 25: 2001. [Abstract]  

D. Reardon, K. Fink, B. Nabors, T. Cloughesy, S. Plotkin, D. Schiff, J. Raizer, S. Krueger, M. Picard, and T. Mikkelsen

Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009
J Clin Oncol (Meeting Abstracts) 2007 25: 2002. [Abstract]  

K. J. Goli, A. Desjardins, J. E. Herndon, II, J. N. Rich, D. A. Reardon, J. A. Quinn, S. Sathornsumetee, D. A. Bota, H. S. Friedman, and J. J. Vredenburgh

Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2003. [Abstract]  

E. Galanis, K. A. Jaeckle, M. J. Maurer, J. M. Reid, M. M. Ames, C. Giannini, J. S. Hardwick, D. F. Moore, Jr., J. A. Zwiebel, and J. C. Buckner

N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2007 25: 2004. [Abstract]  

M. J. Van Den Bent, A. Brandes, R. Rampling, M. Kouwenhoven, J. M. Kros, A. F. Carpentier, P. Clement, B. Klughammer, T. Gorlia, and D. Lacombe

Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
J Clin Oncol (Meeting Abstracts) 2007 25: 2005. [Abstract]  

U. Bode, S. Buchen, M. Warmuth-Metz, T. Pietsch, F. Bach, and G. Fleischhack

Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents
J Clin Oncol (Meeting Abstracts) 2007 25: 2006. [Abstract]  

M. Bredel, H. Phillips, G. R. Harsh, K. Aldape, and B. I. Sikic

A regulatory network of canonical nuclear factor-B activation predicts high-grade glioma outcome
J Clin Oncol (Meeting Abstracts) 2007 25: 2007. [Abstract]  

S. Puget, A. Valent, I. Bieche, P. Dessen, A. Kauffmann, M. Peyre, C. Dirven, C. Sainte-Rose, G. Vassal, and J. Grill

Identification of novel candidate genes for ependymoma progression in chromosomal regions over-represented at recurrence and detected by CGH array
J Clin Oncol (Meeting Abstracts) 2007 25: 2008. [Abstract]  

W. Taal, D. Brandsma, H. G. de Bruin, J. E. Bromberg, A. T. Swaak-Kragten, W. M. Eijkenboom, and M. J. van den Bent

The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide
J Clin Oncol (Meeting Abstracts) 2007 25: 2009. [Abstract]  

W. R. Shapiro, M. P. Mehta, C. Langer, A. Bezjak, R. Timmerman, D. Brachman, J. Suh, J. A. Smith, S. Phan, and M. F. Renschler

Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non- small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials
J Clin Oncol (Meeting Abstracts) 2007 25: 2010. [Abstract]  

J. R. Perry, L. Rogers, N. Laperriere, J. Julian, W. Geerts, G. Agnelli, M. Malkin, R. Sawaya, R. Baker, M. Levine for the Ontario Clinical Oncology Group and PRODIGE Investigators, Hamilton, Ontario, Canada

PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma
J Clin Oncol (Meeting Abstracts) 2007 25: 2011. [Abstract]  

S. A. Grossman, S. Desideri, X. Ye, K. Szajna, M. Chamberlain, G. Lesser New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium

Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2012. [Abstract]  

M. Ekenel, F. M. Iwamoto, L. S. Ben Porat, K. S. Panageas, J. Yahalom, L. M. DeAngelis, and L. E. Abrey

What is the role of whole brain radiation therapy (WBRT) and high-dose cytarabine (Ara-C) as consolidation treatment after initial chemotherapy for primary CNS lymphoma (PCNSL)?
J Clin Oncol (Meeting Abstracts) 2007 25: 2013. [Abstract]  

L. Angelov, N. D. Doolittle, T. Siegal, D. F. Kraemer, D. Peereboom, K. Jahnke, S. Ference, G. Barnett, J. McGregor, E. A. Neuwelt on behalf of The Blood Brain Barrier Disruption (BBBD) Consortium

Blood brain barrier disruption (BBBD) and intra-arterial methotrexate based therapy for newly diagnosed primary CNS lymphoma: The BBBD Consortium Experience
J Clin Oncol (Meeting Abstracts) 2007 25: 2014. [Abstract]  

P. M. Kiewe, S. Maza, D. Munz, A. Korfel, and E. Thiel

F-18-labeled fluorodeoxyglucose positron emission tomography for evaluation of disease extent, response to treatment and follow-up in primary CNS lymphoma
J Clin Oncol (Meeting Abstracts) 2007 25: 2015. [Abstract]  

R. P. Sanders, A. Onar, J. M. Boyett, A. Broniscer, M. Fouladi, F. A. Boop, R. A. Sanford, L. E. Kun, T. M. Merchant, and A. Gajjar

M1 medulloblastoma should be considered high risk at any age
J Clin Oncol (Meeting Abstracts) 2007 25: 2016. [Abstract]  

R. Jakacki, P. Burger, T. Zhou, E. Holmes, R. Packer, J. Goldwein, M. Mehta, and I. Pollack

Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701
J Clin Oncol (Meeting Abstracts) 2007 25: 2017. [Abstract]  

E. Franceschi, A. Tosoni, M. Ermani, V. Blatt, P. Amistà, G. Sotti, S. Bartolini, D. Grosso, L. M. Pasetto, and A. A. Brandes

Should adult medulloblastoma patients at low risk receive adjuvant chemotherapy? Long-term results of a prospective study
J Clin Oncol (Meeting Abstracts) 2007 25: 2018. [Abstract]  

G. B. Roldán, J. Scott, D. George, J. Easaw, E. Yan, I. Parney, G. Cairncross, and P. Forsyth

Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 2019. [Abstract]  

J. H. Sampson, K. D. Aldape, M. R. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, G. E. Archer, D. Mitchell, D. D. Bigner, D. A. Reardon, and A. B. Heimberger

Temozolomide as a vaccine adjuvant in GBM
J Clin Oncol (Meeting Abstracts) 2007 25: 2020. [Abstract]  

L. M. Liau, R. M. Prins, S. K. Odesa, M. Y. Yang, M. S. Lin, H. Khan-Farooqi, H. Soto, A. Lai, M. Bosch, A. Boynton, and T. F. Cloughesy

Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod, following radio-chemotherapy for newly diagnosed glioblastoma
J Clin Oncol (Meeting Abstracts) 2007 25: 2021. [Abstract]  

K. Kramer, S. Modak, B. H. Kushner, M. Souweidane, S. Wolden, J. Humm, P. Zanzonico, P. Smith-Jones, S. Larson, and N. Cheung

Metastatic neuroblastoma (NB) to the central nervous system (CNS): Improved outcome with combined modality including 131-I-8H9 or 131-I-3F8 radioimmunotherapy (RIT) delivered through the cerebrospinal fluid (CSF)
J Clin Oncol (Meeting Abstracts) 2007 25: 2022. [Abstract]  

E. Razis, P. Selviaridis, J. Fletcher, S. Labropoulos, R. Caprioli, G. Karkavelas, M. Zhu, T. Kalebic, J. Norris, and G. Fountzilas

Biochemical evidence of tumor response and measurable levels of the drug in glioblastoma tissue from patients treated with imatinib
J Clin Oncol (Meeting Abstracts) 2007 25: 2023. [Abstract]  

J. F. De Groot, M. R. Gilbert, K. R. Hess, T. Hanna, M. Groves, C. Conrad, K. Aldape, H. Colman, V. Puduvalli, and W. A. Yung

Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2007 25: 2024. [Abstract]  

U. Bogdahn, A. Mahapatra, V. E. Olyushin, C. Mouli, V. E. Parfenov, G. Stockhammer, S. Ludwig, G. Wuerth, H. Heinrichs, and K. Schlingensiepen

A phase IIb actively controlled study with the TGF-beta-2 inhibitor AP 12009 for recurrent or refractory anaplastic astrocytoma
J Clin Oncol (Meeting Abstracts) 2007 25: 2025. [Abstract]  

A. A. Brandes, R. Stupp, P. Hau, S. Sleijfer, D. Lacombe, T. Gorlia, H. Yun, A. Tosoni, R. Mirimanoff, and M. J. van den Bent

EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial
J Clin Oncol (Meeting Abstracts) 2007 25: 2026. [Abstract]  

S. Sathornsumetee, J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, M. J. Egorin, A. J. Salvado, H. S. Friedman, and D. A. Reardon

Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2007 25: 2027. [Abstract]  

N. A. Mohile, L. E. Abrey, S. C. Lymberis, S. Karimi, B. L. Hou, and P. H. Gutin

A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2028. [Abstract]  

A. Desjardins, D. P. Barboriak, J. E. Herndon, II, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, H. S. Friedman, and J. J. Vredenburgh

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11)
J Clin Oncol (Meeting Abstracts) 2007 25: 2029. [Abstract]  

A. Narayana, S. Chheang, E. Knopp, N. Peccerelli, J. Babb, G. Johnson, M. Gruber, J. Allen, D. Zagzag, and M. Law

Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2030. [Abstract]  

J. Sul, K. S. Panageas, A. B. Lassman, A. Hormigo, C. Nolan, I. T. Gavrilovic, S. A. Grimm, L. M. DeAngelis, and L. E. Abrey

A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2007 25: 2031. [Abstract]  

W. Wick, A. Wick, J. Schuth, M. Platten, G. Reifenberger, and M. Weller

One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma
J Clin Oncol (Meeting Abstracts) 2007 25: 2032. [Abstract]  

R. Soffietti, R. Rudà, E. Laguzzi, L. Buttolo, A. Pace, C. Carapella, M. Riva, M. Salvati, A. Silvani, and M. Caroli

Treatment of gliomatosis cerebri with temozolomide: A retrospective study of the AINO (Italian Association for Neuro- Oncology)
J Clin Oncol (Meeting Abstracts) 2007 25: 2033. [Abstract]  

T. Jauch, P. Hau, and U. Bogdahn

Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas (HGG)
J Clin Oncol (Meeting Abstracts) 2007 25: 2034. [Abstract]  

G. R. D’Agostino, M. Balducci, C. Anile, S. Manfrida, G. Di Lella, A. Fiorentino, G. Mantini, G. Apicella, A. Pompucci, and N. Cellini

An analysis of two different schedules of radiochemotherapy with concomitant temozolomide in high grade gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2035. [Abstract]  

J. A. Quinn, J. J. Vredenburgh, J. N. Rich, D. A. Reardon, A. Desjardins, S. Gururangan, A. H. Friedman, J. H. Carter, S. Threatt, and H. S. Friedman

Phase II trial of Gliadel plus O⁶-benzylguanic (O⁶-BG) for patients with recurrent glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2007 25: 2036. [Abstract]  

M. P. Mehta, A. Dagnault, P. Chabot, J. Suh, E. Chang, M. Fortin, R. Timmerman, J. Grecula, L. Eubank, and M. F. Renschler

Identification of occult brain metastases amenable to stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment planning MRI: Results of a phase II trial of MGd and whole brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS)
J Clin Oncol (Meeting Abstracts) 2007 25: 2037. [Abstract]  

B. Friday, C. Yu, L. Yang, D. Wigle, and J. Sarkaria

Potentiation of proteasome inhibitor-induced apoptosis in glioma cells by histone deacetylase inhibitors
J Clin Oncol (Meeting Abstracts) 2007 25: 2038. [Abstract]  

P. Y. Wen, V. Puduvalli, J. Kuhn, J. Reid, T. Cloughesy, W. A. Yung, S. M. Chang, H. I. Robbins, R. McGovern, M. Ames, and M. D. Prados

Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03)
J Clin Oncol (Meeting Abstracts) 2007 25: 2039. [Abstract]  

H. Nakagawa, M. Yoshida, T. Motozaki, K. Yoshioka, and K. Itoh

Clinical results of continuous intrathecal or intracavitary administration of sodium butyrate for patients with recurrent and progressive malignant glioma: Experience with 23 cases
J Clin Oncol (Meeting Abstracts) 2007 25: 2040. [Abstract]  

S. Ryu, J. Rock, R. Jain, S. Ellika, J. Jin, and J. Anderson

Single fraction radiosurgery of epidural spinal cord compression: Tumor control and neurologic outcome
J Clin Oncol (Meeting Abstracts) 2007 25: 2041. [Abstract]  

H. M. El-Shenshawy, A. Abd El-Razek, and H. Bader

Hypofractionated radiotherapy versus conventional fractionated radiotherapy in elderly patients with glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2007 25: 2042. [Abstract]  

Y. Wang, N. Makhani, and M. Tsao

Evaluation of clinical markup with CT simulation in whole brain radiation therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 2043. [Abstract]  

F. Bokstein, F. Kovner, Z. Ram, H. Templehoff, A. A. Kanner, D. T. Blumenthal, and B. Corn

A common sense approach to radiation treatment planning of temporal lobe GBM
J Clin Oncol (Meeting Abstracts) 2007 25: 2044. [Abstract]  

R. Kazerooni, C. Conrad, C. Baud, M. Johansen, N. Thapar, C. Meyer, W. Priebe, and T. Madden

Phase I clinical pharmacokinetics of RTA 744: A blood brain barrier penetrating anthracycline active against high-grade glioma
J Clin Oncol (Meeting Abstracts) 2007 25: 2045. [Abstract]  

K. Jahnke, D. F. Kraemer, D. Fortin, S. Bell, N. D. Doolittle, K. R. Knight, L. L. Muldoon, and E. A. Neuwelt

Intra-arterial chemotherapy and osmotic blood-brain barrier disruption for primitive neuroectodermal tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2046. [Abstract]  

M. de Wit, V. Lange-Brock, A. Kruell, and C. Bokemeyer

Leptomeningeal metastases: Results of different therapeutic approaches
J Clin Oncol (Meeting Abstracts) 2007 25: 2047. [Abstract]  

J. B. Fiveash, S. M. Sawrie, B. L. Guthrie, S. A. Spencer, R. F. Meredith, J. M. Markert, R. A. Nordal, R. M. Conry, and L. B. Nabors

A phase II study of radiosurgery and temozolomide for patients with one to four brain metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 2048. [Abstract]  

Y. Ko, T. Neuhaus, R. Müller, G. Grabenbauer, J. Hedde, H. Schüller, M. Kocher, S. Stier, R. Ullrich, and R. Fietkau

A phase III trial of topotecan and whole brain radiation (WBRT) therapy for patients with CNS metastases due to lung cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2049. [Abstract]  

F. M. Iwamoto, A. M. Omuro, J. J. Raizer, C. P. Nolan, A. Hormigo, A. B. Lassman, I. T. Gavrilovic, and L. E. Abrey

A phase II trial of temozolomide and vinorelbine for patients with recurrent brain metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 2050. [Abstract]  

A. F. Ferreira Filho, S. Saueressig, D. L. da Silva, M. P. dos Santos, A. P. Wunder, R. Santana, and C. Zetler

Clinical, pathological and immunistochemistry characterization of primary breast cancer metastasizing to the central nervous system (CNS): Analysis of time to development of CNS metastasis
J Clin Oncol (Meeting Abstracts) 2007 25: 2051. [Abstract]  

T. S. Armstrong, T. Mendoza, I. Gning, M. L. Smith, M. R. Gilbert, J. Weinberg, and C. Cleeland

The utility of the MDASI-BT in assessing symptoms in patients with brain metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 2052. [Abstract]  

D. A. Bota, A. Desjardins, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, K. Goli, A. Salvado, H. S. Friedman, and D. A. Reardon

Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma
J Clin Oncol (Meeting Abstracts) 2007 25: 2053. [Abstract]  

L. W. Buie, C. Lindley, T. Shih, M. Ewend, J. K. Smith, M. Skelton, L. Kwock, D. Morris, C. Tucker, and F. Collichio

Plasma pharmacokinetics and cerebrospinal fluid concentrations of erlotinib in high-grade gliomas: A novel, phase I, dose escalation study
J Clin Oncol (Meeting Abstracts) 2007 25: 2054. [Abstract]  

G. Dresemann, C. Hosius, Z. Nikolova, and L. Letvak

Single center phase II trial analysing the role of imatinib/hydroxyurea in patients (pts) with pretreated non-progressive glioblastoma (GBM) as maintenance treatment
J Clin Oncol (Meeting Abstracts) 2007 25: 2055. [Abstract]  

F. S. Viola, A. Katz, A. Arantes, A. Gaiger, C. Vasconcellos, V. Passos, and C. H. Barrios

Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression
J Clin Oncol (Meeting Abstracts) 2007 25: 2056. [Abstract]  

H. I. Robins, P. Y. Wen, S. M. Chang, J. Kuhn, K. Lamborn, T. Cloughesy, M. R. Glibert, W. K. Yung, J. Dancey, and M. D. Prados

Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02)
J Clin Oncol (Meeting Abstracts) 2007 25: 2057. [Abstract]  

L. B. Nabors, M. Rosenfeld, M. Chamberlain, S. Phuphanich, T. Batchelor, J. Supko, S. Desideri, Y. Xiaobu, J. Wright, and S. Grossman

A phase I trial of sorafenib (BAY 43–9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
J Clin Oncol (Meeting Abstracts) 2007 25: 2058. [Abstract]  

S. Gururangan, C. Turner, C. F. Stewart, M. Kocak, T. Y. Poussaint, J. M. Boyett, L. E. Kun, V. Karsten, S. L. Gerson, and H. S. Friedman

Phase I trial of VNP40101M in children with recurrent brain tumors—A Pediatric Brain Tumor Consortium (PBTC) study
J Clin Oncol (Meeting Abstracts) 2007 25: 2059. [Abstract]  

S. Gardner, M. Fisher, J. Belasco, P. Phillips, and J. Finlay

Phase I dose escalation of temozolomide with thiotepa and carboplatin with autologous hematopoietic cell reinfusion in patients with recurrent/refractory malignant brain tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2060. [Abstract]  

A. Dicker, M. Werner-Wasik, M. Machtay, G. Mallon, M. Ramirez, D. Andrews, and W. J. Curran, Jr

A phase I trial using the proteasome inhibitor bortezomib and concurrent temazolomide and radiotherapy for high grade gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2061. [Abstract]  

C. A. Conrad, E. Maher, T. Cloughesy, M. Groves, M. Gilbert, T. Madden, V. Levin, W. Priebe, C. Meyer, and W. Yung

Final results of a phase I trial with the novel anthracycline derivative RTA 744 in patients with primary brain tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2062. [Abstract]  

S. Phuphanich, M. Chamberlain, T. Mikkelsen, X. Ye, S. A. Grossman, T. Batchelor, G. Lesser, J. D. Fisher, S. Desideri New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium

A phase I study of SDX-102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2063. [Abstract]  

E. G. Shaw, S. A. Grossman, K. A. Carson, J. D. Fisher, L. Kleinberg New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium

Phase I study of gadolinium texaphyrin in newly diagnosed glioblastoma
J Clin Oncol (Meeting Abstracts) 2007 25: 2064. [Abstract]  

J. Kirkpatrick, A. Desjardins, J. Quinn, J. Rich, J. Vredenburgh, S. Sathornsumetee, S. Gururangan, C. Sidor, H. Friedman, and D. Reardon

Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2007 25: 2065. [Abstract]  

T. Aoki, K. Nojima, T. Mizutani, M. Ishikawa, A. Takasu, and N. Hashimoto

Phase II study of ifosfamide, carboplatin and etoposide (ICE) in recurrent glioblastoma
J Clin Oncol (Meeting Abstracts) 2007 25: 2066. [Abstract]  

G. J. Lesser, V. Stieber, D. Case, G. Enevold, R. Rosdhal, S. Tatter, T. Ellis, K. McMullen, E. Shaw Wake Forest University Community Clinical Oncology Program Research Base (WFURB)

A phase II trial of thalidomide (Thal) and procarbazine (Pro) in adults with recurrent or progressive malignant gliomas (MG)
J Clin Oncol (Meeting Abstracts) 2007 25: 2067. [Abstract]  

M. L. Affronti, J. M. Day, J. E. Herndon, II, J. N. Rich, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, R. E. McLendon, and H. S. Friedman

Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients
J Clin Oncol (Meeting Abstracts) 2007 25: 2068. [Abstract]  

H. Yoon, A. F. Hottinger, L. M. DeAngelis, A. B. Lassman, and L. E. Abrey

Clinical outcome of glioblastoma multiforme patients with long-term survival
J Clin Oncol (Meeting Abstracts) 2007 25: 2069. [Abstract]  

J. N. Rich, M. L. Affronti, J. M. Day, J. E. Herndon, II, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, and H. S. Friedman

Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 2070. [Abstract]  

M. Vinjamuri, R. Adumala, R. Altaha, J. Hobbs, and E. Crowell

Retrospective analysis of glioblastoma multiforme (GBM) patients treated initially with BCNU compared to temozolomide (TMZ) with concomitant radiation therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 2071. [Abstract]  

H. M. Strik, J. H. Buhk, H. C. Bock, M. Nitsche, A. Giese, and M. Baehr

Rechallenge of malignant gliomas with temozolomide —Can it be effective?
J Clin Oncol (Meeting Abstracts) 2007 25: 2072. [Abstract]  

M. Glas, H. Koch, B. Hirschmann, T. Jauch, A. Steinbrecher, U. Bogdahn, and P. Hau

Pegylated liposomal doxorubicin in recurrent high-grade glioma: Comparison of clinical trial results and compassionate use
J Clin Oncol (Meeting Abstracts) 2007 25: 2073. [Abstract]  

J. Portnow, B. Badie, B. Xi, A. Liu, D. Hovda, D. Hirt, and T. W. Synold

Intracerebral microdialysis for determination of the neuropharmacokinetics and neuropharmacodynamics of temozolomide in patients with primary or metastatic brain tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2074. [Abstract]  

K. Lamborn, W. Wu, M. Prados, K. Jaeckle, S. Chang, P. Novotny, and J. Buckner

Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma
J Clin Oncol (Meeting Abstracts) 2007 25: 2075. [Abstract]  

T. Kang, T. Jin, and D. Peereboom

Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience
J Clin Oncol (Meeting Abstracts) 2007 25: 2077. [Abstract]  

S. Raval, S. Hwang, and L. Dorsett

Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2007 25: 2078. [Abstract]  

J. J. Raizer, L. Gallot, R. Cohn, J. Chandler, R. Levy, C. Getch, H. Batjer, M. Marymont, C. Tellez, A. Mellot, and S. Newman

A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2079. [Abstract]  

G. Vassal, N. Hamelin, P. Opolon, R. Versace, and B. Geoerger

The topoisomerase I inhibitor gimatecan exhibits anti-tumor activity against malignant glioma xenografts as single agent and in combination
J Clin Oncol (Meeting Abstracts) 2007 25: 2081. [Abstract]  

A. Korfel, L. Fischer, B. Gleissner, P. Martus, M. Novrousian, U. Krümpelmann, H. Klasen, H. Kirchen, and E. Thiel

PCR of immunoglobulin heavy-chain (IgH) complementary determining region III (CDRIII) for diagnosis of meningeal dissemination (MD) in primary CNS lymphoma (PCNSL): A prospective evaluation
J Clin Oncol (Meeting Abstracts) 2007 25: 2082. [Abstract]  

E. Ditomaso, A. Stemmer-Rachamimov, A. Potts, M. Drottar, R. K. Jain, and S. R. Plotkin

Correlation between VEGF expression and MVD in sporadic and NF2-related schwannomas
J Clin Oncol (Meeting Abstracts) 2007 25: 2083. [Abstract]  

M. Preusser, M. Hassler, K. Elandt, E. Gelpi, J. Hainfellner, M. Baur, and C. Marosi

Analysis of MGMT promoter methylation status in high grade glioma patients with long term and conventional survival times: A retrospective study
J Clin Oncol (Meeting Abstracts) 2007 25: 2084. [Abstract]  

K. Tsuboi, E. Ishikawa, T. Yamamoto, S. Takano, A. Matsumura, and T. Ohno

A clinical trial of autologous formalin-fixed tumor vaccine (AFTV) for patients with glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2007 25: 2085. [Abstract]  

J. K. Altman, L. Gallot, R. Cohn, J. Chandler, R. Levy, C. Getch, M. Marymont, C. Tellez, and J. J. Raizer

Recurrent primary central nervous system lymphoma (PCNSL) treated with pemetrexed
J Clin Oncol (Meeting Abstracts) 2007 25: 2086. [Abstract]  

B. Falsini, I. Lazzareschi, A. Ruggiero, L. Ziccardi, L. Placentino, C. Colosimo, C. Di Rocco, and R. Riccardi

Longitudinal assessment of childhood optic gliomas: Relationship between brain imaging and optic pathway function
J Clin Oncol (Meeting Abstracts) 2007 25: 2087. [Abstract]  

Developmental Therapeutics: Cytotoxic Chemotherapy:

A. Dowlati, S. Manda, L. Patrick, S. Remick, J. Gibbons, and P. Fu

Multi-institutional phase I trials involve more patients and longer accrual time compared to single institution trials
J Clin Oncol (Meeting Abstracts) 2007 25: 2500. [Abstract]  

P. T. Ho, R. A. Fleming, L. Pandite, T. A. Lampkin, and A. A. Flynn

Tumor response rate as a function of number of prior therapies in phase II and III trials of topotecan (T) and eniluracil/5FU (EU)
J Clin Oncol (Meeting Abstracts) 2007 25: 2501. [Abstract]  

F. Innocenti, L. Janisch, S. Das, J. Ramirez, L. House, M. L. Maitland, R. Salgia, and M. J. Ratain

A genotype-directed phase I study of irinotecan in advanced cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 2502. [Abstract]  

J. G. Kuhn, H. A. Burris, III, S. F. Jones, D. W. Hein, N. T. Willcutt, F. A. Greco, D. S. Thompson, A. A. Meluch, R. S. Schwartz, and D. M. Brown

Phase I/II dose-escalation trial of amonafide for treatment of advanced solid tumors: Genotyping to optimize dose based on polymorphic metabolism
J Clin Oncol (Meeting Abstracts) 2007 25: 2503. [Abstract]  

K. Fujita, W. Yamamoto, H. Endo, F. Nagashima, W. Ichikawa, T. Miya, K. Araki, K. Kodama, M. Narabayashi, and Y. Sasaki

Effects of CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxipyridine (CDHP) on pharmacokinetics (PK) of tegafur (FT) and 5-fluorouracil (5-FU) in the patients treated by S-1
J Clin Oncol (Meeting Abstracts) 2007 25: 2504. [Abstract]  

L. Fan, J. Y. Guo, C. I. Wong, R. Lim, H. L. Yap, Y. M. Khoo, P. Iau, B. C. Goh, H. S. Lee, and S. C. Lee

Genetic variants in human carbonyl reductase 3 (CBR3) and their influence on doxorubicin pharmacokinetics in Asian breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 2505. [Abstract]  

F. A. de Jong, J. M. van der Bol, R. H. Mathijssen, W. J. Loos, L. E. Friberg, R. H. van Schaik, M. J. de Jonge, A. S. Planting, A. Sparreboom, and J. Verweij

Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia
J Clin Oncol (Meeting Abstracts) 2007 25: 2506. [Abstract]  

G. A. Bjarnason, A. Seth, Z. Wang, N. Blanas, M. Straume, and T. A. Martino

Diurnal rhythms (DR) in gene expression in human oral mucosa: Implications for gender differences in toxicity, response and survival and optimal timing of targeted therapy (Rx)
J Clin Oncol (Meeting Abstracts) 2007 25: 2507. [Abstract]  

M. Castaing, Jr., M. A. Loriot, M. Barrois, I. Miran, C. Mulot, P. Laurent-Puig, J. P. Pignon, M. Ducreux, and V. Boige

Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000–05 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 2508. [Abstract]  

E. Marcuello, L. Pare, A. Altes, E. Del Rio, L. Sedano, A. Barnadas, and M. Baiget

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving 5-fluorouracil (FU)/oxaliplatin (OX) as first-line chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 2509. [Abstract]  

C. Falandry, B. You, G. Milano, E. Chatelut, C. Rebischung, O. Glehen, D. Mille, J. Delord, G. Lledo, V. Trillet-Lenoir, and G. Freyer

Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOGEN trial
J Clin Oncol (Meeting Abstracts) 2007 25: 2510. [Abstract]  

P. A. Bradbury, A. L. Marshall, M. H. Kulke, W. Zhou, R. S. Heist, L. Su, T. J. Lynch, Jr, F. A. Shepherd, D. C. Christiani, and G. Liu

Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2511. [Abstract]  

J. Wei, B. Liu, Z. Zou, X. Qian, W. Zhang, and L. Yu

ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 2512. [Abstract]  

C. H. Takimoto, A. Ricart, M. Mita, A. C. Mita, Q. Chu, A. W. Tolcher, J. Sarantopoulos, A. Mita, and E. K. Rowinsky

Phase I evaluation of a 24-h infusion of TAS-106 every 3 weeks (wks) in patients (pts) with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2513. [Abstract]  

S. Danson, P. Johnson, T. Ward, M. Dawson, O. Denneny, A. Watson, D. Jowle, P. Sharpe, C. Dive, and M. Ranson

Final results of a phase I clinical trial of the bioreductive drug RH1
J Clin Oncol (Meeting Abstracts) 2007 25: 2514. [Abstract]  

R. L. Ilaria, Jr, G. R. Simon, M. Sovak, M. K. Burton, A. L. Cleverly, A. K. Sykes, D. P. De Alwis, M. M. Wagner, and D. R. Spriggs

Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 2-hour IV infusion in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2515. [Abstract]  

J. E. Lancet, G. Nichols, S. Assouline, M. Ward, M. Burton, M. Mintz, C. Rousseau, A. Kalita, P. J. Brabant, and O. Odenike

A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS)
J Clin Oncol (Meeting Abstracts) 2007 25: 2516. [Abstract]  

E. Gallerani, T. A. Yap, A. Lopez, C. Coronado, H. Shaw, A. Florez, B. de las Heras, H. Cortes-Funes, J. de Bono, and L. Paz-Ares

Phase I study of PM00104, a novel cytotoxic anti-cancer drug, administered to patients with advanced solid tumors or lymphoma
J Clin Oncol (Meeting Abstracts) 2007 25: 2517. [Abstract]  

F. G. De Braud, N. Isambert, G. Curigliano, G. Spitaleri, E. Ferrant, C. Ramazeilles, L. Bolloni, and P. Fumoleau

A phase I dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion every 3 weeks in patients (pt) with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2518. [Abstract]  

W. M. McHayleh, R. Sehgal, D. M. Potter, R. B. Royds, T. G. Nekrassova, S. P. Ivy, S. Ramalingam, C. P. Belani, C. L. Naret, and M. J. Egorin

Analysis of renal function in patients entered onto CTEP-sponsored phase I studies since 1979
J Clin Oncol (Meeting Abstracts) 2007 25: 2519. [Abstract]  

N. Chen, H. Lau, L. Kong, J. Zeldis, R. Knight, and O. Laskin

Pharmacokinetics of lenalidomide in subjects with various degrees of renal function
J Clin Oncol (Meeting Abstracts) 2007 25: 2520. [Abstract]  

S. G. Poole, M. J. Dooley, and D. Rischin

Calculating carboplatin doses using the 4-variable modification of diet in renal disease (4-v MDRD) estimate of glomerular filtration rate (GFR) in the Calvert formula
J Clin Oncol (Meeting Abstracts) 2007 25: 2521. [Abstract]  

S. A. Jennings, M. L. de Lemos, A. Levin, and N. Murray

Evaluation of Cockcroft-Gault (CG) and abbreviated modified diet in renal disease (MDRD) formulae in dosing of cancer drugs other than carboplatin
J Clin Oncol (Meeting Abstracts) 2007 25: 2522. [Abstract]  

B. Paule, F. Saliba, M. Gil-Delgado, C. Puozzo, S. Favrel, A. Ravaud, J. Delord, and P. Fumoleau

Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results
J Clin Oncol (Meeting Abstracts) 2007 25: 2523. [Abstract]  

S. Lee, M. Watson, X. Xu, C. I. Wong, P. Iau, N. Sukri, S. E. Lim, B. Chuah, H. McLeod, and B. C. Goh

Use of tumor gene expression signatures and drug-induced changes to discriminate early response in human breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2524. [Abstract]  

S. Wu, S. Chasalow, H. Lee, L. Xu, B. Paul, O. Mokliatchouk, W. F. Symmans, K. E. Zerba, L. Pusztai, and E. Clark

Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 2525. [Abstract]  

G. Selvaggi, P. Ceppi, M. Longo, M. Giaj Levra, S. Cappia, M. Volante, S. Novello, M. Papotti, and G. V. Scagliotti

Clinical impact of ERCC1 and TOPOII gene expression in small-cell lung cancer patients treated with platinum/etoposide
J Clin Oncol (Meeting Abstracts) 2007 25: 2526. [Abstract]  

O. Mir, J. Alexandre, A. Tran, F. Rabillon, V. Girre, V. Dieras, G. Pons, J. M. Treluyer, and F. Goldwasser

Relationship between glutathione-S-transferase P1 Ile¹⁰⁵Val polymorphism and docetaxel neurosensory toxicity
J Clin Oncol (Meeting Abstracts) 2007 25: 2527. [Abstract]  

W. Zamboni, L. J. Maruca, S. Strychor, B. A. Zamboni, S. Ramalingam, R. P. Edwards, D. M. Friedland, R. G. Stoller, C. P. Belani, and R. K. Ramanathan

Age and body composition related-effects on the pharmacokinetic disposition of STEALTH liposomal CKD- 602 (S-CKD602) in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2528. [Abstract]  

M. Joerger G. EORTC-PAMM-NDDG

Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG
J Clin Oncol (Meeting Abstracts) 2007 25: 2529. [Abstract]  

J. Latz, L. Claret, J. Symanowski, C. Falcoz, R. Bruno, I. Smith, and H. Calvert

Evaluation of pemetrexed (PEM) dosing paradigms using exposure-response relationships (ERRs)
J Clin Oncol (Meeting Abstracts) 2007 25: 2530. [Abstract]  

J. Hannemann, H. Halfwerk, A. Velds, C. Loo, E. J. Rutgers, S. Rodenhuis, and M. J. van de Vijver

Prospective analysis of mRNA expression signatures as predictive tests in primary breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2531. [Abstract]  

J. K. Chan, D. S. Kapp, E. Mechetner, and I. Yu

Biomarker and in vitro chemoresistance profiles of undifferentiated ovarian cancers
J Clin Oncol (Meeting Abstracts) 2007 25: 2532. [Abstract]  

R. Dua, P. Nhonthachit, C. Rinehart, C. L. Arteaga, R. Nahta, F. J. Esteva, J. Winslow, M. Bates, and C. Petropoulos

Patterns of HER-family receptor dimerization in trastuzumab susceptible and trastuzumab resistant cell lines
J Clin Oncol (Meeting Abstracts) 2007 25: 2533. [Abstract]  

R. F. Riedel, A. Porrello, E. Chenette, A. Potti, J. R. Nevins, and P. G. Febbo

A genomic approach to identify mechanisms associated with chemotherapy resistance
J Clin Oncol (Meeting Abstracts) 2007 25: 2534. [Abstract]  

A. Sabharwal, P. Corrie, A. Seebaran, D. Anderson, J. Carmichael, P. Mortimer, G. P. Margison, A. Watson, and M. R. Middleton

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2535. [Abstract]  

J. Kim, S. Choi, H. Yi, J. Lim, M. Lee, I. Hyun, and C. Kim

Prediction of response to chemotherapy using sequential F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2536. [Abstract]  

G. A. McArthur, R. M. Hicks, D. R. Shalinsky, D. Binns, C. O’Kane, A. Hogg, R. Fisher, T. J. McCarthy, and K. A. Anderes

Positron-emission tomography reveals early flare in uptake of FLT in tumors following chemotherapy with gemcitabine
J Clin Oncol (Meeting Abstracts) 2007 25: 2537. [Abstract]  

R. Ikeda, K. Yoshida, A. Takagane, A. Tsuburaya, O. Kobayashi, H. Sunouchi, M. Matsukawa, K. Tanimoto, K. Hiyama, and M. Nishiyama

Pharmacogenomic (PG) analysis for prediction of individual response to paclitaxel in 5-FU-refractory metastatic gastric cancer: Prediction formula of tumor response using novel marker genes and genotypes associated with the toxicity
J Clin Oncol (Meeting Abstracts) 2007 25: 2538. [Abstract]  

H. Isobe, N. Yamamoto, H. Kunikane, N. Masuda, K. Eguchi, M. Shibuya, Y. Takeda, T. Ogura, A. Yokoyama, M. Harada, and K. Watanabe

A phase I/II, pharmacokinetic (PK) and pharmacogenomic (PG) study of weekly irinotecan (CPT-11) therapy for elderly patients with advanced non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2539. [Abstract]  

J. J. Grau, M. Monzo, M. Vargas, S. Jansa, m. Campayo, L. Alos, J. Domingo-Domenech, and E. Verger

Single nucleotide polymorphisms (SNPs) analysis of CYP2C8, GSTT1, GSTP1, MDR1(A), MDR1(B) and ERCC1 as predictor of survival after weekly paclitaxel for relapsed advanced head & neck cancer patients (AHNCP)
J Clin Oncol (Meeting Abstracts) 2007 25: 2540. [Abstract]  

C. Mercier, J. Ciccolini, C. Dupuis, V. Secq, L. Padovani, T. Pignon, L. Dahan, F. Duffaud, J. Seitz, B. Lacarelle, and R. Favre

Prospective phenotypic screening for DPD deficiency in patients upon fluoropyrimidines administration: Impact on the reduction of drug-induced toxicities
J Clin Oncol (Meeting Abstracts) 2007 25: 2541. [Abstract]  

C. A. Slapak, P. M. LoRusso, D. Mendelson, A. K. Sykes, D. P. De Alwis, M. M. Wagner, R. L. Ilaria, Jr, and M. S. Gordon

Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 24-hour continuous infusion in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2542. [Abstract]  

N. J. Zojwalla, C. H. Takimoto, A. G. Lucarelli, R. Clark, A. C. Mita, M. M. Mita, O. Romero, E. L. Schuck, I. Krivelevich, and C. J. Sweeney

A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 2543. [Abstract]  

R. M. Glasspool, A. V. Boddy, T. R. Evans, M. J. Griffin, A. Anthoney, A. Barker, R. E. Longley, C. J. Twelves, C. J. Edwards, and H. E. Wilcox

A phase I study of a novel taxane, TL310, orally administered every week in patients (pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2544. [Abstract]  

G. J. Fetterly, J. S. Owen, K. Stuyckens, J. A. Passarell, P. Zannikos, A. S. Matos, M. A. Izquierdo, and J. J. Perez-Ruixo

Mechanism-based PKPD model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET- 743) treatment
J Clin Oncol (Meeting Abstracts) 2007 25: 2545. [Abstract]  

E. E. Brouwers, A. D. Huitema, W. Boogerd, J. H. Beijnen, and J. H. Schellens

Relationship between persistent neurotoxicity and long-term platinum exposure after treatment with cisplatin
J Clin Oncol (Meeting Abstracts) 2007 25: 2546. [Abstract]  

J. Delord, P. Schöffski, E. Brain, H. Dumez, J. Robert, S. Faivre, V. Dubois, K. Vialatte, J. Deshayes, and D. Ravel

Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2547. [Abstract]  

M. N. Stein, A. Tan, K. Taber, R. Fernandez, N. G. Agrawal, E. Vandendries, K. Hsu, A. Walker, K. Holen, and G. Wilding

Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2548. [Abstract]  

G. Batist, W. Miller, L. Mayer, A. Janoff, C. Swenson, A. Louie, K. Chi, S. Chia, and K. Gelmon

Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 2549. [Abstract]  

S. Madajewicz, N. J. Zojwalla, A. G. Lucarelli, P. Hentschel, J. Giardelli, E. L. Schuck, I. Krivelevich, B. Y. Wong, N. J. Vogelzang, and S. Sharma

A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 2550. [Abstract]  

J. Fourie, L. K. Mattison, T. E. Wood, J. A. Posey, III, A. Modak, and R. B. Diasio

The 2-¹³C-5-fluorouracil breath test (FUBT) as a novel, rapid method for assessment of dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Initial characterization and comparison to the 2-¹³C-uracil breath test (UraBT)
J Clin Oncol (Meeting Abstracts) 2007 25: 2551. [Abstract]  

K. Gleason, C. Tigue, P. Yarnold, J. McKoy, C. Angelotta, D. Courtney, B. Edwards, J. Bohlius, and C. Bennett

Recombinant erythropoietin (Epo)/darbepoetin (Darb) associated venous thromboembolism (VTE) in the oncology setting: Findings from the Research on Adverse Drug Events And Reports (RADAR) project
J Clin Oncol (Meeting Abstracts) 2007 25: 2552. [Abstract]  

J. R. Goffin and D. Tu

Phase II stopping rules employing response rates and early progression
J Clin Oncol (Meeting Abstracts) 2007 25: 2553. [Abstract]  

B. Brennan, L. Siu, B. Dhesy-Thind, C. Cripps, A. Gandhi, M. Abt, K. Smith, K. Rittweger, S. Hussain, and S. Choudhury

Pharmacokinetic (PK) interactions between capecitabine (X), oxaliplatin (O) and bevacizumab (A) when used in combination for first-line treatment of metastatic colorectal cancer (MCRC)
J Clin Oncol (Meeting Abstracts) 2007 25: 2554. [Abstract]  

G. Giacone, L. Handskemager, H. Mouridsen, J. Tjornelund, S. Langer, J. Buter, A. Rasmussen, P. Buhl, K. Dahlstrom, and P. Grundtvig

Treatment of anthracycline extravasation with dexrazoxane: Pharmacokinetics and update on efficacy and safety from three multicenter trials
J Clin Oncol (Meeting Abstracts) 2007 25: 2555. [Abstract]  

R. Chadha, A. Mita, M. Iwasaki, Y. M. Lassere, K. R. Bogaard, S. A. Waldrum, J. L. Abbruzzese, and M. B. Thomas

Phase I study to determine the safety and pharmacokinetics of 4-hour intravenous infusion of TAS-106 on a once per week for 3 consecutive weeks every 28-day schedule in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2556. [Abstract]  

V. Guarcello, J. Fourie, M. J. Lawton, W. W. Peters, M. J. Heslin, and R. B. Diasio

Elucidating the mechanisms responsible for the previous failure of phase III clinical trials with eniluracil (EU) and development of a novel scheduling approach to optimize the efficacy of EU/5-fluorouracil (5-FU) combination therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 2557. [Abstract]  

A. Oaknin, R. Plummer, R. Salazar, A. Robinson, B. Pardo, A. A. Razak, C. Cuadra, L. Flores, M. A. Izquierdo, and H. Calvert

Phase I combination study of plitidepsin and carboplatin in advanced solid tumours
J Clin Oncol (Meeting Abstracts) 2007 25: 2558. [Abstract]  

C. Zanon, M. Airoldi, R. Passera, L. Cattel, P. Milla, U. Jaehde, A. Drescher, L. Branciforte, I. Gozzelino, and F. Pedani

Effects of reduced glutathione (GSH) on oxaliplatin pharmacokinetics (OXA pk) and on Pt-DNA adducts formation in advanced colorectal cancer patients treated by FOLFOX4 regimen
J Clin Oncol (Meeting Abstracts) 2007 25: 2559. [Abstract]  

J. R. Infante, S. F. Jones, M. Lawton, P. Wing, R. K. Malik, W. P. Peters, and H. A. Burris, III

A phase I study evaluating a novel schedule of oral eniluracil (EU) combined with escalating doses of oral 5-fluorouracil (5- FU)
J Clin Oncol (Meeting Abstracts) 2007 25: 2560. [Abstract]  

S. Manda, C. Mauser, J. Bokar, M. Cooney, J. Brell, S. Krishnamurthi, P. Savvides, P. Ivy, S. Remick, and A. Dowlati

Phase I trial of combination becatecarin and oxaliplatin in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2561. [Abstract]  

D. D. Von Hoff, J. A. Nieves, L. K. Vocila, S. D. Weitman, and E. Cvitkovic

The complete phase Ib clinical trial: A method to accelerate new agent development
J Clin Oncol (Meeting Abstracts) 2007 25: 2562. [Abstract]  

E. Brendel, E. Zafarana, C. Figuerola, M. Ludwig, C. Lathia, K. Burk, C. Robert, J. C. Soria, and J. P. Armand

Pharmacokinetic results of a phase I trial of sorafenib (S) in combination with dacarbazine (DTIC) in patients with advanced metastatic melanoma or other solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2563. [Abstract]  

M. M. Woo, L. Rodriguez, H. Gu, K. Crenshaw-Williams, F. Rocha, S. Freestone, J. Dickson, D. Jodrell, and J. B. Mangold

Absorption, metabolism, and excretion of ¹⁴C gimatecan (LBQ707) after oral administration in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2564. [Abstract]  

R. L. Oostendorp, P. O. Witteveen, B. Schwartz, J. H. Beijnen, E. E. Voest, and J. H. Schellens

Phase I and pharmacological study of orally administered indibulin in advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2565. [Abstract]  

C. Garufi, C. Focan, S. Tumolo, B. Coudert, S. Iacobelli, N. Tubiana, S. Marreaud, M. Lentz, T. Gorlia, F. Lévi EORTC Chronotherapy Group

Time finding study of chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L) and oxaliplatin (O) (chronoIFLO) against metastatic colorectal cancer: Results from randomized EORTC 05011 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 2566. [Abstract]  

J. A. Florian, Jr., M. J. Egorin, W. C. Zamboni, J. L. Eiseman, T. F. Lagattuta, C. P. Belani, G. S. Chatta, H. I. Scher, D. B. Solit, and R. S. Parker

A physiologically-based pharmacokinetic (PBPK) and pharmacodynamic (PD) model of docetaxel (Doc) and neutropenia in humans
J Clin Oncol (Meeting Abstracts) 2007 25: 2567. [Abstract]  

M. Bonneterre, N. Penel, M. Vanseymortier, E. Dansin, S. Clisant, Y. Vendel, M. Degardin, A. Adenis, R. Beuscart, and J. Bonneterre

Prognostic factors for cancer patients with good performance status considered for inclusion in phase I clinical trials
J Clin Oncol (Meeting Abstracts) 2007 25: 2568. [Abstract]  

M. Modiano, P. Plezia, J. Baram, R. Catane, A. Cohn, M. Basche, M. Kurman, G. Tapolsky, and S. Yancik

A phase I study of TPI 287, a third generation taxane, administered every 21 days in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2569. [Abstract]  

E. Chuang, L. Vahdat, T. Caputo, G. Goldberg, A. Flam, P. Christos, A. Colevas, F. Muggia, and S. Wadler

Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229
J Clin Oncol (Meeting Abstracts) 2007 25: 2570. [Abstract]  

A. Stopeck, S. Moulder, S. Jones, J. Cohen, M. McDowell, G. Cropp, Z. Zhong, S. Wells, A. Hannah, and H. Burris

Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules
J Clin Oncol (Meeting Abstracts) 2007 25: 2571. [Abstract]  

L. Musib, C. Darstein, J. Suico, J. Baldwin, and P. Welch

Effects of a potent CYP3A inhibitor on the pharmacokinetics and safety of enzastaurin
J Clin Oncol (Meeting Abstracts) 2007 25: 2572. [Abstract]  

N. P. van Erp, H. Gelderblom, M. van Glabbeke, A. van Oosterom, J. Verweij, H. Guchelaar, B. Peng, and I. Judson

Effect of smoking on imatinib pharmacokinetics
J Clin Oncol (Meeting Abstracts) 2007 25: 2573. [Abstract]  

Y. Rustum, L. Pendyala, P. Creaven, M. Ross, W. Brady, V. Badmaev, J. Prey, and M. G. Fakih

A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (Iri) in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2574. [Abstract]  

J. J. Hwang, J. L. Marshall, T. Ahmed, H. Chun, M. Basche, A. Cohn, M. Kurman, G. Tapolsky, G. Tapolsky, and E. Allen

A phase I study of TPI287: A third generation taxane administered weekly in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2575. [Abstract]  

L. J. Maruca, R. K. Ramanathan, S. Strychor, B. A. Zamboni, S. Ramalingam, R. P. Edwards, J. K. Kim, Y. J. Bang, H. P. Lee, and W. C. Zamboni

Age-related effects on the pharmacodynamic (PD) relationship between STEALTH liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2576. [Abstract]  

E. Sausville, P. LoRusso, M. Quinn, K. Forman, C. Leamon, D. Morganstern, S. Bever, and R. Messmann

A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 2577. [Abstract]  

R. D. Carvajal, A. Tse, N. Wu, M. Gonen, R. Lefkowitz, H. Dials, A. Barbi, J. Mui, G. K. Schwartz, and M. Shah

Pharmacokinetics (PK) of split-dose flavopiridol (F) administered with CPT-11 (CPT) and cisplatin (Cis)
J Clin Oncol (Meeting Abstracts) 2007 25: 2578. [Abstract]  

P. C. Adamson, H. Zhao, A. Sievert, A. Troxel, and R. Aplenc

A simulation study to define the number of patients necessary to meet primary pharmacokinetic (pk) aims of phase I oncology trials
J Clin Oncol (Meeting Abstracts) 2007 25: 2579. [Abstract]  

A. Lopez-Martin, L. Paz-Ares, E. Calvo, D. Castellano, C. Valverde, S. Neciosup, E. Vilar, B. San Antonio, I. Garcia-Ribas, H. Cortes-Funes, and J. Bellmunt

Phase I study of bi-weekly pemetrexed (P) plus cisplatin (C) in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 2580. [Abstract]  

Developmental Therapeutics: Immunotherapy:

A. Ribas, S. Antonia, J. Sosman, J. M. Kirkwood, B. Redman, T. F. Gajewski, D. Pavlov, C. Bulanhagui, J. Gomez- Navarro, and L. H. Camacho

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3000. [Abstract]  

L. Fong, B. Kavanagh, Y. Hou, S. O’Brien, J. Valiente, V. Weinberg, B. I. Rini, and E. J. Small

Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells
J Clin Oncol (Meeting Abstracts) 2007 25: 3001. [Abstract]  

A. W. Tolcher, M. L. Rothenberg, J. Rodon, D. Delbeke, A. Patnaik, L. Nguyen, F. Young, Y. Hwang, C. Haqq, and I. Puzanov

A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3002. [Abstract]  

J. Baurain, M. Stas, B. Neyns, G. Schuler, T. Velu, K. Thielemans, N. Van Baren, T. Dorval, M. Marchand, and P. Coulie

Comparing immunogenicities of tumor-specific antigens administered as therapeutic vaccines in metastatic melanoma patients
J Clin Oncol (Meeting Abstracts) 2007 25: 3003. [Abstract]  

M. Ross, L. H. Camacho, E. M. Hersh, C. K. Brown, J. Richards, P. Mitsky, E. Wasserman, S. Lee, N. Bercovici, D. Landais, and A. Ribas

Clinical and Immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi-institutional phase II clinical trial
J Clin Oncol (Meeting Abstracts) 2007 25: 3004. [Abstract]  

J. D. Wolchok, H. Gallardo, M. Perales, T. Rasalan, J. Wang, P. B. Chapman, S. E. Krown, P. O. Livingston, M. Heywood, and J. Yuan

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3005. [Abstract]  

M. A. Di Nicola, C. Carlo-Stella, R. Zappasodi, L. Passoni, D. Liliana, M. Magni, P. Matteucci, R. Mortarini, A. Anichini, and A. M. Gianni

Immunization of indolent non-Hodgkin’s lymphoma patients with autologous monocyte-derived dendritic cells loaded with heat shocked and killed autologous tumor cells: A phase I study
J Clin Oncol (Meeting Abstracts) 2007 25: 3006. [Abstract]  

T. F. Schwarz, G. Dubin HPV Vaccine Study Investigators for Adult Women

Human papillomavirus (HPV) 16/18 l1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years
J Clin Oncol (Meeting Abstracts) 2007 25: 3007. [Abstract]  

A. Letsch, C. Scheibenbogen, A. Busse, A. M. Asemissen, A. Schmittel, W. K. Hofmann, L. Uharek, I. W. Blau, E. Thiel, and U. Keilholz

Phase II trial of vaccination with WT1 peptide, GM-CSF, and KLH in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results
J Clin Oncol (Meeting Abstracts) 2007 25: 3008. [Abstract]  

D. Laheru, C. Yeo, B. Biedrzycki, S. Solt, E. Lutz, B. Onners, I. Tartakovsky, J. Herman, R. Hruban, S. Piantadosi, and E. Jaffee

A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas
J Clin Oncol (Meeting Abstracts) 2007 25: 3010. [Abstract]  

V. E. Herrin, M. S. Achtar, S. M. Steinberg, T. L. Whiteside, E. Wieckowski, M. Czystowska, C. Visus, J. A. Berzofsky, and S. N. Khleif

A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 3011. [Abstract]  

A. Chiappori, M. Sereno, D. Gabrilovich, N. Mirza, M. Dunn, W. Janssen, R. Smilee, K. Menander, S. Chada, and S. Antonia

Phase II trial of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy (CT)
J Clin Oncol (Meeting Abstracts) 2007 25: 3012. [Abstract]  

M. Morse, R. Chapman, T. Clay, T. Osada, A. Hobeika, J. Green, T. Davis, and T. Keler

Antigen presenting cell (APC)-targeted hCGß vaccine for cancer therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 3013. [Abstract]  

J. P. Holmes, A. Amin, C. E. Storrer, A. M. Smith, Y. H. Jama, A. McNeil, D. Craig, S. Ponniah, and G. E. Peoples

Clinical and immunologic effects of a HER2/neu (E75) peptide vaccine booster in previously vaccinated breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 3014. [Abstract]  

D. Atanackovic, N. K. Altorki, Y. Cao, E. Ritter, C. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic

Booster vaccination of non-small cell lung cancer (NSCLC) patients with MAGEA3 protein and AS02B adjuvant
J Clin Oncol (Meeting Abstracts) 2007 25: 3015. [Abstract]  

A. Palucka, J. Banchereau, L. Vence, J. Connolly, J. Fay, and H. Ueno

Comprehensive analysis of melanoma antigen specific T cell repertoire: EPIMAX (EPItope MAXimum)
J Clin Oncol (Meeting Abstracts) 2007 25: 3016. [Abstract]  

H. Singh-Jasuja, S. Walter, T. Weinschenk, A. Mayer, P. Y. Dietrich, M. Staehler, A. Stenzl, S. Stevanovic, H. Rammensee, and J. Frisch

Correlation of T-cell response, clinical activity and regulatory T-cell levels in renal cell carcinoma patients treated with IMA901, a novel multi-peptide vaccine
J Clin Oncol (Meeting Abstracts) 2007 25: 3017. [Abstract]  

E. Ritsou, H. Le Buanec, F. Haghighi Rad, P. Larcier, D. Zagury, and G. Uzan

VEGF kinoid vaccine, a therapeutic arm against tumor angiogenesis and metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 3018. [Abstract]  

G. A. Daniels, M. Chan, C. C. Wu, R. Tawatao, D. Messmer, B. Eftimie, H. Cottam, and D. Carson

Covalent coupling of a novel TLR7 agonist to antigen elicits an effective immune response in a murine melanoma tumor model
J Clin Oncol (Meeting Abstracts) 2007 25: 3019. [Abstract]  

M. J. Jaeger, A. M. Schoberth, M. M. Heiss, A. Lahr, and H. Lindhofer

Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites
J Clin Oncol (Meeting Abstracts) 2007 25: 3020. [Abstract]  

E. Zhukovsky, S. Chu, M. Bernett, S. Karki, W. Dang, P. Hammond, C. Edler, N. Polder, C. Chan, J. Jacinto, and J. Desjarlais

XmAb Fc engineered anti-CD19 monoclonal antibodies with enhanced in vitro efficacy against multiple lymphoma cell lines
J Clin Oncol (Meeting Abstracts) 2007 25: 3021. [Abstract]  

C. Renner, G. Ritter, L. Pan, E. Venkatramin, E. W. Hoffman, R. Venhaus, L. Old, A. Knuth, E. Jäger, and M. Pfreundschuh

Phase I trial of huA33 antibody plus 5-fluorouracil (5FU), leucovorin, and oxaliplatin in patients with metastatic colorectal cancer [LUD2003–005]
J Clin Oncol (Meeting Abstracts) 2007 25: 3022. [Abstract]  

J. B. Bartlett, L. Wu, M. Adams, P. Schafer, G. Muller, and D. Stirling

Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab
J Clin Oncol (Meeting Abstracts) 2007 25: 3023. [Abstract]  

P. Braly, C. Chu, Y. Collins, R. Edwards, A. Gordon, W. McGuire, L. M. Smith, C. Nicodemus, and M. Method

Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC)
J Clin Oncol (Meeting Abstracts) 2007 25: 3024. [Abstract]  

M. Andreeff, J. Dembinski, M. Studeny, X. Ling, T. McQueen, A. Klopp, and F. Marini

Mesenchymal stem cells selectively engraft into tumor stroma and produce potent antitumor proteins in situ
J Clin Oncol (Meeting Abstracts) 2007 25: 3025. [Abstract]  

J. M. Zimmerer, A. Lehman, A. Ruppert, T. Olencki, K. Kendra, M. J. Walker, and W. E. Carson, III

Interferon-alpha-2b induced signal transduction and gene regulation in patient immune cells is not enhanced by a dose increase from 5 MU/m² to 10 MU/m²
J Clin Oncol (Meeting Abstracts) 2007 25: 3026. [Abstract]  

W. Wang, H. Edington, U. Rao, D. Jukic, S. Land, and J. M. Kirkwood

The response of IFNAR2 to high-dose IFN2b during a neoadjuvant clinical trial
J Clin Oncol (Meeting Abstracts) 2007 25: 3027. [Abstract]  

A. Mani, J. Roda, M. Caligiuri, G. Fleming, P. Kaufman, A. Brufsky, W. Carson, III, and C. Shapiro

A phase II trial of trastuzumab and low dose interleukin-2 in patients with metastatic breast cancer who have previously failed trastuzumab
J Clin Oncol (Meeting Abstracts) 2007 25: 3028. [Abstract]  

D. M. Kofler, T. Elter, A. Gianella-Borradori, S. Busby, C. M. Wendtner, and M. Hallek

A phase Ib trial of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed B-cell chronic lymphocytic leukemia (B-CLL)
J Clin Oncol (Meeting Abstracts) 2007 25: 3029. [Abstract]  

R. J. Tesi, H. Tran, J. Christensen, J. Morales, M. Karimi, M. Sagy, and V. Palath

Induction of apoptosis of myeloid leukemia with CSC17.1, a unique monoclonal antibody targeting CD45RA
J Clin Oncol (Meeting Abstracts) 2007 25: 3030. [Abstract]  

M. Schmidt, U. Reinhold, J. A. Kurbacher, O. Rieckmann, H. Huncke, A. Radmacher, I. A. Cree, and C. M. Kurbacher

A pilot study of bevacizumab (Bev) and continous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in heavily pretreated patients with refractory solid tumors: Preliminary results
J Clin Oncol (Meeting Abstracts) 2007 25: 3031. [Abstract]  

C. F. Mojcik, N. S. Young, L. Luzzatto, G. Socié, P. Hillmen, and R. A. Brodsky

Safety and efficacy of eculizumab with concomitant erythropoietin therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)
J Clin Oncol (Meeting Abstracts) 2007 25: 3032. [Abstract]  

K. Sharma, W. H. Wilson, K. Dunleavy, P. M. Shovlin, H. X. Chen, J. E. Janik, and J. Gea-Banacloche

BK viral infections in patients treated with alemtuzumab
J Clin Oncol (Meeting Abstracts) 2007 25: 3033. [Abstract]  

M. Karmely, D. B. Rubinstein, and D. H. Wreschner

Generation of antibodies that target and kill MUC1 expressing cancer cells via a novel cell-tethered MUC1 /ß junction epitope
J Clin Oncol (Meeting Abstracts) 2007 25: 3034. [Abstract]  

K. Y. Chung, I. Gore, L. Fong, A. Venook, P. Dorazio, D. Healey, D. Pavlov, and L. B. Saltz

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum
J Clin Oncol (Meeting Abstracts) 2007 25: 3035. [Abstract]  

A. Beano, E. Signorino, M. A. Polimeni, M. Mistrangelo, M. Ardine, R. Spadi, M. Donadio, L. Ciuffreda, and L. Matera

Correlation between NK function and response to trastuzumab in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3036. [Abstract]  

N. M. Reddy, F. Hernandez-Ilizalituri, J. Knight, and M. S. Czuczman

Antitumor effects of lenalidomide in combination with IDEC114 (anti CD80) in lymphoma bearing severe combined immunodeficiency (SCID) mouse model
J Clin Oncol (Meeting Abstracts) 2007 25: 3037. [Abstract]  

S. Antonia, J. Sosman, J. M. Kirkwood, B. Redman, T. F. Gajewski, D. Pavlov, C. Bulanhagui, L. H. Camacho, and A. Ribas

Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206
J Clin Oncol (Meeting Abstracts) 2007 25: 3038. [Abstract]  

N. Pathan, J. Byrd, K. Hariharan, P. Chu, and A. Molina

Lumiliximab (anti-CD23 antibody) mediates apoptosis and antitumor activity in chronic lymphocytic leukemia (CLL) cells and CD23⁺ lymphoma cell lines
J Clin Oncol (Meeting Abstracts) 2007 25: 3039. [Abstract]  

H. K. Hariharan, T. Murphy, D. Clanton, L. Berquist, P. Chu, T. Yun, A. Molina, and S. Ho

Combining galiximab with the chemotherapeutic agents fludarabine or doxorubicin improves efficacy in animal models of lymphoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3040. [Abstract]  

X. Kang, D. Patel, S. Ng, M. Melchior, D. Ludwig, and D. Hicklin J

High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab
J Clin Oncol (Meeting Abstracts) 2007 25: 3041. [Abstract]  

D. Mahadevan, H. Garewal, C. Riley, Y. Zhu, K. Engelhardt, L. Cooke, R. Nagle, J. Saldanha, and D. Von Hoff

Humanized anti-CEACAM6 PEGylated scFv: A promising novel therapy for pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3042. [Abstract]  

J. Hu, H. Guo, H. Xu, and N. V. Cheung

Construction and targeting of a 5F11-scFv-methioninase fusion protein for antibody-directed enzyme pro-drug therapy (ADEPT) against neuroblastoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3043. [Abstract]  

M. Dechant, M. Peipp, T. Schneider-Merck, T. Beyer, J. J. Lammerts van Bueren, W. K. Bleeker, P. W. Parren, J. G. van de Winkel, and T. Valerius

Lung cancer-derived EGFR mutations affect responses to tyrosine kinase inhibitors, but not to monoclonal antibodies
J Clin Oncol (Meeting Abstracts) 2007 25: 3044. [Abstract]  

J. Horiguchi, Y. Koibuchi, N. Rokutanda, R. Nagaoka, M. Kikuchi, A. Sato, Y. Ishikawa, H. Odawara, Y. Iino, and I. Takeyoshi

Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3045. [Abstract]  

M. Sebastian, M. Jaeger, P. Kiewe, W. Schuette, R. Wiewrodt, H. Lindhofer, B. Mueller, H. Friccius-Quecke, H. Friccius- Quecke, and A. Schmittel

Effects of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion
J Clin Oncol (Meeting Abstracts) 2007 25: 3046. [Abstract]  

L. A. Lampson and C. A. Tripp

Antibody-secreting cells to deliver antibody against brain metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 3047. [Abstract]  

H. Kimura, T. Iizasa, and A. Ishikawa

Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor draining lymph nodes in primary lung cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 3048. [Abstract]  

R. J. Ricafort, M. Stephan, R. O’Reilly, and M. Sadelain

In vitro expansion of CMV-specific CD4+ T-cells by artificial antigen presentation for adoptive immunotherapy in the post- transplant setting
J Clin Oncol (Meeting Abstracts) 2007 25: 3049. [Abstract]  

L. Duval, H. Schmidt, T. Steiniche, K. Kaltoft, K. Fode, J. J. Jensen, S. M. Soerensen, M. I. Nishimura, and H. von der Maase

Accumulation of lymphocytes following adoptive transfer of allogeneic T lymphocytes equipped with an HLA-A2 restricted, MART-1 reactive T Cell Receptor
J Clin Oncol (Meeting Abstracts) 2007 25: 3050. [Abstract]  

Y. C. Wei, J. J. Stephenson, J. Li, K. E. Burgin, H. Bouton-Verville, S. Jakubchak, L. M. Holmes, K. Meyer, J. Martin, S. D. Trocha, and T. E. Wagner

A phase II clinical study of dendritoma vaccination combined with low dose interleukin-2 in advanced melanoma patients
J Clin Oncol (Meeting Abstracts) 2007 25: 3051. [Abstract]  

A. Dutour, D. Lee, S. Napier, E. Yvon, H. Finney, M. Brenner, and R. Rousseau

Anti-leukemia activity of CD33-specific chimeric cytotoxic T lymphocytes in vitro and in vivo is impaired by addition of the CD28 costimulatory endodomain
J Clin Oncol (Meeting Abstracts) 2007 25: 3052. [Abstract]  

U. Toh, T. Fujii, S. Takamori, M. Fukunaga, E. Ogo, N. Seki, H. Yamana, and K. Shirouzu

Combination of gemcitabine and adoptive cell therapy of autologous anti-tumor CTL induces clinical activities in patients with refractory lung cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3053. [Abstract]  

C. Bengala, V. Rasini, R. Sternieri, M. Dominici, A. Andreotti, R. Gelmini, L. Cafarelli, P. Bevini, A. Berti, and P. Conte

Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis
J Clin Oncol (Meeting Abstracts) 2007 25: 3054. [Abstract]  

I. D. Davis, B. Brady, M. Millward, B. K. Skrumsager, U. Mouritzen, P. E. Kristjansen, and G. McArthur

Anti-tumor activity of recombinant human Interleukin-21 (rIL-21): Preliminary data from a phase 2a study in patients with stage IV malignant melanoma (MM) without prior treatment
J Clin Oncol (Meeting Abstracts) 2007 25: 3055. [Abstract]  

S. Lee, V. Rusciano, and J. P. Dutcher

Efficacy of gabapentin on pruritus induced by interleukin-2 (IL-2) treatment in patients with metastatic renal cell carcinoma and melanoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3056. [Abstract]  

G. Curigliano, G. Spitaleri, T. De Pas, C. Noberasco, L. Giovannoni, H. Menssen, L. Zardi, A. Milani, D. Neri, and F. de Braud

A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3057. [Abstract]  

A. D. Cohen, A. Diab, M. A. Perales, F. Duan, R. Jenq, G. Rizzuto, D. Hirschorn-Cymmerman, T. Merghoub, J. D. Wolchok, and A. N. Houghton

Agonist anti-GITR antibody induces CD8 T cell-mediated tumor rejection
J Clin Oncol (Meeting Abstracts) 2007 25: 3058. [Abstract]  

A. Amin, A. Stojadinovic, J. P. Holmes, C. E. Storrer, A. M. Smith, Y. H. Jama, D. Craig, S. Ponniah, and G. E. Peoples

Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with a preventive HER2/neu E75-peptide vaccine
J Clin Oncol (Meeting Abstracts) 2007 25: 3059. [Abstract]  

C. Salvador, B. Li, R. Hansen, D. Cramer, and J. Yan

Cytotoxicity of bevacizumab is enhanced by ß-glucan in tumors expressing membrane-bound VEGF
J Clin Oncol (Meeting Abstracts) 2007 25: 3060. [Abstract]  

B. S. Craft, R. Kurzrock, R. Herbst, K. Culotta, C. Stewart, V. Dorsey, S. Lippman, D. Gingher, N. Bekele, and D. Karp

The changing face of phase I protocols: A closer look at study requirements
J Clin Oncol (Meeting Abstracts) 2007 25: 3061. [Abstract]  

M. M. Mita, A. D. Ricart, A. C. Mita, A. Patnaik, J. Sarantopoulos, K. Sankhala, R. J. Fram, A. Qin, J. Watermill, and A. W. Tolcher

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3062. [Abstract]  

C. Cerveny, L. Grosmaire, E. Espling, R. Bader, C. Nilsson, P. Baum, A. Wahl, J. Ledbetter, and M. Hayden-Ledbetter

Depletion of Normal and Malignant B cells with a CD37-specific SMIP molecule
J Clin Oncol (Meeting Abstracts) 2007 25: 3063. [Abstract]  

P. J. Squiban, E. Bompas, J. Bennouna, V. Levy, H. Sicard, S. Lafaye de Micheaux, E. Viey, S. Salot, J. Tiollier, and F. Calvo

V9V2 T () lymphocytes: a promising approach for immunotherapy of solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3064. [Abstract]  

J. Nesselhut, T. Nesselhut, R. Chang, D. Marx, W. Brockmann, I. Wilke, C. Matthes, D. Lorenzen, W. Stücker, H. Peters, and W. Lüke

Dendritic cell therapy in glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2007 25: 3065. [Abstract]  

R. A. Madan, J. L. Gulley, W. L. Dahut, S. M. Steinberg, D. J. Liewehr, J. Schlom, and P. M. Arlen

Five-year overall survival (OS) in non-metastatic androgen-independent prostate cancer (AIPC) patients (pts) treated with nilutamide (N), vaccine (V), and combination therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 3066. [Abstract]  

M. S. Achtar, A. Toubaji, V. Herrin, B. Gause, M. Hamilton, R. Berhens, F. Grollman, S. Bernstein, and S. Khleif

Phase II clinical trial of mutant Ras peptide vaccine in combination with GM-CSF and IL-2 in advanced cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 3067. [Abstract]  

S. Brown, C. Cunningham, G. Mary, Crowley Medical Research Trial Network, M. Morse, F. A. Greco, D. McCune, H. Khong, R. Steis, B. Mills, G. Ishioka, and J. Bender

Phase II trial of a 10-epitope CTL vaccine, EP-2101, in metastatic NSCLC patients
J Clin Oncol (Meeting Abstracts) 2007 25: 3068. [Abstract]  

A. Cao, J. Hernandez-McClain, J. Willis, R. Harrop, W. Shingler, P. Chikoti, N. Drury, and R. Amato

Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon- (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 3069. [Abstract]  

D. Z. Chang, K. Zhu, S. Kopetz, K. Voo, Y. Li, P. Hwu, L. Radvanyi, and J. L. Abbruzzese

Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs
J Clin Oncol (Meeting Abstracts) 2007 25: 3070. [Abstract]  

A. B. Deisseroth, Y. Tang, H. Akbulut, J. Maynard, and L. Petersen

Donor lymphocyte infusions from Ad-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost (VPP) vaccinated allodonors decrease tumor cell growth post allograft
J Clin Oncol (Meeting Abstracts) 2007 25: 3071. [Abstract]  

A. Floercken, J. Kopp, R. Schabath, K. Joehrens-Leder, H. Pohla, D. Schendel, T. Blankenstein, B. Dörken, J. Westermann, and A. Pezzutto

HLA-A0201-positive, IL-7/B7.1-cotransfected allogeneic tumor cells as a vaccine in metastatic renal cell cancer—A clinical phase-I trial
J Clin Oncol (Meeting Abstracts) 2007 25: 3072. [Abstract]  

S. Slovin, P. Gregor, J. Wolchok, A. Pedraza, F. Orlandi, M. Jefferson, M. Jefferson, C. Fernandez, J. Rudolph, A. Houghton, and H. Scher

A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)—A phase I trial of proof of principle
J Clin Oncol (Meeting Abstracts) 2007 25: 3073. [Abstract]  

U. Galili, K. Wigglesworth, and U. Abdel-Motal

Xenograft-like destruction of tumors and their conversion into vaccines by intratumoral injection of -gal glycolipids
J Clin Oncol (Meeting Abstracts) 2007 25: 3074. [Abstract]  

D. Soulieres, C. Smith, P. M. Ellis, N. Murray, K. Jasas, A. Maksymiuk, G. Goss, M. H. Falk, and C. Butts

A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease
J Clin Oncol (Meeting Abstracts) 2007 25: 3075. [Abstract]  

K. Brämswig, R. Knittelfelder, S. Gruber, A. B. Riemer, R. Kammerer, W. Zimmermann, R. Horvat, C. C. Zielinski, O. Scheiner, and E. Jensen-Jarolim

Vaccination with a CEA epitope mimic leads to reduced growth of tumor transplants
J Clin Oncol (Meeting Abstracts) 2007 25: 3076. [Abstract]  

N. N. Petenko, I. N. Mikhaylova, G. Z. Chkadua, E. V. Ogorodnokova, L. Y. Vishnyakova, S. A. Hatirev, E. A. Cheremushkin, Z. G. Kadagidze, L. V. Demidov, and A. Y. Baryshnikov

Dendritic cell based vaccine therapy of melanoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3077. [Abstract]  

Developmental Therapeutics: Molecular Therapeutics:

H. M. Prince, D. George, A. Patnaik, M. Mita, M. Dugan, D. Butterfoss, E. Masson, K. W. Culver, H. A. Burris, III, and J. Beck

Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3500. [Abstract]  

D. W. Northfelt, R. F. Marschke, Jr, E. Bonnem, C. E. Ooi, R. Gerwien, T. Hawthorne, A. Clarke, P. Buhl-Jensen, D. Von Hoff, and J. Grem

A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3501. [Abstract]  

A. Daud, M. Schmitt, D. Marchion, E. Bicaku, S. Minton, M. Egorin, J. Zwiebel, A. Chiappori, D. Sullivan, and P. Munster

Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 3502. [Abstract]  

D. Miura, K. Yoneyama, Y. Furuhata, and H. Kawabata

Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by a rapid recruitment of natural killer cells in Her-2 overexpressing breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3503. [Abstract]  

M. M. Hipp, N. Hilf, S. Walter, D. Werth, L. Kanz, T. Weinschenk, H. Singh, and P. Brossart

Sorafenib but not sunitinib affects the induction of immune responses
J Clin Oncol (Meeting Abstracts) 2007 25: 3504. [Abstract]  

C. S. Higano, E. Y. Yu, S. H. Whiting, M. S. Gordon, P. LoRusso, F. Fox, T. L. Katz, J. M. Roecker, and J. D. Schwartz

A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3505. [Abstract]  

F. Huang, W. Hurlburt, R. Hafezi, X. Han, J. Chen, J. Carboni, R. M. Attar, L. Helman, E. Clark, and A. Dongre

Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor
J Clin Oncol (Meeting Abstracts) 2007 25: 3506. [Abstract]  

J. S. de Bono, A. Adjei, G. Attard, M. Pollak, P. Fong, P. Haluska, L. Roberts, D. Chainese, L. Terstappen, and A. Gualberto

Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R): Method of detection, incidence and potential applications
J Clin Oncol (Meeting Abstracts) 2007 25: 3507. [Abstract]  

E. Dijkers, M. N. Lub-de Hooge, J. G. Kosterink, P. L. Jager, A. H. Brouwers, L. R. Perk, G. A. van Dongen, and E. G. de Vries

Characterization of ⁸⁹Zr-trastuzumab for clinical HER2 immunoPET imaging
J Clin Oncol (Meeting Abstracts) 2007 25: 3508. [Abstract]  

S. Cresta, D. Tosi, C. Sessa, L. Viganò, M. Maur, D. Hess, A. Locatelli, D. S. Wages, J. Albanell, L. Gianni SENDO- Southern Europe New Drug Organization

Phase 1b study defining the optimal dosing combinations of the mTOR inhibitor AP23573 and Paclitaxel (PTX)
J Clin Oncol (Meeting Abstracts) 2007 25: 3509. [Abstract]  

M. J. Ratain, K. L. Napoli, K.Knightley Moshier, X. Jiang, G. F. Fleming, T. F. Gajewski, E. Jacobsen, and E. E. Cohen

A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 3510. [Abstract]  

S. Di Cosimo, M. Scaltriti, D. Val, F. Rojo, M. Guzman, J. Jimenez, J. Seoane, J. Arribas, and J. Baselga

The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 3511. [Abstract]  

A. Patnaik, A. Ricart, J. Cooper, K. Papadopoulos, M. Beeram, C. Mita, M. M. Mita, D. Hufnagel, E. Izbicka, A. W. Tolcher National Cancer Institute

A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 3512. [Abstract]  

S. Ellard, K. A. Gelmon, S. Chia, M. Clemons, H. Kennecke, B. Norris, L. McIntosh, and L. Seymour

A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3513. [Abstract]  

D. Feldman and A. C. Koong

Irestatin, a potent inhibitor of IRE1 and the unfolded protein response, is a hypoxia-selective cytotoxin and impairs tumor growth
J Clin Oncol (Meeting Abstracts) 2007 25: 3514. [Abstract]  

C. P. Hart, S. Ammons, J. X. Duan, D. Jung, J. Wang, H. Jiao, F. Meng, L. Lan, J. W. Evans, and M. Matteucci

Discovery of TH-302: An achiral hypoxia-activated cytotoxic prodrug
J Clin Oncol (Meeting Abstracts) 2007 25: 3515. [Abstract]  

M. B. Jameson, D. Rischin, M. Pegram, J. Gutheil, A. Patterson, W. Denny, and W. Wilson

A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3516. [Abstract]  

K. L. Blackwell, J. Chi, C. Sidor, P. Burke, T. LaVallee, H. S. Shaw, V. Liotcheva, D. Sims, L. Hobbs, J. Arnott, and M. W. Dewhirst

The effects of paclitaxel (PTX) and 2-methoxyestradiol (2-ME₂) on tumor oxygenation and HIF-1 in breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3517. [Abstract]  

S. Kummar, R. Kinders, M. Gutierrez, L. Rubinstein, R. E. Parchment, L. R. Phillips, J. Low, A. J. Murgo, J. E. Tomaszewski, J. H. Doroshow NCI Phase 0 Working Group

Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 3518. [Abstract]  

C. I. Wong, C. H. Thng, R. Soo, C. S. Chen, N. Sukri, N. Gupta, E. McKeegan, S. C. Lee, R. Humerickhouse, and B. C. Goh

Phase I and biomarker study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 3519. [Abstract]  

J. Tabernero, A. Cervantes, K. Hoekman, H. I. Hurwitz, D. I. Jodrell, P. Hamberg, M. Stuart, T. P. Green, R. B. Iacona, and J. Baselga

Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers
J Clin Oncol (Meeting Abstracts) 2007 25: 3520. [Abstract]  

W. M. Fiedler, G. Giaccone, P. Lasch, I. Van der Horst, N. M. Brega, S. Raber, D. Shalinsky, V. Ljubmir, C. Bokemeyer, E. Boven Pfizer A6191002 Study Team

Phase I trial of SU014813 in patients (pts) with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 3521. [Abstract]  

L. S. Rosen, D. Hong, L. Chap, R. Kurzrock, A. Garcia, E. Rasmussen, L. Nguyen, Y. Hwang, C. Storgard, and R. S. Herbst

First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3522. [Abstract]  

G. C. Jayson, C. Ton, G. J. Parker, A. Jackson, S. Mullamitha, K. Zinkewich-Peotti, R. Felix, J. Soranson, and L. Rolfe

Phase I and DCE-MRI evaluation of CDP791, a di-Fab PEG conjugate that inhibits VEGFR2
J Clin Oncol (Meeting Abstracts) 2007 25: 3523. [Abstract]  

N. Lewis, J. P. Eder, F. Guo, K. J. Pierce, and A. J. Olszanski

Phase 1 study of CP-868,596 an oral, highly specific PDGFR inhibitor
J Clin Oncol (Meeting Abstracts) 2007 25: 3524. [Abstract]  

A. Garcia, L. Rosen, C. C. Cunningham, J. Nemunaitis, C. Li, N. Rulewski, A. Dovholuk, R. Savage, T. Chan, R. Bukowksi, and T. Mekhail

Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose
J Clin Oncol (Meeting Abstracts) 2007 25: 3525. [Abstract]  

J. P. Eder, E. Heath, L. Appleman, G. Shapiro, D. Wang, L. Malburg, A. x. Zhu, T. Leader, A. Wolanski, and P. LoRusso

Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3526. [Abstract]  

L. L. Siu, H. A. Burris, L. Mileshkin, D. R. Camidge, D. Rischin, E. X. Chen, S. Jones, D. Yin, and H. Fingert

Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3527. [Abstract]  

S. Diab, S. Eckhardt, A. Tan, G. Frenette, L. Gore, W. Depinto, J. Grippo, M. DeMario, S. Mikulski, and S. Papadimitrakopoulou

A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs)
J Clin Oncol (Meeting Abstracts) 2007 25: 3528. [Abstract]  

T. A. Yap, D. S. Boss, P. C. Fong, M. Roelvink, A. Tutt, J. Carmichael, M. J. O’Connor, S. B. Kaye, J. H. Schellens, and J. S. de Bono

First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers
J Clin Oncol (Meeting Abstracts) 2007 25: 3529. [Abstract]  

A. D. Van den Abbeele, J. T. Yap, D. S. Grayzel, J. Walker, and G. D. Demetri

Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 3530. [Abstract]  

U. N. Vaishampayan, E. A. Sausville, M. N. Horiba, M. Quinn, L. K. Heilbrun, A. Burger, P. Ivy, J. Li, and P. Lorusso

Phase I trial of intravenous 17-allylaminogeldanamycin (A) and oral sorafenib (B) in pretreated advanced malignancy: Plasma Hsp90 induction correlates with clinical benefit
J Clin Oncol (Meeting Abstracts) 2007 25: 3531. [Abstract]  

P. G. Richardson, A. Chanan-Khan, S. Lonial, A. Krishnan, M. Carroll, G. F. Cropp, M. Albitar, R. G. Johnson, A. Hannah, and K. Anderson

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)
J Clin Oncol (Meeting Abstracts) 2007 25: 3532. [Abstract]  

A. N. Tse, R. Carvajal, M. Shah, H. Dials, M. Fogel, E. O’Reilly, K. Chung, R. Maki, N. Wu, M. Egorin, and G. K. Schwartz

Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3533. [Abstract]  

P. LoRusso, D. Hong, E. Heath, R. Kurzrock, D. Wang, M. Hsu, L. Goyal, J. Wiezorek, C. Storgard, and R. Herbst

First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3534. [Abstract]  

Y. Pan, R. Xu, M. Peach, C. Huang, D. Branstetter, B. Durbin, R. Herbst, G. Eckhardt, D. Mendelson, and P. Holland

Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3535. [Abstract]  

K. Nakagawa, T. Satoh, I. Okamoto, M. Miyazaki, R. Morinaga, A. Tsuya, Y. Hasegawa, M. Terashima, S. Ueda, and M. Fukuoka

Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan
J Clin Oncol (Meeting Abstracts) 2007 25: 3536. [Abstract]  

A. Protheroe, A. Reid, G. Attard, A. Davies, J. Spicer, L. Vidal, E. Bone, L. Hooftman, A. Harris, and J. De-Bono

First in-human phase 1 trial of a novel amino-peptidase inhibitor, CHR-2797
J Clin Oncol (Meeting Abstracts) 2007 25: 3537. [Abstract]  

A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, G. K. Abou-Alfa, A. Desai, J. Hwang, M. Villalona-Calero, E. C. Dees, L. D. Lewis, and M. J. Ratain

Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301
J Clin Oncol (Meeting Abstracts) 2007 25: 3538. [Abstract]  

C. Gallo-Stampino, G. Rizzardi, S. Toma, A. Corti, P. Scifo, G. Citterio, V. Gregorc, A. Del Maschio, F. Caligaris-Capio, and C. Bordignon

Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies (NGR002 phase I trial)
J Clin Oncol (Meeting Abstracts) 2007 25: 3540. [Abstract]  

H. E. Uronis, J. Bendell, G. Blobe, M. Morse, D. Geier, A. Nixon, L. Howard, D. Evans, H. Li, and H. Hurwitz

A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3541. [Abstract]  

N. S. Azad, C. Annunziata, T. Barrett, C. Chen, S. Steinberg, V. E. Kwitkowski, D. McNally, H. Kotz, L. Minasian, and E. C. Kohn

Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results
J Clin Oncol (Meeting Abstracts) 2007 25: 3542. [Abstract]  

F. Robert, A. Sandler, J. H. Schiller, J. Ilagan, W. VerMeulen, K. Harper, G. Liu, L. Tye, R. Chao, and A. Traynor

A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
J Clin Oncol (Meeting Abstracts) 2007 25: 3543. [Abstract]  

A. F. Shields, E. Heath, P. DeLuca, M. Pilat, A. Wozniak, S. Gadgeel, T. Puchalski, J. Xu, Q. Liu, and P. LoRusso

AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study
J Clin Oncol (Meeting Abstracts) 2007 25: 3544. [Abstract]  

O. M. hahn, C. Yeng, M. Medved, G. Karczmar, E. Kistner, B. Manchen, M. Mitchell, T. Karrison, M. Ratain, and W. M. Stadler

Dyamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): Results of a randomized, phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 3545. [Abstract]  

S. J. Faivre, E. Raymond, J. Douillard, E. Boucher, H. Y. Lim, J. S. Kim, S. Lanzalone, M. J. Lechuga, L. Sherman, and A. Cheng

Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 3546. [Abstract]  

A. O. Soriano, F. Braiteh, G. Garcia-Manero, L. H. Camacho, D. Hong, S. Moulder, C. Ng, and R. Kurzrock

Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: A phase I study
J Clin Oncol (Meeting Abstracts) 2007 25: 3547. [Abstract]  

J. C. Bendell, D. George, A. Nixon, D. Yu, W. Petros, R. Beci, C. Arrowood, D. Lockamy, M. O’Neill, and H. Hurwitz

Results of a phase I study of bevacizumab (BV), everolimus (EV), and erlotinib (E) in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3548. [Abstract]  

D. S. Hong, L. Camacho, C. Ng, J. Wright, R. A. Newman, S. Moulder, N. Tannir, J. Wheler, R. Khan, and R. Kurzrock

Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers (NCI protocol 7156 supported by NCI grant UO1 CA062461)
J Clin Oncol (Meeting Abstracts) 2007 25: 3549. [Abstract]  

P. J. O’Dwyer, P. LoRusso, A. DeMichele, V. Gupta, A. Barbi, H. Dials, I. Chen, R. Courtney, K. Wilner, and G. K. Schwartz

A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
J Clin Oncol (Meeting Abstracts) 2007 25: 3550. [Abstract]  

M. S. Gordon, D. S. Mendelson, C. Sweeney, N. Erbeck, R. Patel, T. Kakkar, L. Yan, S. G. Eckhardt, and L. Gore

Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3551. [Abstract]  

W. A. Messersmith, S. Krishnamurthi, B. A. Hewes, C. M. Zacharchuk, R. Abbas, P. Martins, E. Dowling, A. Volkert, E. Martin, and A. I. Daud

Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3552. [Abstract]  

R. Hassan, S. Bullock, A. Premkumar, R. J. Kreitman, H. Kindler, M. Willingham, and I. Pastan

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin for targeted therapy of mesothelin expressing mesotheliomas, ovarian and pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3553. [Abstract]  

L. H. Camacho, D. S. Hong, C. Gutierrez, C. A. Parker, M. A. Purdom, N. M. Tannir, S. Moulder, R. P. Gale, B. Schwartz, and R. Kurzrock

Organic arsenic in patients (pts) with advanced solid tumors: Phase-1 results of zio-101 (s-dimethylarsino-glutathione)
J Clin Oncol (Meeting Abstracts) 2007 25: 3554. [Abstract]  

F. Farace, P. Vielh, A. Plantade, S. Amsellem, L. Bouaita, G. Vassal, J. M. Bidart, K. Fizazi, and B. Escudier

Circulating endothelial cells and progenitor cells in metastatic renal cell cancer: Predictive value during anti-angiogenic therapy?
J Clin Oncol (Meeting Abstracts) 2007 25: 3555. [Abstract]  

J. Soria, V. Lazar, N. Lassau, C. Pena, C. Massard, C. Robert, S. Koscielny, E. Deutsch, E. Zafarana, and J. P. Armand

Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US)
J Clin Oncol (Meeting Abstracts) 2007 25: 3556. [Abstract]  

J. F. Morere, G. Des Guetz, J. Mourad, B. I. Lévy, and J. Breau

Mechanism of bevacizumab-induced arterial hypertension: Relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3557. [Abstract]  

D. Santini, B. Vincenzi, F. Battistoni, S. Galluzzo, L. Rocci, F. Uzzalli, O. Venditti, C. Grilli, G. Dicuonzo, and G. Tonini

In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis
J Clin Oncol (Meeting Abstracts) 2007 25: 3558. [Abstract]  

D. J. Jonker, L. S. Rosen, M. Sawyer, G. Wilding, C. Noberasco, G. Jayson, G. Rustin, G. McArthur, L. Velasquez, and S. Galbraith

A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings
J Clin Oncol (Meeting Abstracts) 2007 25: 3559. [Abstract]  

C. van Herpen, J. Drevs, H. van Cruijsen, E. E. Voest, C. J. Punt, J. Robertson, O. Saunders, U. Zirrgiebel, C. Unger, and G. Giaccone

Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies
J Clin Oncol (Meeting Abstracts) 2007 25: 3560. [Abstract]  

P. Harter, J. Huober, J. Pfisterer, P. Wimberger, S. Loibl, P. Stopfer, R. Kaiser, V. Reichardt, A. du Bois AGO Ovarian Cancer Study Group

A phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies
J Clin Oncol (Meeting Abstracts) 2007 25: 3561. [Abstract]  

S. Hirawat, G. L. Elfring, V. J. Northcutt, N. Paquette-Lamontagne, T. Davis, M. Weetall, J. Babiak, and L. L. Miller

Phase 1 studies assessing the safety, PK, and VEGF-modulating effects of PTC299, a novel VEGF expression inhibitor
J Clin Oncol (Meeting Abstracts) 2007 25: 3562. [Abstract]  

Y. Hwang, E. Ashton, C. Storgard, S. Wong, E. Malseed, J. Hill, L. Goyal, and J. Evelhoch

Comparison of 1- and 2-dimensional measurements with volumetric measurements for evaluation of change in tumor size
J Clin Oncol (Meeting Abstracts) 2007 25: 3563. [Abstract]  

J. Marshall, J. Posey, J. Hwang, S. Malik, R. Shen, K. Kazempour, L. R. White, K. M. Fraser, C. G. Chang, and C. H. Ahn

A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3564. [Abstract]  

C. Shih, N. Laurie, J. Holzmacher, A. Davidoff, and M. Dyer

AAV-mediated delivery of interferon-ß for the treatment of retinoblastoma in preclinical models
J Clin Oncol (Meeting Abstracts) 2007 25: 3565. [Abstract]  

A. J. Murgo, S. Kummar, E. R. Gardner, W. Figg, X. Chen, M. Yancey, P. Ivy, B. Conley, J. H. Doroshow, M. E. Gutierrez NCI 17-DMAG Working Group

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly
J Clin Oncol (Meeting Abstracts) 2007 25: 3566. [Abstract]  

Q. S. Chu, J. Knox, G. Batist, P. Venner, K. N. Chi, L. Woods, H. A. Burris, III, R. K. Malik, W. P. Peters, and D. J. Jonker

An open label safety and efficacy phase 2a study of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3567. [Abstract]  

S. C. Pacey, R. Wilson, M. Walton, M. Eatock, J. Moreno-Farre, E. Gallerani, V. Davergne, F. Raynaud, P. Workman, and I. Judson

A phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17- DMAG, alvespimycin) administered weekly
J Clin Oncol (Meeting Abstracts) 2007 25: 3568. [Abstract]  

A. Jimeno, A. Chan, X. Zhang, J. Wheelhouse, A. Solomon, S. C. Cosenza, M. Reddy, M. Rudek, P. Kulesza, E. Reddy, and M. Hidalgo

Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3569. [Abstract]  

S. L. Sanborn, M. Cooney, J. Gibbons, J. Brell, P. Savvides, S. Krishnamurthi, J. Bokar, N. Horvath, A. Ness, and S. Remick

Phase I trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3570. [Abstract]  

G. Emons, M. Kaufmann, A. Günthert, C. Gründker, S. Loibl, V. I. Tzekova, M. T. Velikova, S. Tomov, H. Sindermann, J. Engel, and A. V. Schally

Phase I study of ZEN-008 (AN-152), a targeted cytotoxic LHRH analog, in female patients with cancers expressing LHRH receptors
J Clin Oncol (Meeting Abstracts) 2007 25: 3571. [Abstract]  

J. F. Spicer, L. Vidal, H. Pandha, T. Yap, C. White, M. Coffey, B. Thompson, S. Kaye, K. Harrington, and J. De Bono

Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3572. [Abstract]  

W. R. Schelman, J. Kolesar, K. Schell, R. Marnocha, J. Eickhoff, D. Alberti, G. Wilding, and H. Bailey

A phase I study of vorinostat in combination with bortezomib in refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3573. [Abstract]  

R. Sinha, R. Moliffe, M. Scurr, L. Vidal, S. A. Engelholm, P. Buhl Jensen, A. Normann, S. Li, J. De Bono, and U. Lassen

A phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3574. [Abstract]  

M. A. Smith, J. M. Maris, S. T. Keir, R. B. Lock, H. Carol, R. Gorlick, E. A. Kolb, N. Keshelava, C. P. Reynolds, C. Morton, and P. J. Houghton

Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG
J Clin Oncol (Meeting Abstracts) 2007 25: 3575. [Abstract]  

P. Tang, A. Oza, C. Townsley, L. Siu, G. Pond, P. Sarveswaran, S. Webster, J. Zwiebel, and E. Chen

A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 3576. [Abstract]  

S. F. Jones, R. B. Cohen, E. C. Dees, Y. Lee, J. A. Papas, M. R. Cooper, K. M. Galvin, and H. A. Burris, III

Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
J Clin Oncol (Meeting Abstracts) 2007 25: 3577. [Abstract]  

P. C. Fong, S. Settatree, R. Sinha, A. Hardcastle, P. W. Hellemans, J. Arts, K. H. Brown, M. Janicot, W. Aherne, and J. S. De Bono

A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours
J Clin Oncol (Meeting Abstracts) 2007 25: 3578. [Abstract]  

X. Wang, K. Reeves, R. Luo, S. Wu, L. Xu, M. Ayers, F. Lee, E. Clark, and F. Huang

Identification of predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring
J Clin Oncol (Meeting Abstracts) 2007 25: 3579. [Abstract]  

J. F. Deeken, T. Cormier, D. K. Price, S. Steinberg, K. Tran, D. J. Liewehr, S. B. Ockers, P. Hardenbol, W. Dahut, X. Miao, and W. D. Figg

A pharmacogenetic study of docetaxel and thalidomide in patients with androgen-independent prostate cancer (AIPC) using targeted human DMET genotyping platform
J Clin Oncol (Meeting Abstracts) 2007 25: 3580. [Abstract]  

J. Han, S. Lee, D. Lee, H. Kim, and J. Lee

Pharmacogenetic prediction for tumor response, toxicity, and survival of NSCLC patients treated with irinotecan and cisplatin chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 3581. [Abstract]  

D. Camidge, R. S. Herbst, M. Gordon, S. Eckhardt, R. Kurzroc, B. Durbin, J. Ing, J. Ling, J. Sager, and D. Mendelson

A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 3582. [Abstract]  

H. C. Pitot, M. Saleh, J. Holmlund, J. Maleski, and A. Forero

Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers
J Clin Oncol (Meeting Abstracts) 2007 25: 3583. [Abstract]  

S. Goel, H. Burris, D. Mendelson, R. Gollamudi, J. Stern, N. Frazer, S. Jones, M. Gordon, and S. Mani

A phase I study of intravenous tetra-O-methyl nordihydroguaiaretic acid in patients with refractory malignancy
J Clin Oncol (Meeting Abstracts) 2007 25: 3584. [Abstract]  

K. P. Papadopoulos, D. W. Northfelt, D. M. Hufnagel, A. D. Ricart, P. P. Griffin, M. D. Oslund, D. D. Von Hoff, W. G. Rice, J. K. Lim, and R. F. Marschke

Phase I clinical trial of CX-3543, a protein-rDNA quadruplex inhibitor
J Clin Oncol (Meeting Abstracts) 2007 25: 3585. [Abstract]